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Abstract
The latency-associated nuclear antigen (LANA1) of Kaposi’s sarcoma- 
associated herpesvirus (KSHV) is a multi-function protein involved in 
maintenance of the viral episome and has been shown to interact with 
several proteins including p53 and pRB. It is likely that the multi­
functional role of LANA1 exceeds these observations therefore the 
work in this thesis aimed to study LANA1 at both the transcription and 
protein-protein interaction level. I developed a lentiviral system for the 
infection of primary endothelial cells with LANA1, to analyse changes 
in gene expression profiles by gene expression microarrays. While 
the system was successfully developed, no significant changes in 
gene expression could be attributed to LANA1. Subsequently, using 
the yeast two-hybrid system and large-scale immunoaffinity 
purification coupled to mass spectrometry, I identified 26 novel binding 
partners of the KSHV LANA1 complex. The majority of these proteins 
have functions in splicing or mRNA processing and further analysis 
lead to the discovery of predominant protein domains. Several of the 
identified proteins, including heterogeneous nuclear ribonucleoprotein 
(hnRNP) A1, A2/B1, D and I, constitute members of the human H- 
complex. hnRNP A1, A2/B1 and D are also implicated in telomere 
biogenesis. I show that LANA1 binds UP1, the proteolytic derivative 
of hnRNP A1, which modulates telomere elongation and maintenance. 
Furthermore, I show an in vivo interaction between LANA1 and human 
telomerase reverse transcriptase (hTERT) and the ability of LANA1 to 
recover telomerase activity from cell lysates. These findings suggest 
a function for LANA1 in the maintenance of telomeres and may have 
important implications for the role of LANA1 in KSHV-related tumours.
I propose models for the role of these complexes in splicing and 
telomere biogenesis.
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For my parents
Chapter 1 Introduction
1.1 Kaposi’s sarcoma-associated herpesvirus
In 1994 the discovery of new herpesvirus DNA in Kaposi’s sarcoma 
(KS) biopsies by representational differential analysis (RDA) led to the 
identification of Kaposi’s sarcoma-associated herpesvirus (KSHV, also 
termed human herpesvirus-8[HHV-8]) (Chang et al. 1994). 
Subsequent characterisation and phylogenic analysis placed KSHV 
within the gamma-2 herpesviruses, genus Rhadinovirus (Moore et al. 
1996b). Sequencing of the KSHV genome revealed an array of 
cellular homologues, alongside several unique opening reading frames 
(ORFs) (Russo et al. 1996). KSHV is a lymphotropic 
gammaherpesvirus that has been implicated in the pathogenesis of 
several malignancies, other than KS, including multicentric 
Castleman’s disease (MCD) and primary effusion lymphoma (PEL) 
(Sarid etal. 1999).
1.1.1 Kaposi’s sarcoma
1.1.1.1 Characteristics
Moritz Kaposi, a Hungarian dermatologist, originally described KS in 
1872 (Kaposi 1872). Presenting primarily as vascular skin lesions in 
men of Mediterranean origin (Fig 1.1), KS remained overshadowed by 
other human malignancies until its appearance in New York and 
California in gay men, signalling the start of the AIDS pandemic 
(Centers for Disease Control 1981). KS occurs in four forms; classic 
KS (Mediterranean), iatrogenic KS (post-organ transplant), African 
endemic KS (prevalent before HIV) and AIDS-KS. Classic KS is seen 
predominantly in elderly men of Mediterranean origin. AIDS-KS is 
seen in HIV infected individuals whose continuing immunosuppression 
leads to an inability to control a broad spectrum of diseases.
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Fig 1.1
Fig 1.1 -  Images of a KS lesion and KS histology
A, A KS lesion showing the characteristic vascular appearance.
B, The spindle cell morphology of KS-related spindle cells.
AIDS-KS is the most common neoplasm in AIDS patients. A further 
form of KS occurs due to iatrogenic immunosuppression during organ 
transplantation (Alkan etal. 1997;Kedda etal. 1996).
1.1.1.2 Histogenesis
The histopathologv of KS is unusually complex and involves a wide 
range of different cell types. KS tissue also shows a high level of 
infiltration by inflammatory cells. The formation of KS can be divided 
into three distinct stages of histogenesis; patch, plaque and nodular. 
The early stage, also termed the patch stage, is characterised by 
irregular endothelial spaces around normal dermal blood vessels and 
is associated with a varying level of inflammatory cells. The plaque 
stage follows, whereby the appearance of characteristic spindle cells 
is first seen and finally the nodular stage occurs by the expansion of 
spindle cells through the dermis, culminating in the formation of 
vascular channels with red blood cells. The precise identity of these 
spindle cells remains unknown, although they are proposed to derive 
from the endothelial cell lineage (Boshoff et al. 1995a;Dupin et al. 
1999). However, these spindle cells have also been reported to 
express cell surface markers of smooth muscle, dendritic cell and 
macrophage origin (Nickoloff and Griffiths 1989;Sturzl et al. 1992), 
inferring that the cells could represent mesenchymal precursor cells.
1.1.1.3 Epidemiology
The strongest evidence for association between KSHV infection and 
KS is provided by molecular epidemiological and seroepidemiological 
surveys. The polymerase chain reaction (PCR) is widely used to 
detect KSHV and to allow molecular characterisation and phylogenic 
analysis of the virus. This powerful tool has allowed the creation of a 
global picture of KSHV infection, allowing comparison with the 
incidence and risk of disease. Using PCR the link between KS and 
KSHV was established. KSHV is present in all forms of KS 
(Ambroziak et al. 1995;Boshoff et al. 1995b;Dupin et al. 1995b), but is
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absent from various other skin tumours (Adams et al. 1995). KSHV is 
almost universally present in archival KS biopsies (Cathomas et al. 
1996;Uthman et al. 1996). Seroepidemiological studies of KSHV have 
been conducted in various areas of the world. A summary of these 
findings are shown below.
North America and Northern Europe
Serological assays, which detect the presence of anti-KSHV 
antibodies, provide evidence for close association between KSHV and 
KS. Homosexual AIDS-KS patients show 88% seroprevalence by 
immunofluoresence assay (IFA) for KSHV, compared to 30% in 
homosexual AIDS patients without KS (Gao et al. 1996b). No HIV- 
infected patients with haemophilia or HIV negative blood donors tested 
positive for anti-KSHV antibodies (Gao et al. 1996b). In normal blood 
donors the incidence of KSHV is low <1%. These data suggest that 
KSHV may be sexually transmitted (Kedes et al. 1996).
Mediterranean Europe
Classic KS is primarily associated with elderly Mediterranean men 
(Franceschi and Geddes 1995). In Italy a higher prevalence of anti- 
KSHV latency-associated nuclear antigen (LANA1) antibodies was 
detected in blood donors than in Northern Europe and North America, 
which correlates with the increased incidence of KS (Whitby et al.
1998). Strikingly, the incidence of KS within Italy strongly mirrors the 
geographical distribution of KSHV (Whitby et al. 1998). Direct 
comparison between blood donor isolates from North America and 
Italy again shows a higher incidence of KSHV in Italian donors (Gao et 
al. 1996b). In Israel, the seroprevalence of KSHV also correlates with 
the incidence of KS in Sephardic and Ashkenazi Jews (Davidivici et al.
1999).
20
Africa
The seroprevalence of KSHV may also vary within a geographical 
area on the basis of race. In South Africa, a cohort of black cancer 
patients (no.=3591) was tested for the presence of KSHV antibodies 
by I FA against LANA1 (Sitas et al. 1999). Black cancer patients had a 
higher seroprevalence of KSHV than Caucasians had within the same 
area (Sitas et al. 1999). Seroprevalence increased with age, number 
of sexual partners, and decreasing levels of education (Sitas et al. 
1999). In a small sub-group of cancer patients that had KS, 83% 
tested positive for KSHV antibodies (Sitas et al. 1999).
1.1.1.4 KS and KSHV
The pattern of infection suggested early on in the appearance of KS in 
AIDS patients that an infectious agent may be involved (Beral et al. 
1990). While KS was rarely seen in HIV-infected haemophiliac and 
intravenous drug users, it was more commonly seen in heterosexually 
acquired HIV patients and most commonly seen in homosexual and 
bisexual men (Beral 1991). The appearance of KS therefore 
appeared to be linked to sexual practices, suggesting a role for a 
sexually-transmitted pathogen (Beral et al. 1990). A direct role for 
KSHV in the aetiology of KS has been proposed, as the presence of 
KSHV in HIV positive patients is a strong predictive factor for the 
development of KS (Whitby et al. 1995). In the majority of AIDS-KS 
patients, seroconversion against KSHV occurs prior to the clinical 
appearance of KS, further supporting a role for the virus in KS 
aetiology (Gao et al. 1996a). KS is a particularly vascular tumour, 
characterised by the involvement of endothelial blood vessel cells. To 
play a role in KS formation, KSHV must be able to infect and express 
viral genes within endothelial cells. This was confirmed when KSHV 
DNA was detected in KS tumour cells, but not in other non-KS skin 
tumours (Boshoff et al. 1995a;Staskus etal. 1997).
21
1.1.1.5 KS and HIV
AIDS-KS tumour cells express a broad array of cytokines that produce 
angiogenic, autocrine and paracrine effects (Ensoli et al. 1989). 
Histologically, AIDS-KS tumour cells show evidence of inflammation 
(Samaniego et al. 1995). KSHV encodes a variety of genes with 
cytokine activities including macrophage inflammatory proteins 
(vMIPs) and a viral interleukin-6 (vlL-6). The production and 
subsequent effects of these chemokines may play a significant role in 
KS pathology, as vMIP-l and vMIP-ll both have angiogenic properties 
(Boshoff et al. 1997). The role of vMIPs in angiogenesis during KS 
and Multicentric Castleman’s disease (MCD)(see section 1.1.2) 
formation may be synergistic with other factors including vascular 
endothelial growth factor (VEGF) and IL-6 (Boshoff et al. 1997).
The epidemiological link between HIV-1 and KS has been well 
documented, highlighting a strong correlation between HIV and the 
formation of KS (Sitas et al. 1997). Initially it was assumed that the 
role of HIV in AIDS-KS pathogenesis was limited to the destruction of 
the immune system. A more direct role for HIV in KS pathogenesis 
has become apparent. Acute infection of T-cells can lead to the 
extracellular release of Tat, which can stimulate the growth of vascular 
spindle cells from HIV positive KS lesions (Barillari et al. 1992;Ensoli 
et al. 1993). It has also been proposed that HIV Tat can stimulate the 
replication of KSHV between 3 and 20 fold, in a wide range of KSHV 
positive cell lines and in primary cells (Harrington, Jr. et al. 1997).
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Lymphoproliferative disorders
Although the discovery of KSHV was linked closely to the study of KS 
(Chang et al. 1994), there are other human malignancies associated 
with KSHV. KSHV is believed to play a central role in the 
development of two lymphoproliferative disorders; a subset of 
multicentric Castleman’s disease (MCD) and body cavity based 
primary effusion lymphoma (PEL).
1.1.2 Castleman’s disease
1.1.2.1 Characteristics
Castleman's disease (CD) describes a polyclonal lymphoproliferative 
disorder, with a poorly understood aetiology (Castleman et al. 1956).
1.1.2.2 Histogenesis
The clinical formation of CD can be identified as one of two distinct 
variants. These variants, termed hyaline vascular and plasma cell are 
identified by their histopathology. The hyaline vascular form is 
predominant and is usually a localised solitary mass in the 
mediastinum or retroperitoneum (Boshoff 1999). The systemic plasma 
cell variant of CD, also termed Multicentric Castleman's disease 
(MCD), is characterised by general lymphadenopathy and B cell 
symptoms and can occur in both HIV positive and HIV negative 
patients (Boshoff and Weiss 1998). The formation of CD and MCD 
may be cytokine driven. Human IL-6 is detectable at high levels in 
biopsies, and soluble IL-6 is present in the high levels in the circulating 
blood of MCD patients.
1.1.2.3 Epidemiology
Detection of KSHV in MCD was first described in biopsies from a 
cohort of French patients (Soulier et al. 1995). All biopsies taken from 
HIV-positive patients suffering from MCD showed the presence of the
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virus (14/14), whereas a lower ratio (7/17) was seen in biopsies from 
HIV-negative patients (Soulier et al. 1995).
1.1.2.4 MCD and KSHV
Following the initial studies by Soulier et al, other groups have since 
confirmed the presence of KSHV in MCD (Barozzi et al. 1996;Dupin et 
al. 1995a). The relationship between KSHV and MCD has been 
formalized by the discovery that KSHV is associated with a distinct 
variant of MCD (Dupin et al. 2000). Monoclonal antibodies against 
LANA1 were used for immunohistochemistry studies on MCD 
revealing an association with micro-lymphoma formation in the mantle 
zone of B cell follicles (Dupin et al. 2000). As KSHV is detectable 
only in B-cell lineage derived plasmablasts of MCD, the KSHV-related 
form is termed plasmablastic MCD (Dupin et al. 2000). These 
distinctive plasmablasts are not present in KSHV-negative MCD and 
may therefore represent a virus specific form of the disease.
Previous reports have hinted at a viral role in the cytokine driven 
lymphoproliferation of MCD (Peterson and Frizzera 1993). KSHV 
interleukin-6 (vlL-6) may play a role in the formation of MCD, as levels 
of cellular IL-6 are high in CD biopsies. Although the presence of 
KSHV vlL-6 has been confirmed in MCD, its exact role, if any, remains 
unclear (Parravicini etal. 1998).
1.1.2.5 MCD and HIV
During HAART therapy for HIV, KS often spontaneously resolves, 
leading to the conclusion that immune system control of KS may be 
important. This is not necessarily the case for MCD disease in HIV- 
patients. Despite treatment with HAART and lowered HIV viral load, 
MCD often does not resolve (Dupin et al. 2000;Zietz et al. 1999).
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1.1.3 Body cavity primary effusion lymphoma
1.1.3.1 Characteristics
Primary effusion lymphoma (PEL), previously called body cavity 
lymphoma, presents as either a pleural or pericardial effusion of B cell 
origin. Usually confined to AIDS patients, PEL is a rare non-Hodgkin's 
lymphoma (NHL), which responds poorly to treatment and is rapidly 
fatal. Initially PEL was defined as an unusual type of effusion 
lymphoma in AIDS patients and was linked closely with the presence 
of EBV, but with a distinctive absence of c-myc rearrangements 
(Karcher et a\. 1992;Knowles et al. 1989;Walts et at. 1990). This was 
unusual as the EBV associated malignancy, Burkitt’s lymphoma is 
characterised by c-myc translocation to the Ig heavy chain locus, 
leading to overexpression of c-myc, a powerful human oncogene. The 
presence of KSHV DNA in PEL was first demonstrated by Chang et al 
(Chang et al. 1994) and later in further work by Cesarman et al 
(Cesarman etal. 1995).
1.1.3.2 Histogenesis
Despite a lack of B cell surface antigens, PEL is believed to be 
derived from a B cell lineage. This is indicated by the presence of 
clonal immunoglobulin gene rearrangement and the observation of 
some plasma cell differentiation (Ansari et al. 1996;Cesarman et al. 
1996b;Cesarman et al. 1996a). All PEL lacking c-myc translocation 
events are positive for KSHV and lack p53 alterations (Nador et al. 
1996).
1.1.3.3 PEL and KSHV
In comparison with KS, KSHV is present in higher copy numbers in 
PEL and these cells are often co-infected with EBV, suggesting a 
shared role between KSHV and EBV in PEL formation (Cesarman et 
al. 1995;Otsuki et al. 1996). KSHV DNA detected by Southern blot 
reveals the number of KSHV genomes as 50-150 copies per cell,
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considerably higher as compared to KS (Boshoff 1999). Cell lines 
derived from PELs are largely latent, expressing only a subset of 
herpesvirus genes and not producing viral particles. However, within 
PEL a small percentage of lytic cells are observed (Boshoff et al.
1998). PEL cells have been shown to release and are dependent on 
several growth factors in vitro. Factors released from KSHV-infected 
PEL include human IL-10, human IL-6 and viral IL-6 (Jones et al.
1999). PEL cells were found to be dependent on human IL-10 and 
viral IL-6 for proliferation, suggesting an essential role for these factors 
in PEL development (Jones et al. 1999).
1.1.3.4 PEL and HIV
PEL occurs predominantly in advanced stages of HIV-related 
immunosuppresion, but are occasionally seen in HIV-negative 
individuals, including women (Komanduri et al. 1996;Nador et al. 
1996;Said et al. 1996;Strauchen et al. 1997). However PEL, in 
common with KS, are seen primarily in gay men (Jaffe 1996;Nador et 
al. 1996).
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1.2 KSHV transmission
The principle route of transmission for KSHV remains unknown. The 
epidemiology of KS has always suggested that a sexually transmitted 
agent may be involved (Beral et al. 1990). In normal blood donors the 
incidence of KSHV is low <1%. Early observations of AIDS patients 
showed those who acquired HIV via sexual contact, rather than 
parentally, showed a much higher incidence of KS (Beral et al. 1990). 
Data have shown that a significant proportion of KSHV-infected 
individuals, who have become immune suppressed due to AIDS, will 
develop KS (Kedes et al. 1996). It has also been shown through 
epidemiology that infection with KSHV occurs as an adult, not as a 
child, suggesting a link with the onset of sexual maturity (Blauvelt et 
al. 1997).
Research has been published on the presence of KSHV in semen and 
prostate samples. One study has shown that semen from HIV positive 
homosexual males, tested by nested PCR, shows 91% positivity for 
KSHV, in contrast to 23% in healthy sperm donors. Further testing 
showed the presence of KSHV in saliva and semen from KS patients 
(Ambroziak et al. 1995). However, other studies have failed to detect 
the presence of KSHV in semen and prostate from AIDS-KS patients 
and healthy donors (Corbellino et al. 1996;Monini et al. 1996). KSHV 
was only detected in the semen of HIV-infected homosexual men (Lin 
et al. 1995). PCR, and in particular nested PCR, are prone to false 
positives, which may account for the differences in these studies.
Another suggested route for KSHV is through contact with saliva. 
Testing of HIV-positive individuals saliva revealed the presence of 
KSHV (Koelle et al. 1997) as did the saliva from HIV-negative Italian 
classic KS patients (Cattani et al. 1999). Further, more recent studies 
show that KSHV is mainly present in sputum, and epidemiological 
evidence supports kissing as a major route of transmission (Pauk et 
al. 2000).
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1.3 KSHV molecular virology
1.3.1 Viral proteins
KSHV encodes over 85 open reading frames (ORFs) and several of 
these proteins are unique to the virus (Russo et al. 1996). Viral 
proteins that are unique to KSHV are designated with a K and a 
number. The unique proteins within KSHV number K1-K15 (Fig 1.2). 
As with other herpesviruses, the KSHV encoded proteins are classed 
as lytic or latent as determined by their role in the life cycle of the 
virus. The main latent proteins of the virus are the viral cyclin 
(vcyclin), the latency-associated nuclear antigen (LANA1), viral FLICE 
inhibitory protein (vFLIP), viral interferon regulatory factors (vIRFs) 
and a transmembrane protein designated K15. The main lytic proteins 
that could be involved in disease formation are the viral G-protein 
coupled receptor (vGPCR), viral interleukin-6 (vlL-6) and viral bcl-2 
(vbcl-2).
1.3.2 Latent proteins
The main latent transcript of KSHV encodes three proteins; viral cyclin 
(vcyclin), KSHV FLICE inhibitory protein (v-FLIP) and the latent 
nuclear antigen (I.ANA1) (Talbot et al. 1999). Two forms of the 
transcript exist as 1.7kb and 5.32kb transcripts, the smaller of which is 
a splice variant that lacks LANA1 (Talbot et al. 1999). vcyclin is a 
latently expressed cyclin D homologue which aids in the progression 
of cells through the cell cycle by forming a stable complex with cellular 
proteins (Cesarman et al. 1996b). The KSHV Flice inhibitory protein 
(FLIP) is a putative anti-apoptotic protein (Thome et al. 1997). The 
major latency-associated nuclear antigen (LANA1) of KSHV is a 
nuclear protein that plays an important role in the life cycle of KSHV 
(see later).
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1.3.2.1 K15
K15, positioned at the far right hand side of the viral genome, was 
originally identified as a spliced transmembrane protein (Rainbow et 
al. 1998). K15 was further shown to have similarities with Latent 
Membrane Protein (LMP) 1 and LMP2A of EBV (Glenn et al. 1999) 
and is expressed in one of two forms; predominant (P) and minor (M). 
P and M forms of K15 are present in 85% and 15% of viral samples, 
respectively (Hayward 1999). More recently K15 has been shown to 
be latently expressed and bind HAX-1, a novel anti-apoptotic protein, 
inferring a role for K15 in blocking apoptosis (Sharp et al. 2002).
1.3.2.2 Viral interferon regulatory factor (vIRF)
Cellular interferons are proteins produced by cells in response to viral 
infections. Three types of interferon are produced: a-interferon, p- 
interferon and y-interferon (Challand and Young 1998). Interferon 
regulating factors are proteins that act as transcription factors. KSHV 
encodes a homologue of cellular interferon regulatory factor which has 
been designated vIRF. vIRF is encoded by open reading frame 9
(ORF 9) and has been shown to be a putative viral oncogene (Gao et
al. 1997). vIRF interferes with normal cellular interferon signaling 
(Gao et al. 1997) via the repression of cellular IRF-1 mediated 
transcription (Zimring et al. 1998). vlRF-2 was identified as a 18kDa 
protein and was found to interact with cellular IRF-1 and IRF-2, but not 
IRF-3 (Burysek et al. 1999). vlRF-3 was identified as a 73kDa protein 
with homology to KSHV vlRF-2 and cellular IRF-4 (Lubyova and Pitha
2000). vlRF-3 functions as a dominant negative mutant of IRF-3 and 
IRF-7, which are essential for the activation of alpha and beta 
interferon genes (Lubyova and Pitha 2000).
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1.3.2.3 Viral cyclin (vcyclin)
Cellular cyclins play an essential role in the regulation of normal cell 
proliferation and progression through the cell cycle. Dysregulation of a 
cell’s normal proliferation is a major factor in the formation of 
malignancy. Viruses often exploit the cell cycle to use the cells’ 
replication machinery for replication of viral DNA. There are several 
types of cyclins including A, D and E, each possessing different roles 
at different stages of the cell cycle. Cyclin D is particularly important 
as through an interaction with cyclin-dependent kinase 6 (cdk6) the 
cyclin D/cdk6 complex phosphorylates pRB. The interaction between 
D-type cyclin and cdk6 is transient and can be regulated by other 
cellular proteins termed cyclin-dependent kinase inhibitors (cdki). 
Active pRB is hypophosphorylated and can interact with E2F, 
abrogating its function. Through this mechanism pRB performs an 
essential role as a cell cycle regulator. The phosphorylation of pRB 
into its hyperphosphorylated form leads to release of E2F and 
progression of the cell cycle.
KSHV encodes a D-type cyclin homologue (Cesarman et al. 1996b), 
(Chang et al. 1996), (Li et al. 1997). The co-expression of vcyclin 
(also called cyclin K) and pRB in a pRB negative cell line (SOAS) 
resulted in a failure of pRB mediated cell cycle arrest (Chang et al.
1996). vcyclin also forms a complex with cdk6 and is capable of 
phosphorylating both pRB and histone H1 (Godden-Kent et al. 1997), 
however this complex is stable and is not sensitive to inhibition by 
cdkis (Swanton etal. 1997).
Cyclin K also inhibits the growth suppression activities of STAT3 by 
associating with it via its activation domain and preventing its DNA- 
binding and transcriptional activities (Lundquist et al. 2003).
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1.3.2.4 Viral FLIP (vFLIP)
FLIP proteins were originally identified in viruses and therefore 
designated vFLIPs. They are present in human molluscipoxvirus 
(Senkevich et al. 1996) and in several members of the gamma 
herpesviruses, including Herpesvirus Saimiri (HVS) and KSHV. 
Regardless of virus species, the vFLIPs are structurally similar, 
possessing two death-effector domains. Cellular FLIP protein (FLICE- 
inhibitory protein) was originally identified as an apoptosis inhibitor 
mainly expressed in muscular and lymphatic tissues (Irmler et al. 
1997). Two isoforms were discovered, short (FLIPs) and long (FLIPl), 
produced by one spliced transcript. KSHV has ‘captured’ the shorter 
RNA species. Through their death-effector domains both cellular and 
viral FLIPs interact with Fas-associated death domain (FADD) to 
prevent death-receptor mediated apoptosis. vFLIP has more recently 
been shown to activate IKappaB kinase (IKK) by binding to IKK- 
gamma (Field et al. 2003).
1.3.2.5 Latency-associated nuclear antigen (LANA1)
The structure of LANA1 is unusual and can be divided into three 
regions on the basis of its amino acids. LANA1 possesses a proline 
rich amino terminus (aa1-337), which includes the nuclear targeting 
domain (Piolot et al. 2001), an extensive central repeat region that 
includes a putative leucine zipper and a carboxyl terminus implicated 
in dimerisation of the protein (Schwam et al. 2000) (Fig 1.3). LANA1 
and the viral episomes accumulate in heterochromatin-associated 
nuclear bodies and show a characteristic nuclear stippling pattern in 
all KSHV infected tumor cells (Dupin et al. 1999;Mattsson et al. 
2002b;Szekely et al. 1999). One of the most important roles of 
LANA1 is in the persistence of the viral episome. Many DNA viruses, 
including EBV, Human Papilloma virus (HPV) and SV40 employ 
strategies for the passing on of viral episomes to daughter cells.
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Fig 1.3 -  Amino acid structure and protein interaction partners of 
LANA1
A, The structure of the KSHV latent nuclear antigen (LANA1) as 
predicted from primary amino acid sequence (Adapted from Lim et al,
2001). Interaction partners where precise mapping is unknown are 
shown underneath.
B, Interaction domains of LANA1. Proteins whose interaction has 
been mapped to LANA1 domains.
Key:
ATF4 (Activating transcription factor 4)
CREB2 (Cyclic AMP response element binding protein 2)
PRB (Retinoblastoma protein)
SAP30 (Sin3 associated polypeptide 30)
CIR (CBF1 interacting corepressor)
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LANA1 binds to heterochromatin and tethers the viral episome during 
latent infection, ensuring the virus persists in daughter cells (Ballestas 
et al. 1999;Cotter and Robertson 1999). The interaction of LANA1 
with histone H1 is believed to be important for this function. The 
functional homologue of LANA1 in EBV, EBNA1, is also essential for 
the maintenance of the viral episome (Yates et al. 1985) and has been 
identified as a histone H1 interacting protein (Aiyar et al. 1998). The 
amino terminus of LANA1 mediates this interaction between amino 
acids 5-22 (Piolot et al. 2001). LANA1 has recently been shown, in a 
similar role to EBV EBNA1, to mediate the replication of plasmid DNA 
carrying viral terminal repeats (Grundhoff and Ganem 2003).
LANA1 has been shown to interact with a wide range of proteins and 
exhibits a wide range of cellular activities. LANA1 has been reported 
to bind proteins including p53 (Friborg et al. 1999), pRB (Radkov et al. 
2000), RING-3 (Platt et al. 1999), ATF4/CREB2 (Lim et al. 2000), 
cAMP response element-binding protein-binding protein (CBP) (Lim et 
al. 2001) and members of the mSIN3 complex (Krithivas et al. 2000).
Yeast two-hybrid screening and subsequent confirmatory experiments 
including in vitro and in vivo binding assays identified RING3 as an 
interaction partner of LANA1 (Platt et al. 1999). RING3 is a human 
homologue of the drosophila female sterile hometic (fsh) gene and the 
interaction with LANA1 leads to phosphorylation of LANA1 (Platt et al.
1999). This kinase activity was not however due to RING3 and 
suggests a further interaction with a cellular kinase as part of the 
LANA1-RING3 complex (Platt et al. 1999).
Several well characterised viral oncoproteins have been shown to bind 
to p53 and pRB (summarised in Table 1.1).
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Table 1.1
SV40 
Large T 
antigen
papillomavirus adenovirus KSHV
LANA1E6 E7 E1A E1B
binds p53 + + - - + +
binds pRB + - + + - +
binds Histone H1 ? - + ? ? +
Episomal maintenance ? + + + - +
Transforms primary 
rodent cells in 
cooperation with a 
cellular oncogene
+ + + + + +
Table 1.1 - Comparison of KSHV LANA1 with other viral oncoproteins. 
Adapted from Boshoff and Weiss (Boshoff and Weiss 1998).
LANA1 protects against cell death by binding to p53 and thereby 
inhibiting its pro-apoptotic role (Friborg et al. 1999). The interaction 
between LANA1 and p53 was shown to inhibit the transcriptional 
activity of p53 (Friborg et al. 1999). pRB is an important cellular 
protein that plays a central role in the regulation of normal cell 
proliferation (see vcyclin section). As such pRB is targeted by several 
viral oncoproteins. LANA1 was shown to bind the 
hypophosphorylated form of pRB and thereby prevent its suppression 
of E2F and allowing progression of the cell cycle (Radkov et al. 2000). 
Furthermore, LANA1 was shown to transform primary rat embryonic 
fibroblasts in cooperation with the oncogene Hras (Radkov et al. 
2000). RING3, which as discussed earlier interacts with LANA1, is 
also a component of the pRB/E2F complex possibly aiding in the 
interaction between LANA1 and pRB (Denis et al. 2000; Radkov et al. 
2000).
Yeast two-hybrid was also used to identify ATF4/CREB2 (Lim et al.
2000) as a binding partner. Further work showed cAMP response
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element-binding protein-binding protein (CBP) to be bound by LANA1 
(Lim et al. 2001). LANA1 interacts with ATF4/CREB2, a member of 
the ATF/CREB transcription factor family, via its bZIP domain (Lim et 
al. 2000). Based on previous research that showed a LANA1- 
mediated repression of NFkB-dependent transcription, the interaction 
between LANA1 and CBP was tested, as NFkB used CBP as a 
transcriptional co-activator (Lim et al. 2001). An interaction between 
LANA1 and CBP was confirmed and through this interaction LANA1 
repressed not only the transcriptional activity of CBP, but also its 
histone acetyltransferase (HAT) activity (Lim et al. 2001). Through an 
interaction with the proteins of the mSin3 corepressor complex LANA1 
can mediate transcriptional repression (Krithivas et al. 2000). Yeast 
two-hybrid analysis identified SAP30 as an interaction partner, with 
further interactions between LANA1 and both mSin3A and CIR being 
demonstrated by glutathione-s-transferase (GST) pulldown assays 
(Krithivas et al. 2000). These interactions were shown to be mediated 
by amino acids 1-340 (Krithivas et al. 2000). LANA1 has been shown 
to be a potent repressor of various promoters when bound to DNA 
(Schwam et al. 2000). A further interaction with the heterochromatin- 
associated protein is also suggested to play a role in transcriptional 
repression (Lim et al. 2003).
Using the yeast-two system LANA1 was found to interact with a novel 
cellular protein, KLIP1 (Pan et al. 2003). KLIP1, which contains two 
leucine zipper motifs, represses herpes simplex virus thymidine kinase 
promoter activity. The presence of LANA1 prevents this 
transcriptional repression. This represents evidence of a cellular 
transcriptional repressor binding to LANA1.
LANA1 has also been shown to be a transcriptional activator of 
several different promoters including E2F (Radkov et al. 2000) and is 
suggested to contribute to cellular immortalisation by upregulating 
human telomerase reverse transcriptase (hTERT) , an essential 
component of the human telomerase complex (Knight et al. 2001).
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LANA1 has also been shown to alter the transcriptional activity of 
other viral promoters (Groves et a l 2001). LANA1 can activate two 
major essential EBV latent promoters, the LMP and EBNA C 
promoters, suggesting a role for LANA1 in the modulation of EBV 
virus transcription in co-infected B cell lymphoma cells (Groves et al.
2001). Human IL-6 (hlL-6), a cytokine directly implicated in the 
pathogenesis of KSHV-related malignancies, is detected in KS, PEL 
and MCD, along with the expression of vlL-6 from the viral genome. A 
link between LANA1 and hlL-6 was shown when upregulation of the 
hlL-6 promoter was detected in the presence of LANA1 and the AP1 
site was found to be required for this activity (An et al. 2002).
Recently LANA1 has been shown to modulate the Wnt signaling 
pathway (Fujimoro et al. 2003). p-catenin activates genes containing 
Tcf and Lef binding sites by forming nuclear complexes with Tcf and 
Lef transcription factors (Fujimoro et al. 2003). Screening interaction 
partners of LANA1 by yeast two-hybrid revealed GSK-3p as a binding 
partner. By binding to GSK-3p, a negative regulatory factor of p- 
catenin, dysregulation of the p-catenin pathway occurs. Dysregulation 
of the p-catenin pathway is frequently seen in cancers.
An attempt has been made to study the effects of LANA1 on the 
transcriptome using gene expression microarrays (Renne et al. 2001). 
This study investigated the effects of LANA1 on the activity of several 
synthetic promoters and found that LANA1 activated synthetic 
constructs containing ATF, AP1, CAAT and SP1 sites but repressed 
HIV-LTR and NFkB-dependent reporter genes (Renne et al. 2001). 
Results from gene expression microarrays showed limited modulation 
of cellular genes, including upregulation of several interferon 
responsive genes (Renne et al. 2001).
Overall LANA1 is a multifunctional protein possibly influencing a large 
number of cellular functions.
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1.3.3 Lytic proteins
1.3.3.1 Viral GPCR (vGPCR)
KSHV GPCR and vcyclin were identified from a PEL-derived virus 
genomic clone (Cesarman et al. 1996b). KSHV GPCR (vGPCR) was 
confirmed as a signaling receptor with constitutive activity in the 
phosphoinositide-inositoltriphosphate-protein kinase C signaling 
pathway with homology to human cellular IL-8 receptors and a GPCR 
from HVS (Arvanitakis et al. 1997). Work on a mouse model encoding 
the vGPCR showed that transgenic expression in hematopoeitic cells 
resulted in the formation of angioproliferative lesions (Yang et al. 
2000). The lesions appeared in several different areas including the 
skin, heart, skeletal tissue and intestine and resembled KS both in 
clinical presentation and histology (Yang et al. 2000).
1.3.3.2 Viral lnterleukin-6 (vlL-6)
Human lnterleukin-6 (hlL-6) is a cytokine that is implicated in the 
survival and replication of B cells. KSHV encodes vlL-6, a protein that 
has significant sequence similarity to that of hlL-6 (Moore et al. 
1996a;Nicholas etal. 1997).
1.3.3.3 Viral bcl-2 (vbcl-2)
Cellular bcl-2 is a protein that plays a pivotal role in apoptosis. KSHV 
encodes a bcl-2 gene with sequence similarity to cellular bcl-2, 
termed vbcl-2, from ORF 16 (Cheng et al. 1997;Sarid et al. 1997). 
The KSHV vbcl-2 is expressed during the lytic phase of the virus 
lifecycle (Sarid et al. 1997) (Sarid et al. 1998) and can overcome bax- 
mediated apoptosis (Cheng et al. 1997;Sarid et al. 1997). It is 
possible that the vbcl-2 encoded by KSHV may play a role in the 
survival of tumors via an anti-apoptosis mechanism.
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1.3.3.4 K1
ORF K1 is commonly used to subtype KSHV into subtypes A, B, C 
and D (McGeoch and Davidson 1999; Nicholas et al. 1998). These 
subtypes of KSHV possess between 15-30% amino acid differences 
within their respective K1 ORFs. The use of K1 to subtype KSHV 
allows the study of KSHV ethical and geographical distribution. K1 is 
a transforming protein that contains functional immunoreceptor 
tyrosine-based activation motifs (ITAMs) (Lee et al. 1998b; Lee et al. 
1998a). Studies have suggested that K1 may be involved in the 
activation of NFkB signaling (Prakash et al. 2002) and K1 has recently 
been shown to activate the Akt signaling pathway (Tomlinsen and 
Damania 2004).
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1.4 Related viruses
The gammaherpesviruses are a subfamily of herpesviruses 
characterised by their association with transient and chronic 
lymphoproliferative disorders due to an ability to induce cell 
proliferation (Boshoff 1999) (Table 1.2A). The gammaherpesviruses 
are further subdivided into Lymphocryptovirus and Rhadinovirus on 
the basis of genome structure. KSHV is a member of the 
gammaherpesviruses and is classified as a Rhadinovirus. KSHV 
shares significant homology with other members of this group, which 
include herpesvirus saimiri (HVS), rhesus rhadinovirus (RRV) and 
murine herpesvirus 68 (MHV-68) (Neipel et al. 1998) (Table 1.2B). In 
terms of human herpesviruses, KSHV is most similar to Epstein-Barr 
virus (EBV). Recently, sequences of KSHV-like herpesviruses have 
been discovered in chimpanzees and in gorillas (Lacoste et al. 2000).
The rhadinoviruses as a group have expanded with the discovery of 
several new viruses that are more closely related to KSHV than HVS 
or EBV. Newly discovered viruses include retroperitoneal fibromatosis 
herpesvirus which were isolated from vascular fibroproliferative 
neoplasm present in two macaque species; Macaca nemestrina and 
Macaca mulatto (Rose et al. 1997) and Chlorocebus rhadinovirus 1 
(Greensill et al. 2000). Interestingly, retroperitoneal fibromatosis is 
histologically similar to KS in humans.
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Table 1.2A&B
The human herpesvirus family and subfamily
Herpesvirus genus Example viruses Associated human diseases
Alphaherpesvirus Herpes simplex virus type 1 Oral-facial herpes
Herpes simplex virus type 2 Genital herpes
Varicella-zoster virus Chicken pox, Shingles
Betaherpesvirus Cytomegalovirus Congenital disease, CMV retinitis
Human Herpesvirus 6 Febrile illness, exanthem subitum
Human Herpesvirus 7 Febrile illness
Gammaherpesvirus Epstein-Barr virus (EBV) Infectious mononucleosis (IM), 
Burkitts lymphoma (BL), 
Nasopharyngeal carcinoma 
(NPC), AIDS-central nervous 
system (CNS) lymphoma, post­
transplantation lymphoproliferative 
disease (PTLD)
Kaposi’s sarcoma- 
associated herpesvirus 
(KSHV)
Kaposi’s sarcoma (KS)
Multicentric Castleman’s disease 
(MCD)
Primary effusion lymphoma (PEL)
Source: (Timbury 1997)
KSHV-related herpesviruses
Virus Abbreviation Host species
Epstein-Barr virus EBV Humans
Herpesvirus saimiri HVS Squirral monkeys 
(New World primates)
Herpesvirus ateles HVA Spider monkeys 
(New World primates)
Alcelaphine herpesvirus AHV-1 Ruminants
Bovine herpesvirus 4 BHV4 Cows
Equine herpesvirus 2 EHV2 Horses
Murine herpesvirus 68 MHV68 Mice, Bank Vole
Retroperitoneal fibromatosis herpesvirus RFHVMn & 
RFHVMm
Old World primates
Rhesus monkey rhadinovirus RRV Old World primates
Adapted from (Boshoff 1999)
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1.5 Virus mediated gene delivery
1.5.1 Development
In 2000, the field of gene therapy became 10 years old (Mountain 
2000). Gene therapy aims to treat disease at the genetic level, thereby 
treating the cause, not the symptoms of disease. Gene therapy 
employs many different methods for the introduction of therapeutic 
DNA to human cells (Mountain 2000). Viruses that have been 
reverse-engineered as delivery vectors are commonly used. Types of 
viruses adapted for gene therapy include adenovirus, retrovirus 
(including lentiviruses), herpesviruses (Elliot and O'Hare 1999) and 
other less common viruses such as Sendai virus. These viruses 
share an important common feature of being engineered to be 
replication deficient; once infection has occurred the viruses do not 
possess the genetic information to replicate.
1.5.2 Lentiviral vectors
Lentiviruses are increasingly the most widely used type of gene 
delivery vector. They possess several advantages over other vectors 
including adenovirus, herpesviruses, vaccinia virus (Carroll and Moss
1997) and even over other members of the retrovirus family (Federico 
1990;Verma and Somia 1999).
Initial work on the use of lentiviruses as a vehicle for gene delivery 
concentrated on the use of a three-construct system. This consisted 
of a plasmid carrying all of the HIV-1 genes required for production of 
the virus particles, a plasmid carrying an envelope gene, vesicular 
stomatitis virus glycoprotein (VSVg) and a plasmid carrying the gene 
which would ultimately be expressed from the virus positioned with a 
promoter between two viral long terminal repeats (LTR) (Naldini et al.
1996).
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Lentiviruses offer greater scope for the infection of mammalian cells 
as they are able to infect both non-dividing and dividing cells (Fouchier 
et al. 1997). Retroviruses require cellular mitosis for the transport of 
viral nucleoprotein complexes into the nucleus, whereas lentivirus 
nucleoprotein complexes are specifically transported in the absence of 
mitosis (Fouchier et al. 1997).
These three plasmids are co-transfected into a packaging cell line, 
often HEK 293T, from which infectious particles are released. The 
system is shown in Fig 1.4. These HIV-1 based lentiviruses, when 
pseudotyped with an envelope coat protein (such as vesicular 
stomatitis virus glycoprotein, VSVg), can infect a broad range of cells 
including quiescent haematopoietic progenitor cells (CD34+, CD38-) 
(Akkina et al. 1996;Case et al. 1999) and quiescent primary fibroblasts 
(Reiser et al. 1996). The VSVg envelope was employed for this study, 
as it is able to enter a wide range of cells by means of endocytosis 
(Superti et al. 1987;Yamada and Ohnishi 1986). Comparison of 
methods has shown the efficiency of the lentivirus system. In tests on 
human B cell precursor acute lymphoblastic leukemia cells, 
transfection methods showed a maximum of 12% in Nalm-6 cells, 
whereas infection with a VSVg-pseudotyped lentivirus gave greater 
than 90% positive cells (Mascarenhas et al. 1998). The lentiviruses 
were based on the pHR CMV system developed by Naldini et al 
(Mascarenhas etal. 1998;Naldini etal. 1996).
Further work has aimed at the ultimate goal of the gene delivery 
systems: the treatment of human disease at the genetic level, 
commonly termed gene therapy. HIV-based lentiviruses have been 
used in studies for the treatment of cystic fibrosis (Goldman et al.
1997). Individual organs have also been the target of gene delivery, 
often with a view to treat diseases specific to them and attempts have 
included the liver and muscle as target areas (Kafri et al. 1997).
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Fig 1.4 -  HIV-1 based lentiviral vector production
Three plasmids are used to co-transfect 293T packaging cells.
In this instance, these three plasmids are VSVg (encoding the 
envelope protein), p8.91 (encoding HIV-1 genes required for virus 
production) and pHR-CMV (carries the gene to be packaged 
in the viruses).
Development of the lentiviral system has continued since its first use. 
Although highly efficient and to date safe, the use of human-tropic 
lentiviruses as the basis for a gene delivery system has raised 
concerns. Other systems have therefore been developed including a 
system based on simian immunodeficiency virus (SIV) (White et al.
1999). The HIV/SIVpack/G system uses components from both HIV 
and SIV viruses, and as there is low sequence similarity between the 
two viruses, there is a reduced risk of recombination (White et al.
1999).
Other work has concentrated on the further development of technical 
aspects. One of the problem areas of the lentivirus-based system is 
the requirement for multiple transfections of packaging cells, often 
triple-transfections. To improve this, stable packaging lines have 
been created that express one or several of the genes required for 
packaging (Carroll etal. 1994;Corbeau etal. 1996;Yu et al. 1996).
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1.6 Gene expression microarrays
1.6.1 Principles and development
Microarray technology developed using the principles of a common 
molecular biology technique: Southern blotting. Initially gene 
expression microarrays were constructed from cDNA and bound to a 
solid surface i.e. nitrocellulose membrane. Currently there are two 
main forms of gene expression microarray (GEM) available: cDNA 
arrays and oligonucleotide arrays. Both systems have advantages 
and disadvantages, often depending on the precise application they 
are being used for. Microarrays are a means of determining the 
expression patterns of thousands of different genes at the same time. 
Essentially, cDNA is created from cellular total RNA or mRNA and 
labelled either radioactively or with a fluorescent dye. These labelled 
probes are then hybridised to the array cDNA/oligo supported on a 
matrix. Scanners are used to convert the signals obtained from 
specific interactions on the arrays into measured hybridization signals 
from which software quantifies the levels of each hybridisation. From 
these data an expression pattern/profile is built up for the cell/tissue 
tested.
1.6.2 Applications
Gene expression microarray technology has been employed 
extensively in many different fields of biomedical research. Tissue 
profiling is now a major application of GEM and has allowed an insight 
into various malignancies including rhabdomyosarcoma (Khan et al.
1998) and T-cell lymphoma (Li et al. 2001). GEM technology also 
allows the identification of disease specific markers that can later be 
used in the diagnosis of particular diseases.
GEM technology has been applied to investigating the gene profile of 
endothelial cells under various conditions. The effect of physical 
stress on endothelial cells has been investigated such as laminar
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shear stress (Urbich et al. 2000) and blood circulation (Brooks et al.
2002). Microarrays have also been used to gain an insight into 
changes in gene expression in endothelial cells after challenge with 
various infectious agents including Chlamydia pneumoniae (Coombes 
and Mahony 2001) and KSHV (Poole et al. 2002). This technique has 
allowed important insight into the viral life cycle. The production of 
cDNA arrays of viral genes has been employed for viruses including 
KSHV (Jenner et al. 2001) and cytomegalovirus (CMV) (Chambers et 
al. 1999).
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1.7 Proteomics
1.7.1 Background
Proteomics, despite a recent drastic increase in the use of proteomics 
technologies, is not a new field. Proteomics is essentially an 
amalgamation of several different fields including mass spectrometry, 
chromatography, protein biochemistry and recent fields such as 
bioinformatics. The techniques of proteomics offer hope to areas of 
research previously impossible, as well as enhancing other more 
traditional areas (Abbott 1999;Pandey and Mann 2000).
1.7.2 Mass spectrometry
The applications of mass spectrometry in biological research have 
been steadily growing, and have recently expanded greatly. Mass 
spectrometry, in particular matrix assisted laser desorption ionization -  
time of flight mass spectrometry (MALDI-TOF) and electrospray 
ionization tandem mass spectrometry (ESI-MS) have found 
applications in the study of viruses (Thomas et al. 2000). MALDI-TOF 
MS and ESI MS/MS have gained other wide ranging uses, including 
structural biology, translational modification detection and drug 
discovery, because of their abilities to produce accurate protein 
molecular weight data, thereby allowing timely identification of 
unknown polypeptides.
1.7.2.1 Mass Spectrometry for the characterization of protein 
complexes
This is of particular use in the identification of protein-protein 
interaction studies. There are now an abundance of papers that 
couple the use of mass spectrometry to either chromatographical 
methods or immunoprecipitation for the purification of a protein 
complex that is then identified using mass spectrometry.
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Using proteomic techniques several groups have achieved purification 
and characterisation of protein complexes in both human cells and 
yeast. In human cells, these include the identification of a novel N- 
CoR complex (Underhill et al. 2000) and the protein complex of SV40 
large T antigen (Lanson Jr et al. 2000). A novel N-CoR complex 
which was found to contain members of the mammalian SW1/SNF 
complex and a co-repressor KAP-1 was purified from HeLa cell 
nuclear extracts using chromatography and mass spectrometry 
(Underhill et al. 2000). Affinity chromatography and MALDI were used 
to identify interaction partners of mouse brain profiling I and II, which 
are involved in the process of actin assembly. Immunoprecipitation 
methods have been used to identify interaction partners of human 
BcIXl, an apoptosis inhibitor protein (Gygi et al. 1999).
Proteomics has also allowed new insights into the interactions of yeast 
proteins. These include identification of members of splicing 
complexes (Gottschalk et al. 1999), protein complexes involved in 
motility (Winter et al. 1997), the identification of in vivo substrates of 
the chaperonin GroEL, (Houry et al. 1999), characterization of the 
yeast nuclear pore complex (Rout et al. 2000) and component analysis 
of the human CDC5L complex (Ajuh et al. 2000).
1.7.2.2. MALDl-TOFMS
Biological mass spectrometry is a biophysical technique that allows 
the identification of proteins, peptides and nucleic acids. It is often 
employed as the final step of proteomic techniques i.e. for 
identification of the members of a purified protein complex. Matrix 
assisted laser desorption ionization -  time of flight mass spectrometry 
(MALDI-TOF MS) can detect protein molecules at femtomole and 
subfemtomole levels, that in combination with its ability to analyse 
complex protein suspensions makes it highly adaptable and sensitive 
(Thomas et al. 2000). MALDI works by desorption and ionization of 
polypeptides mounted on a matrix, usually in aromatic organic acids
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(i.e. 4-methoxy cinnamic acid or 3-hydroxypicolinic acid) (Jackson et 
al. 2000), that leads to formation of a gas phase containing the 
peptides. This gas phase can then be directed to a mass analyser 
using electrostatic charge. In MALDI-TOF, the addition of a vacuum 
tube allows the ions to travel to the detector. The detector then 
calculates the mass of peptides based on the ion flight time. The 
resulting data are in the form of estimated peptide molecular weights 
from which a ‘peptide fingerprint’ is produced, which can be compared 
with databases for identification (Thomas et al. 2000). Prior to the 
development of MALDI and ESI-MS, it was not possible to achieve 
identification of polypeptides greater than 1-2kDa (Jackson et al.
2000). A typical protocol will run proteins captured by affinity 
chromatography on an SDS-PAGE gel, visualise bands by silver 
staining or Coomassie staining and excise the bands for digestion in 
trypsin. These proteolytic peptides are then subjected to MALDI-TOF 
MS and their relative masses determined. By searching databases it 
is possible to identify the selected proteins. Where identification of a 
protein is not possible, due to a mixed population of proteins, further 
analysis by tandem MS (MS/MS) may aid in their identification (Mann 
etal. 2001).
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1.7.3 The yeast two-hybrid system
The yeast two-hybrid system is a method of screening for protein- 
protein interaction partners. It is one of several yeast-based methods 
including yeast one-hybrid that tests for DNA-protein interactions and 
yeast three-hybrid that tests RNA-protein interactions. The yeast two- 
hybrid system provides a method for screening polypeptides (bait) 
against cDNA or genomic libraries (prey), and is based upon the 
mechanism of transcriptional activation. In a typical screening 
experiment, the polypeptide of interest is cloned into a plasmid, next to 
a DNA-binding domain from a transcription factor (often LexA). The 
cDNA or genomic library is cloned in frame next to an activation 
domain of the Gal4 yeast transcription factor. The plasmids are 
cotransfected into yeast carrying reporter gene constructs and 
nutritional selection markers (often LacZ and HIS3). If there is no 
interaction between bait and prey, the yeast cell will not survive in the 
absence of histidine and will not turn blue (LacZ-). Only in the 
presence of an interaction between a bait and prey polypeptide will the 
DNA-binding domain of LexA and the activation domain of Gal4 form a 
complex to allow transcriptional activation of the genes LacZ/HIS3. 
Cells containing this interaction will grow in the absence of histidine 
and appear blue. This method of screening is therefore not suitable 
for use with transcription factors/DNA-binding proteins. Advances in 
the yeast two-hybrid system have allowed it to be used for high- 
throughput screening of protein-protein interaction partners. Work 
presented later in this thesis, using a high-throughput yeast two-hybrid 
system, was performed in collaboration with Hybrigenics, Paris. Via 
these advanced methods, interaction maps have been created for 
Helicobacter Pylori (Legrain et al. 2000;Rain et al. 2001) and further 
advances include two-hybrid systems in bacteria (Legrain and Selig
2000) and the use of high-throughput systems in drug discovery 
(Legrain and Strosberg 2002).
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1.8 Aims of this thesis
This thesis is aimed at furthering our understanding of the LANA1 
protein in both its effects on disease relevant primary cells and its 
interactions with cellular proteins. A particular goal of this thesis was 
to study LANA1 at a cellular level, identifying true transcriptional 
targets of LANA1 and provide a global picture of the cellular 
interaction partners. To achieve this goal, several technical aims 
needed to be achieved.
Firstly, the development of lentivirus vectors for the delivery of LANA1 
to disease relevant primary cells for analysis by gene expression 
microarrays. I have aimed to develop the lentiviral system to deliver 
LANA1 to primary human endothelial cells, a cell type implicated as 
the target of KSHV infection and closely involved in the development 
of KS. With this method I aimed to achieve high levels of expression 
in primary cells, aiding in the analysis of the effects of LANA1 on the 
cellular transcriptome. To analyse the transcriptional effects of LANA1 
on a genome-wide scale, I employed gene expression microarray 
(GEM) technology.
Using this technology I determined the effects of LANA1 on the 
cellular transcriptome of primary endothelial cells. After delivery of the 
LANA1 using lentiviruses, RNA was extracted and compared with 
various controls to determine effects specific to LANA1.
Secondly, the development of protein chromatography and purification 
methods for the characterisation of a LANA1 native complex by mass 
spectrometry. To achieve this I used affinity chromatography and 
immunoaffinity purification coupled to mass spectrometry. The latent 
nuclear antigen (Rainbow et al. 1997) of KSHV is known to interact 
with several different proteins in vivo including p53 (Friborg et al.
1999), pRB (Radkov et al. 2000), RING-3 (Platt et al. 1999), HDAC, 
mSIN3A (Krithivas et al. 2000) and GSK-3P (Fujimuro et al.
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2003;Fujimuro and Hayward 2003). To discover the overall complex 
between LANA1 and these various proteins, I have undertaken 
purification and characterisation of the LANA1 protein complex. 
Previous work has shown that using a combination of protein 
purification techniques it is possible to purify a native nuclear protein 
complex and characterise its individual components using mass 
spectrometry. For the purification of the LANA1 complex, BC-3 cells 
(a KSHV positive, EBV negative PEL line) were selected as they show 
high expression of LANA1 and have suitable growth characteristics for 
large-scale culture. During the purification of a protein complex the 
best selection method for an individual protein is affinity 
chromatography. This method of chromatography employs a specific 
antibody permanently cross-linked to a stable media i.e. sepharose 
which can be re-used for many separate purifications. This method 
allows the specific selection of one protein from a background of 
thousands of irrelevant cellular proteins. For LANA1 a specific rat 
monoclonal was selected and used to create an affinity column 
(Kellam et al. 1999). A negative column was also created as a control 
in purifications.
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Chapter 2 Materials and Methods
2.1 Standard methods
2.1.1 Celt culture, transfections & lysis
HEK-293 and HeLa cells were maintained in DMEM + 10% v/v FCS + 
penicillin/streptomycin (5pg/ml) (Gibco BRL, UK) at 5% CO2 . The PEL 
cell line BC-3 was maintained at between 105—106 cells/ml in RPMI + 
10% v/v FCS + penicillin/streptomycin (5pg/ml). For large-scale 
immunoaffinity purification BC-3 cells were washed in PBS and lysed 
in modified RIPA buffer (50mM Tris pH 8.0, 150mM NaCI, 1% v/v 
IGEPAL CA-630, 0.1% w/v SDS, 1mM PMSF, 1/100 mammalian 
protease inhibitor cocktail (Sigma)) with rotation at 4°C for 1h. 
Lysates were centrifuged at 13,000rpm for 30min in a Beckmann high­
speed centrifuge and stored at -80°C. 1x105 HeLa cells were
transfected with either 5pg of pHR CMV emp or pHR CMV LANA1 
using FuGene 6 according to manufacturer’s instructions (Roche 
Diagnostics, Mannheim, Germany). Cells were lysed in RIPA buffer 
(50mM Tris pH 8.0, 150mM NaCI, 1% v/v IGEPAL CA-630, 0.5% w/v 
sodium deoxycholate, 0.1% w/v SDS, 1mM PMSF) 48hrs later and 
diluted to 50% RIPA with ddH20 prior to co-im mu noprecipitation. CB3 
and CB7 cells (a kind gift from B.Chabot, Faculte de Medecine, 
Universite de Sherbrooke, Canada) were maintained in MEM alpha 
medium (Gibco BRL) + 10% v/v FCS (Helena Biosciences, UK) + 
penicillin/streptomycin (5pg/ml) (Gibco BRL). Transfection of CB3 
cells is described in the section TRAP assay.
2.1.2 PCR
The polymerase chain reaction (PCR) was used for the amplification 
of DNA fragments or genes for cloning. PCR was performed on a 
Primus 96-Plus thermocycler (MWG Biotech, UK) under conditions 
suitable for the particular sequence of DNA being amplified. 
Polymerase used included Taq polymerase (Promega, Southampton,
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UK), Pfu (Promega) and Expand High-Fidelity (Roche). A typical 25pl 
reaction mixture would include: 100ng each primer, 2.5^1 x10 PCR 
buffer, 1pl polymerase, 1pl of 10mM dNTPs, target DNA and water to 
25^1. A typical amplification protocol would be: 30cycles of 95°C 1 min, 
64°C 1min, 72°C 4mins followed by 1 cycle 72°C 10mins.
2.1.3 Bacterial transformation
Various cell types were used in the course of this thesis. In general 
the protocol for electroporetic transformation was the same. Cells 
were thawed on ice and 2-5jnl of DNA was added. Cells were shocked 
at 200ohms, 25mF capacitance and 2kV. Time constants were in the 
range of 40-50. After electroporation LB was added and cultures were 
incubated at 37°C with shaking for 1 hr. Cultures were then inoculated 
onto LB+Amp plates and incubated at 37°C overnight.
2.1.4 Agarose gel electrophoresis
Gels were made from agarose (AMRESCO, UK) at between 1-2% in 
0.5xTAE buffer (2M Tris pH 8.0, 5mM EDTA, 5.71% v/v Glacial Acetic 
Acid) and melted in a microwave. 2pl of Ethidium bromide was added 
(Sigma) per 100ml, gels were poured into casting tanks and run in 
0.5xTAE buffer using a mini gel migration trough (MUPID-21). 
DNA/RNA was visualised and photographed using a Kodak camera 
system.
2.1.5 DNA gel extraction
Bands selected for gel extraction were cut with a clean scalpel and 
transferred to a 1.5ml eppendorf. Depending on weight the gel 
fragment was resuspended and melted by incubation in a 50°C water 
bath. 1 gel volume of isopropanol was added and the mix was applied 
to a QIAquick column. Following washes the DNA fragments were 
eluted into a fresh eppendorf and frozen at -20°C for storage.
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2.1.6 DNA ligation
Ligations were performed at 16°C overnight (O/N) followed by 
electroporation into KC-8 cells. Following electroporation cells were 
incubated in Luria Broth (LB) lacking ampicillin (Amp) and then plated 
onto LB + Amp plates. Plates were incubated O/N at 37°C. 20 
colonies were selected and 3ml of LB + Amp was inoculated and 
incubated with shaking at 37°C for 8hrs. Plasmid DNA was extracted 
from 1.5ml of each culture using a miniprep kit (Promega). Positive 
clones of pHR CMV LANA1 were selected and confirmed by restriction 
enzyme digest mapping. A candidate was selected and its sequence 
confirmed by DNA sequencing.
2.1.7 TA cloning
TA cloning of fresh PCR products was performed using the pcDNA 
3.1/V5-His TOPO TA cloning kit (Clontech, UK). PCR was performed 
and products were subjected to agarose gel electrophoresis. Bands 
for cloning were rescued from the gel using a Qiagen gel extraction kit 
(Qiagen, Hilden, Germany). 2pl-4pl of the gel extracted PCR product 
was added to 1pl of salt solution and 1pl of pcDNA 3.1/V5-His TOPO 
and adjusted to a final volume of 5pl with sterile H2O. The reaction 
was mixed and incubated for 5-15mins at RT. Vials of One Shot™ 
Chemical transformation cells were thawed on ice and 2jnl of the 5jul 
cloning reaction was added, mixed gently and incubated on ice for 15- 
30mins. The cells were heat-shocked at 42°C for 30secs and 
transferred to ice. 250jal of pre-warmed SOC (2% w/v Bacto 
Tryptone, 0.55% w/v Bacto Yeast Extract, 10mM NaCI, 10mM KCI) 
(Qiagen, Hilden, Germany) was added to each vial followed by 
incubation of 1 hr at 37°C with shaking. The cultures were then spread 
onto LB+Amp plates and incubated overnight at 37°C.
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2.1.8 Plasmid preparation and purification
The small-scale purification of plasmid DNA was performed using 
Promega minipreps kits. The large-scale purification of plasmid DNA 
was performed using Maxi™ or Mega™ kits.
For the preparation of minipreps, colonies were selected from 
LB+Amp streak plates and 3ml of LB+Amp culture was inoculated with 
a single colony. Cultures were grown at 37°C for 6-7 hours with 
shaking. 1.5ml of the cultures was centrifuged for 5mins at 5,000rpm 
in a bench top centrifuge. The culture pellets were resuspended, 
lysed and neutralised after alkaline protease treatment, according to 
the kit. The lysates were centrifuged through a spin column and 
captured plasmid DNA was washed and eluted into Nuclease-free 
H2O. DNA was either further analysed by restriction enzyme analysis 
and agarose electrophoresis or stored at -20°C until used.
For Maxi™ and Mega™ preps 3ml cultures were grown as above, and 
then used to inoculate 500ml of LB+ Amp that was incubated 
overnight at 37°C with shaking. For high copy number plasmids 
500ml of culture was used with a QIAGEN-tip 2500, but for low-copy 
number plasmids, 2500ml of culture was used. The following day, 
cultured bacteria were pelleted by centrifugation and either stored at -  
20°C until processing or used immediately. Cell pellets were 
resuspended lysed and cleared using reagents from the appropriate 
kit. A pre-equilibrated QIAGEN-tip column was used to capture the 
plasmid DNA. The DNA was eluted, precipitated, air dried and 
redissolved in a suitable volume of TE buffer or MilliQ dh^O. The 
quantity of DNA was determined using a UV spectrophotometer.
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2.1.9 Restriction enzyme analysis
DNA was digested with restriction enzymes to determine correct 
orientation and size of fragments. Digestions were normally 
performed in 10pl at 37°C. A typical mix was 1-5pl of miniprep, 2 units 
of enzyme (1pl), 1pl of BSA and 1pl of 10x buffer. Restriction 
enzymes were obtained from either Promega or New England Biolabs 
and used with the buffers supplied by the manufacturer.
2.1.10 Cloning for this thesis
wt LANA1 in pHR CMV constmct, hnRNPA1/UP1 and GSTs 
Due to a lack of suitable restriction sites within LANA1, amino and 
carboxyl terminus of LANA1 were prepared separately and ligated into 
the pHR CMV vector. The N-terminus of LANA1 (aa1-282) was 
amplified from the parental vector IgH P/E 73cycK13 using PCR with 
the primers (Forward) aaagtacttgatatcgccaccatggcacccccgggaatgcgc 
& (Reverse) catggctgtgtcatcacccca. The PCR product was run on a 
1% agarose gel and the LANA1 band (850bp) was recovered by gel 
extraction (Qiagen). Aliquots of the LANA1 fragment were digested 
with BamHI and EcoRV in preparation for ligation. Restriction digests 
were run on a 1% gel and the digested LANA1 fragment (aa1-275) 
was recovered by gel extraction (Qiagen).
The LANA1 fragment (aa275-1162) was prepared by digestion of the 
parental vector IgH P/E 73cycK13 with BamHI. The BamHI cuts at 
amino acid 275 in LANA1 and beyond the carboxyl terminus of 
LANA1. After digestion the fragment (around 4kb) was recovered by 
gel extraction (Qiagen) and digested with Sfol (2 units) (New England 
Biolabs) to blunt end the carboxyl terminus. The cut site is situated 
after the stop codon of LANA1 and before the start of the vcyclin 
transcript. The final fragment was recovered by gel filtration (Qiagen).
For preparation of the vector, 15pg of lentivirus vector pHR CMV LacZ 
(a kind gift from Prof. M.Collins, Windeyer Institute, UCL) was cut with
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BamHI (4 units) (Promega) and Xhol (4 units) (Promega) that 
removes the LacZ insert. The restriction mix was run on a 1% 
agarose gel and the backbone was recovered using a gel extraction 
kit (Qiagen). Approximately 2pg of the backbone was blunted using 
Klenow (22°C 10 mins, 65°C 15 mins) (Promega). After blunting, the 
vector was dephosphorylated using calf intestinal alkaline 
phosphatase (Boehringer Mannheim) and again gel purified.
Ligations were performed at 16°C overnight (O/N) followed by 
electroporation into KC-8 cells. Following electroporation cells were 
incubated in Luria Broth (LB) lacking ampicillin (amp) and then plated 
onto LB + amp plates. Plates were incubated O/N at 37°C. 20 
colonies were selected and 3ml of LB + amp was inoculated and 
incubated with shaking at 37°C for 8hrs. Plasmid DNA was extracted 
from 1.5ml of each culture using a miniprep kit (Promega). Positive 
clones of pHR CMV LANA1 were selected and confirmed by restriction 
enzyme digest mapping. A candidate was selected and its sequence 
confirmed by DNA sequencing.
GST-LANA1 3-263 was created by cutting pHR CMV-LANA1 with 
Smal (1 unit) and A/col (1 unit) and ligating the fragment into pGEX 
6P-1. GST-LANA1 932-1162 was created by PCR using the primers 
ttgatatcggatccgccaccatggaggagcaggaggtggaaga (forward) and 
cggaattcgctcgagctattatgtcatttcctgtggaga (reverse). The PCR product 
was cut using BamHI (1 unit) & Xho\ (1 unit), cloned into pHR CMV 
and then subcloned using BamHI & XAol sites into pGEX 6P-1. GST- 
LANA1 803-981 and GST-LANA1 982-1113 were created as 
previously described (29).
GST-hnRNP A1 was created by PCR from a human foetal cDNA 
library using the primers:
cgagaggagctgggatccggtatgtctaagtcagagtctcctaaa &
gctgccctcgagtccttaaaatcttctgccactgccatagct. UP1-HA was created 
using the hnRNP A1 forward primer and the reverse primer that
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introduces a carboxyl terminal HA tag: 
cgcctcgagctaagcgtagtctgggacgtcgtatgggtatcgacctctttggctggatga. Both 
hnRNP A1 and UP1-HA PCR products were TA cloned into pcDNA
3.1 A/5 HIS TOPO vectors (Invitrogen, Groningen, The Netherlands). 
pcDNA 3.1 A/5 HIS TOPO hnRNP A1 was digested with BamHI (1 
unit) & Xho\ (1 unit) and ligated into pGEX 6P-1. Sequences of all 
constructs created were verified on a Beckmann sequencer.
2.1.11 Primary microvascular endothelial culture
Primary human microvascular endothelial cells were obtained from 
male or female breast tissue (a kind gift from Dr Mike O’Hare, Ludwig 
Institute of Cancer Research, UCL). Cells were washed with 10mls of 
pre-warmed DMEM + 10% v/v FCS. The wash media was discarded 
and 20mls of pre-warmed Trypsin-EDTA was added. Flasks were 
incubated until rounding of cells was observed under an inverted 
microscope (1-2mins). Pre-warmed DMEM + 10% v/v FCS (25- 
30mls) was added into each flask. Trypsinisation of cells was 
performed as quickly as possible to maintain the stability and quality of 
the cultured primary endothelial cells. Cell suspension was removed 
by gentle pipetting to wash the flask surface and transferred to a 15ml 
Falcon tube. The suspension was centrifuged for 5mins at 22°C at 
1200rpm. The cell pellet was resuspended in 10mls of pre-warmed 
DMEM + 10% v/v FCS +penicillin/streptomycin (5pg/ml). The washing 
step was repeated. After centrifugation the wash media was gently 
removed with a pipette and cells were resuspended in 8mls of EGM-2 
(Clonetics) + 10% v/v FCS (3 x 2mls for continuing culture and 1 x 
2mls for freezing). 3 x 2mls of cell suspension was added into 3 x 
18mls of pre-warmed EGM-2 + 10% v/v FCS + penicillin/streptomycin 
(5pg/ml) in 3 x pre-warmed 75cm2 flasks. Cultures were then 
incubated at 37°C in 5% CO2 . 3 x 600pl of cell suspension was added 
into 3 x cryovials containing 600pl of freezing solution (10ml stock = 
1.8ml DMSO + 8.2ml of DMEM+20% v/v FCS) (final concentration of
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10% v/v DMSO). Cryovials were placed at -80°C then transferred into 
liquid nitrogen for long term storage.
2.1.12 Immunofluoresence assay (IFA)
Cells were prepared on glass slides (after storage in 100% ethanol 
slides were washed twice in PBS/DMEM) in 6 well plates. Infections 
were carried out on cells grown overnight on slides. Cells were 
washed (x3) in ice cold PBS. 1 ml of 1:1 methanol:acetone (chilled to 
-20°C) was added to each well for fixation and slide plates were 
incubated at -20°C for 5mins. Cells were washed (x3) in ice cold 
PBS. 1 ml of blocking buffer (3% w/v BSA, 1 mM MgCfe, 1 mM CaCfe in 
PBS) was added to each well and incubated for 1 hr at 22°C. Cells 
were washed (x3) in ice cold washing buffer (1/10 dilution of blocking 
solution in PBS). Slides were removed from the plates and 
transferred to stands to allow addition of antibodies. Primary antibody 
(LN53/LN72) was added diluted in wash buffer (1:100 - 1:400). Slides 
were incubated with antibodies for 2hr at 22°C. Cells were washed 
(x3) in ice cold washing buffer. Secondary antibody (FITC-conjugated 
rabbit anti-rat IgG [DAKO]) was diluted in wash buffer (1:120/1:240) 
and incubated on cells for 40mins-1hr at 22°C. Cells were washed 
(x3) in ice cold washing buffer. Coverslips were mounted on slides 
using 20pl of 100% glycerol or FITC preservative solution (DAKO). 
Slides were observed on a fluorescent microscope (NIKON) or stored 
at 4°C in silver foil.
2.1.13 Tube formation assay
1ml of Matrigel (Clonetics) was aliquoted per well, using cooled 
pipettes, into a 24 well plate. The Matrigel was allowed to set at room 
temperature. Primary endothelial cells in EGM-2 were added onto the 
Matrigel and observed at various times post-seeding for the formation 
of tubes on the gel surface.
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2.1.14 FACS analysis
For a typical experiment in a 6-well dish cells were washed twice in 
PBS and then trypsinised. Fresh media (DMEM + 10% v/v FCS) was 
added and cells were transferred to FACS tubes. Cells were washed 
twice with PBS and resuspended in a suitable volume of PBS (100^1 
per well of a six well dish). Cells were vortexed prior to analysis on a 
Beckmann FACS calibur machine. Uninfected cells were used to 
adjust the FSC/SSC of cells to be analysed. Cells were then run 
through the FACS and either 5000 or 10000 events were collected. 
Overlays of infected vs uninfected controls were created using 
CellQuest software. In some infections cells were gated and the 
percentage of infection of gated populations was calculated.
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2.2 Protein Biochemistry
2.2.1 Western blotting
Protein was separated on 6% or 15% SDS-PAGE gels depending on 
the size of the protein to be detected. Protein was transferred to 
Hybond P membrane (Amersham Pharmacia Biotech, 
Buckinghamshire, UK) and blocked with 5% w/v milk powder in PBS + 
tween 20 (Sigma, St Louis, MO). LANA1 was detected using anti- 
LANA1 rat monoclonal (LN53) (1:1000), UP1-HA was detected using 
an anti-HA mouse monoclonal antibody (Cambridge Biosciences, UK) 
(1:1000) and hTERT was detected using anti-hTERT rabbit polyclonal 
(1:500) (Santa Cruz Biotechnology Ltd.). hnRNP A1 was detected 
using anti-hnRNP A1 mouse monoclonal (2D32) (1:500) (a kind gift 
from S.Murakami, Kanazawa University, Japan) or anti-hnRNP A1 
(4B10) (1:500) (a kind gift from G.Dreyfuss, Howard Hughes Medical 
Institute). Secondary antibodies used were HRP-conjugated rabbit 
anti-rat IgG (Santa Cruz Biotechnology Ltd.), HRP-conjugated goat 
anti-mouse IgG (Jackson Immunoresearch Laboratories Inc, PA, USA) 
and HRP-conjugated goat anti-rabbit IgG (Santa Cruz Biotechnology 
Ltd.). Bands were visualised using ECL+ (Amersham Pharmacia 
Biotech).
2.2.2 Cell culture, lysis & disruption
BC-3 cells were maintained in RPMI-1640 (Gibco BRL) supplemented 
with 10% v/v FCS and penicillin/streptomycin (5jig/ml) (Gibco BRL). 
Cell densities were maintained at 105 -  106/ml. To harvest cells, 
cultures were centrifuged at approx. 850g (ref) (4°C) and washed 
twice in ice-cold PBS. Cell pellets were resuspended in a suitable 
volume of lysis buffer. For example, low salt buffer (50mM Tris pH
8.0, 50mM NaCI, 1% v/v IGEPAL-CA630, 1mM PMSF, 0.5% v/v 
protease cocktail [Sigma] in dH20), buffers up to 2x107 cells/ml so for 
2x108 cells, 10ml of this lysis buffer was used. Cell suspension was 
sonicated for 6 x 10secs, with 10secs cooling in between, followed by
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incubation for 1 hr with rotation at 4°C. Cell lysates were centrifuged 
for 30mins at 15,000g (4°C). Supernatant was removed and 
transferred to a fresh 15ml Falcon tube. At this stage samples were 
frozen at -80°C. Samples were thawed, filtered through a syringe 
fitted with a 0.22pm filter and diluted 1:5 in MilliQ dH20 (final 10mM 
Tris) and adjusted to pH 7. Samples were then ready for binding to 
the antibody columns.
2.2.3 Yeast two-hybrid screen (collaboration with Hybrigenics)
The yeast two-hybrid assay was used to identify proteins interacting 
with the amino terminus of LANA1. Protein target sequences and 
cDNA plasmids were provided by UCL and yeast two-hybrid screening 
was performed at Hybrigenics. Amino acids 1-337 of LANA1 and 
amino acids 893-1129 of LANA1 (see Fig 2.1 A & B) were cloned as a 
C-terminal LexA fusion protein in the pB27 plasmid. The library used 
for screening was generated from random primed human placental 
mRNA. The cDNA was cloned into the pP6 plasmid derived from 
pACT2 and transformed into E.coli DH10B cells. The library was 
transformed into yeast and 10 million clones were collected, pooled 
and stored at -80°C. Screening was performed to obtain a minimum 
of 50 million tested interactions. The screening conditions were 
optimised for the amino terminus of LANA1. LacZ activity was 
measured using a semi-quantitative Z-Gal overlay assay for all 
selected clones. The inserts of positive clones were amplified by PCR 
and sequenced at their 5’ and 3’ junctions using a PE3700 sequencer. 
Sequences were identified by the GenBank database. Clones 
obtained in different screens against the same library were discounted 
as false positives.
2.2.4 In vitro pulldowns
Briefly, GST fusion protein constructs were transfected into either BL- 
21 (Promega) or FB-810 (Cancer Research UK) cells and colonies 
were inoculated into a 50ml LB+Amp culture and incubated overnight
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at 37°C with shaking. Cultures were added to 450ml LP+Amp and 
incubated for a further 3hrs. IPTG was added to the cultures (final 
1mM) and incubated at 30°C for 2-3hrs. Cultures were centrifuged 
and pellets were resuspended in 5ml PBS + lysozyme + PMSF (final 
0.1 mM) and incubated on ice for 20-30mins. 250pl of 20x Triton-X 
was added and sonicated followed by centrifugation. Cleared lysates 
were either frozen at -80°C or incubated with GST beads (Amersham 
Pharmacia Biotech) for 1 hr at 4°C with rotation. Beads were washed 
extensively in PBS and used in binding assays or stored at -20°C. In 
vitro cleavage of hnRNP A1 was performed according to 
manufacturers’ protocol. GST-hnRNPA1 purified as above was 
incubated in cleavage buffer with Precission Protease (Amersham 
Pharmacia Biotech). Cleaved recombinant hnRNP A1 was collected 
in the supernatant and incubated with the bank of GST-LANA1 
proteins in a buffer previously shown to allow hnRNP A1 telomere 
binding (Dallaire et al. 2000).
2.2.5 Co-immunoprecipitations
BC-3 cells used in small-scale co-immunoprecipitation assays were 
lysed in modified RIPA buffer (50mM Tris pH 8.0, 150mM NaCI, 1% 
v/v IGEPAL CA-630, 0.1% w/v SDS, 1mM PMSF, Sigma Protease 
Cocktail) for 1h at 4°C with rotation, centrifuged for 10min at 
13,000rpm 4°C and stored at -80°C. 5jng of anti-LANA1 or control 
antibody was incubated with lysates for 2hr with rotation. 20pl of 
protein G beads (50:50 slurry) (Amersham Pharmacia Biotech) were 
added and incubated O/N at 4°C. Beads were washed twice in 50% 
modified RIPA buffer for 5min with rotation and bound proteins eluted 
by boiling in 20pl of 2x Laemmli loading buffer (200mM EDTA, 50% 
v/v glycerol, 0.2% w/v Xylene cyanole, 0.2% w/v Bromophenol Blue). 
1x106 HeLa cells were transfected with either 5pg of pHR CMV emp 
or pHR CMV LANA1 using FuGene 6 according to manufacturer’s 
instructions (Roche Diagnostics, Mannheim, Germany). Cells were 
lysed in RIPA buffer (50mM Tris pH 8.0, 150mM NaCI, 1% v/v
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IGEPAL CA-630, 0.5% w/v sodium deoxycholate, 0.1% w/v SDS, 
1mM PMSF) 48hrs later and diluted to 50% RIPA with ddH20  prior to 
incubation with 5jng of LANA1 antibody. 20jnl of protein G beads 
(Amersham Pharmacia Biotech) were added and incubated O/N at 
4°C. Immune complexes were washed in 50% RIPA and protein 
eluted in 2x Laemmli loading buffer.
2.2.6 Telomeric Repeat Amplification Protocol (TRAP) assay
5x105 CB3 cells (a kind gift from B.Chabot) were transiently 
transfected in 24-well plates with 6jil of DMRIE-C (a low toxicity lipid 
transfection reagent) and 2pg of pcDNA/V5-HIS TOPO UP1-HA per 
well. Cells were lysed in CHAPS buffer (+RNasin) and lysates 
equivalent to 5x105 cells were incubated with either GST alone or 
GST-LANA1 (982-1113) overnight at 4°C with rotation. Complexes 
were washed in CHAPS buffer and an aliquot was used to perform a 
TRAP assay to detect telomerase activity (TRAPeze)(Intergen, UK). 
2% and 0.2% of the unbound lysates (FT) and 10% and 1% of the 
bound protein (PD) was used in the TRAP assay. Dilutions of FT and 
PD were used to discount the possibility of contaminating inhibitors of 
telomerase activity. Products were amplified as per the 
manufacturer’s instructions (Intergen). Controls included heat 
treatment, lysis buffer only (CHAPS) and a telomerase positive 
control. PCR products were separated on a 12.5% non-denaturing 
polyacrylamide gel and stained with CYBR Green (Molecular Probes, 
UK) for 15min at a 1 in 10,000 dilution. Images were detected on a 
Storm Scanner (Amersham Pharmacia Biotech).
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2.2.7 Protein yield determination (BCA assay)
A BCA assay system was purchased from Pierce and used to 
determine concentration of proteins in various buffers. Standards 
were prepared using BSA (Sigma, St Louis, MO) in Low salt buffer, 
RIPA [RadiolmmunoProtection Assay] and PBS + 0.1% v/v sodium 
azide (from 10mg/ml or 20mg/ml at 0.6 step dilutions). 5^ il of each 
standard was added to a 96 well plate with 5pl of each sample and a 
5jnl blank (RIPA/Low salt buffer or PBS + 0.1% v/v sodium azide). On 
later experiments an internal control of a known concentration of BSA 
was used. Assay reagents A and B were prepared at a 1:50 
concentration, respectively. The assay plate was incubated at 37°C 
for 30mins and read at 540nm in a 96-well spectrophotometer.
2.2.8 Antibody purification
To prepare a negative control column, Rat IgG (10mg) technical grade 
antibody was purchased from Sigma. A 5ml HiTrap Protein G HP 
column (Amersham Pharmacia Biotech) was equilibrated in 20mM 
Sodium Phosphate pH 7.0. 5mg of rat IgG was diluted 1:5 in 20mM 
Sodium Phosphate pH 7.0 and circulated on the column to allow 
binding. Bound antibody was eluted using 100mM glycine pH 2.7. 
1ml fractions were collected and pH neutralised using 1M Tris pH 8.0. 
Fractions 7-12 were desalted on PD-10 columns (Amersham 
Pharmacia Biotech) and dried by vacuum centrifugation. Purified Rat 
IgG was then resuspended in PBS + 0.1% v/v sodium azide. Antibody 
concentration was determined by BCA assay (4.3mg/ml in 1.5ml = 
6.45mg).
2.2.9 Affinity column construction
To construct LANA1 specific affinity columns anti-LANA1 rat 
monoclonal antibodies were crosslinked to cyanogen bromide 
activated (CNBr) sepharose 4B media (Amersham Pharmacia 
Biotech). 5mg (2.4ml) of LN53 (calculated by BCA assay) antibody 
was dialysed against 1 litre of coupling buffer (0.1M NaHC03 pH 8.0 +
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0.5M NaCI) for 6hrs at 4°C. Fresh coupling buffer was added and the 
antibody was dialysed O/N at 4°C with gentle stirring. To prepare the 
CNBr-Sepharose 4B beads for coupling, 0.5g were suspended in 5mls 
of 1 mM HCI. Clumps were removed by gentle mixing. This slurry was 
added onto a glass-sintered column (15mls) and washed in a total of 
100mls of 1mM HCI. 1ml of CNBr-Sepharose 4B slurry was added to 
2.4mls of dialysed LN53 and incubated at 4°C O/N with gentle 
shaking. The next day a glass-sintered column (15mls) was washed 
with 10mls of coupling buffer. The column was closed and a further 
2mls of coupling buffer was added, followed by the overnight coupling 
reaction (LN53 + CNBr-Sepharose 4B). The column was washed 
through with 10 volumes of coupling buffer, which was collected for 
binding efficiency calculation. The remaining active sites on the 
beads were blocked by 1 hr incubation in 0.1M Tris pH 8.0. Fresh 
0.1M Tris pH 8.0 was added and incubated for a further 1 hr. Beads 
were then washed in 10m!s 0.1M acetate buffer + 0.5M NaCI followed 
by 10mls 0.1M Tris pH 8.0 + 0.5M NaCI. This process was repeated 
for 4 cycles. Finally beads were stored at 4°C in preparation for 
column packing.
A negative column was prepared in a similar manner, except that Rat 
IgG antibody (Sigma) was purified using a 5ml protein G column 
(Amersham Pharmacia Biotech). 5mg of purified rat IgG (1.162ml rat 
IgG + 1.234ml PBS + 0.1% v/v sodium azide) was dialysed against 
1 litre of coupling buffer (6hrs then replaced buffer for O/N), then 
coupled to CNBr-Sepharose 4B using the same protocol. Columns 
were packed at 1 ml/min using a dialysis pump at 4°C. Columns were 
packed in 10mM Tris pH 8.0 and then flushed with 20% ethanol for 
storage.
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2.2.10 AKTA FPLC system operation -  affinity columns
Columns were attached to an AKTA FPLC system and equilibrated 
with buffer (10mM Tris pH 8.0) until baselines were stable. Samples 
were then circulated through the columns at a suitable flowrate 
(0.5ml/min), usually overnight. Unbound protein was removed using 
extensive washes of buffer followed by elution of bound proteins in 
100mM glycine pH 2.7. 1ml fractions were collected and equalised 
with 1 OOjliI of 1M Tris pH 8.0. Fractions were then frozen in 
preparation for desalting and concentration. 1ml aliquots were thawed 
and diluted to 2.5mls with MilliQ dH20. PD-10 desalting columns were 
equilibrated with 25ml MilliQ dH20 and samples added. Flowthrough 
was discarded and protein eluted in 3.5mls of MilliQ dH20. Samples 
were then centrifuged O/N in vacuum conditions to dry protein. 
Protein was then resuspended in lysis buffer and stored at -80°C for 
gel electrophoresis. Identical protocols were followed for both anti- 
LANA1 (LN53) and control columns (Rat IgG).
2.2.11 Immunoaffinity purification
For immunoaffinity purification, BC-3 cells were washed in PBS and 
lysed in modified RIPA buffer (50mM Tris pH 8.0, 150mM NaCI, 1% 
v/v IGEPAL CA-630, 0.1% w/v SDS, 1mM PMSF, Sigma Protease 
Cocktail) with rotation at 4°C for 1h. Lysates were centrifuged at 
13,000rpm for 10min in a Beckmann high-speed centrifuge, filtered 
through a 0.45pm filter and stored at -80°C. To construct LANA1 
specific and control affinity media, 5mg of anti-LANA1 rat monoclonal 
antibody (LN53) or rat IgG (Sigma, St Louis, MO) were crosslinked to 
cyanogen bromide (CNBr) activated sepharose 4B media according to 
the manufacturer’s protocol (Amersham Pharmacia Biotech, 
Buckinghamshire, UK).
For large-scale immunoaffinity purification, 5mg of anti-LANA1 
antibody and rat IgG cross linked to CNBr activated sepharose 4B 
media were incubated with BC-3 cell lysates (diluted to 50% RIPA with
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ddH20) overnight followed by washing in buffer A (25mM Tris pH 8.0, 
75mM NaCI, 0.5mM PMSF) and elution of bound proteins in 100mM 
glycine at pH 2.7. Eluted protein was desalted using PD-10 columns 
(Amersham Pharmacia Biotech, Buckinghamshire, UK) and 
centrifuged overnight (O/N) in vacuum conditions to dryness. Proteins 
were then resuspended in modified RIPA lysis buffer (50mM Tris pH
8.0, 150mM NaCI, 1% v/v IGEPAL CA-630, 0.1% w/v SDS, 1mM 
PMSF, Sigma Protease Cocktail) and stored at -80°C for gel 
electrophoresis. Identical protocols were followed for both anti- 
LANA1 and control experiments. Elutes were separated by 10% SDS- 
PAGE. Proteins were visualised using Coomassie brilliant blue R-250 
staining (BDH laboratories, UK). Bands were excised from the gel, 
transferred to siliconised tubes and stored at -20°C prior to sample 
preparation for mass spectrometry.
2.2.12 SDS-PAGE for MALDI-TOF/Nano HPLC
10% gels were poured in a 10cm x 10cm gel (Biorad) and samples 
loaded. Gels were run at 200V for 5-6hrs and transferred to a ‘clean 
room’ for staining and cutting. Gels were stained in Coomassie 
Brilliant Blue (CBB-R250) [40% v/v Methanol, 10% v/v acetic acid] 
overnight with rocking followed by destaining over 96hrs [40% v/v 
Methanol, 1% v/v acetic acid]. Gels were scanned on a Biorad flatbed 
scanner. Specific polypeptides were selected and prepared for 
cutting.
2.2.13 MALDI-TOF MS, MALDI-LIFT/PSD MS/MS & nano-HPLC- 
ESI-CID MS/MS
Mass spectrometry was performed in collaboration with the Ludwig 
Proteomics group at the Lugwig Institute for Cancer Research and 
later at the Wolfson Institute for Biomedical Research. Proteins in the 
excised gel bands were digested using a similar protocol as published 
elsewhere (Gharbi et al. 2002). Briefly, gel pieces were treated using 
a solution of DTT to reduce protein disulphide bridges (Sigma, St
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Louis, MO) prior to alkylation of free cysteines using iodoacetamide 
(Sigma, St Louis, MO). Proteins were then digested overnight at 37°C 
using 50ng modified sequencing grade trypsin (Promega, 
Southampton, UK) per gel band. Following in-gel digestion peptides 
were recovered using three extractions in 50% v/v acetonitrile, 5% v/v 
TFA, before complete evaporation in a vacuum centrifuge. The dried 
tryptic digests were stored at -20°C.
Peptides from the digests were first analysed by MALDI-TOF MS, 
which was performed upon a Bruker Ultraflex (Bruker Daltonics, 
Bremen, Germany), a-cyano-4-hydroxycinammic acid (HCCA, Sigma) 
and 2,5-dihydroxybenzoic acid (DHB, Bruker Daltonics) were used as 
MALDI matrices. Peptides were resuspended in 5pl 0.1% v/v formic 
acid and an aliquot of 0.5jnl was mixed on-target with 1 jlxI matrix 
solution before drying and introduction to the mass spectrometer. 
Peptide mass fingerprinting was carried out using DHB, which was 
prepared as a saturated aqueous solution.
The mass spectrometer was externally calibrated with the 
Sequazyme™ calibration mixture 2 (5 peptides in the mass range of 1- 
6kDa, Applied Biosystems, Framingham, MA) using a quadratic 
calibration algorithm. Where it was possible, internal calibration of 
peptide mass fingerprints was carried out using the known masses of 
two autolytic trypsin peptide ions {m/z 842.5100 and 2211.1046) and 
optionally with the coomassie brilliant blue peak at m/z 804.2777.
Peptide mass fingerprint data were submitted to Mascot (Matrix 
Sciences, London, UK) and ProteinProspector (UCSF, San Francisco, 
CA) database search algorithms for peptide mass mapping using the 
NCBI non-redundant protein database. When internal calibration of 
the MALDI MS data was possible, a tolerance of 50ppm was used in 
the searches, otherwise a tolerance of 100ppm was used. All other 
parameters and criteria for protein identification are described in an
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earlier publication (Benvenuti et al. 2002b).
Four samples were submitted for tandem mass spectrometric 
analysis. These were carried out using MALDI-PSD/LIFT MS/MS on 
the Bruker Ultraflex or by nano-HPLC-ESI-CID MS/MS on a Q-TOF 
instrument (Micromass, Warrington, Cheshire, UK) coupled to an 
UltiMate HPLC system with autosampler (LC Packings, Amsterdam, 
Netherlands) (Minogue etal. 2001).
MALDI-PSD/LIFT measurements were carried out using a saturated 
matrix solution of HCCA in acetone/0.1% TFA (97:3; vol:vol) 
according to the thin-layer method of Gobom et al. (Gobom et al. 
2001). Peptide ions of strong signal intensity were chosen for MALDI- 
PSD/LIFT, their fragmentation data automatically processed and 
submitted to database searching through MS BioTools™ (Bruker 
Daltonics). Nano-HPLC-ESI-CID measurements were carried out as 
described previously (Benvenuti et al. 2002a) using the remainder of 
the sample.
Both MALDI-PSD/LIFT and nano-HPLC-ESI-CID data were submitted 
for searching against the NCBI non-redundant protein database using 
Mascot. For MALDI-PSD/LIFT data a peptide ion mass tolerance of 
0.5Da and a fragment ion mass tolerance of 1Da were chosen. For 
LC-MS/MS data the mass tolerances were 100ppm for peptide ions 
and 100mmu for fragment ions. In both cases, where the data 
significantly matched to more than one peptide of a particular protein, 
this protein was considered to be a true ‘hit’. If the data from only one 
peptide ion matched a protein but had a significant probability score or 
if it could not be matched to any protein, these spectra were examined 
manually. Manual interpretation of MS/MS data was carried out by 
searching with the main fragment ion masses using 
Protein Prospector’s MS-Tag (UCSF) and/or manual extraction of 
sequence information from the fragment ion spectrum and submission
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of sequence tags to Protein Prospector’s MS-Pattern.
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2.3 Lentivirus and microarray methods
2.3.1 Virus production (polyethylenimine transfection method)
293T cells were maintained in DMEM + 10% v/v FCS + 
penicillin/streptomycin (5pg/ml). For virus production cells were 
seeded at 4x106 in a 75cm2 flask or 8x106 in a 150cm2 flask the 
previous day. 15mins prior to cell transfection media was changed 
(6mls in a 75cm2 flask or 12mls in a 150cm2). For transfections, 
plasmids were mixed in the following quantities (Mix 1) (based on 
150cm2 flask): p8.91 orCRE control 10pg, pHR-CMV-GFP/pHR-CMV- 
LANA1/pHR-CMV-empty 15pg, pHM-G-VSV-G 5pg and made up to 
1400jnl with 150mM NaCI. 10mM (200pl) polyethylenimine (PEI) 
(Sigma) and 1200jnl of 150mM NaCI (Mix 2) were combined to make 
1400pl. Mix 1 and Mix 2 were incubated at 22°C for 15mins then 
combined with gentle shaking. The mixture was added into the 293T 
medium dropwise and incubated for 5 hours at 37°C (5% CO2).
Media was changed (20mls in 150cm2 flask) and virus harvested 
48hrs later by filtration of media through a 0.45|um filter. For 
concentration of virus, supernatants were centrifuged at 25,000rpm for 
11/2-2hrs at 4°C and virus pellets were resuspended in suitable media 
(DMEM/EGM-2). Viruses were then stored at -80°C long term or 4°C 
for short term storage.
2.3.2 RNA extraction
Cells at 48hrs postinfection were washed twice in PBS and total RNA 
was extracted using an RNeasy kit (Qiagen). Briefly, cells were 
centrifuged at 1200rpm for 10mins and resuspended in 350jil of RLT 
buffer (Qiagen) (including p-ME). To homogenise the sample, RLT 
lysate was transferred onto a QIAshredder (Qiagen) and centrifuged 
at 13,000rpm for 2mins and the flowthrough collected. 350pl of 70% 
v/v ethanol was added to the flowthrough and mixed. The 700pl mix 
was transferred to an RNeasy mini spin column and centrifuged at
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13,000rpm for 15secs. 700pJ of RW1 buffer (Qiagen) was added to 
the column and centrifuged at 13,000rpm for 15secs. The column 
was transferred to a fresh collection tube and 500jLtl of RPE was 
added, followed by centrifugation at 13,000rpm. This was repeated 
but centrifuged for 2mins. The column was transferred to a new 
eppendorf and eluted at 13,000rpm for 1min using 30pl of RNase-free 
H2 O. This was repeated with a further 30ml of RNase-free H2 O. RNA 
yield was quantified by UV spectrophometry and quality was 
determined by electrophoresis on a 1% agarose gel. Total RNA was 
stored at -80°C.
2.3.3 p24 quantification by ELISA
24hrs prior to the assay, High bind white plates were coated with 
10OjLil per well of 5mg/ml D7320 anti-p24 antibody in 0.1M NaHCC>3 
(Aalto bioreagents, Dublin). Wells were washed with LBS and 
blocked with LBS+2% w/v milk powder w/v for 1 hr at RT. 80pl of virus 
supernatant + 20pl of PBS containing 5% v/v Empigen BB detergent 
(Surfachem Ltd, UK) was prepared. This was then diluted further at 
either 1 in 20 or 1 in 200 by the addition of PBS + 5% v/v Empigen BB 
detergent. A dilution series of p24 protein in LBS + 0.05% v/v 
Empigen was included on the plate. After blocking plates were 
washed in LBS and 100jnl of each sample added. Plates were 
incubated for 4hrs at RT and then washed twice in LBS. Secondary 
anti-p24 antibody conjugated with alkaline phophatase (EH12E1-AP) 
was diluted to 0.5pg/ml in 4% w/v milk powder + 20% v/v sheep sera 
+ 0.5% v/v Tween 20 in LBS and incubated on the plates for 1 hr. 
Plates were washed 5 times with LBS+0.5% v/v Tween 20 and then 
exposed to 100 pi of alkaline phosphatase substrate Lumi-Phos Plus 
(Aureon Biosystems). Plates were incubated in the dark for 30mins at 
37°C. Plates were read using Stingray software (Dazdaq, UK) and a 
Lucy 1 luminometer (Athos-Labtech) giving data in RLU.
76
2.3.4 Microarray hybridisation and analysis
GF211 array filters were purchased from Research 
Genetics/Invitrogen (Groningen, The Netherlands) and prehybridised 
according to the manufacturers’ specifications. Initially membranes 
were washed with boiling 0.5% w/v SDS followed by incubation in 5ml 
of MicroHyb solution (Research Genetics). 5pg Cot-1 DNA and 5jug 
Poly dA was added and incubated for 2hrs at 42°C. For preparation of 
probe, 2jug of Oligo dT was added to 4-5pg total RNA in of DEPC 
dhhO (1 Ojul total) and placed at 70°C for 10min followed by incubation 
on ice. 6pl of 5X First Strand Buffer (Life Technologies), 1ml DTT 
(0.1M Life Technologies), 1.5pl dNTP mix (20mM dATP, dGTP, 
dTTP), 1.5pl Reverse Transcriptase (Superscript II, Life Technologies) 
and 10pl 33PdCTP were added to the Oligo dT/RNA mix and 
incubated for 90mins at 37°C. The probe was denatured by boiling 
and added to the pre-hybridised membranes and incubated for 16hrs 
at 42°C. Membranes were washed twice at 50°C in 2X SSC, 1% w/v 
SDS and once at 55°C in 0.5X SSC, 1% w/v SDS at 20mins per wash. 
Membranes were then exposed to phosphor imager screens and 
scanned using a Storm Phospholmager (Amersham Pharmacia 
Biotech). Microarray experiments were performed in duplicate. 
Images were imported into Pathways software (Research Genetics) 
and raw intensities were exported to Excel. Raw intensities were 
normalised against mean values for each data set and a list of 
candidate genes were selected that were >3 fold over background and 
showed >1.4 fold up/down regulation. The Pathways image for each 
gene was checked for misalignment and false positives were 
discounted.
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Fig 2.1A LANA1 amino termini sequences used for Hybrigenics yeast
two-hybrid screening
Orf 73 Latent nuclear antigen (LANA1)
Sequence from: 8648,. 12037 (reverse complement of original 
sequence)
ORF 73 N-terminus (as DNA sequence): ATG (1) to ACA (1011)
> Expected PCR DNA: 1011 bp 
> Expected Protein: 337aa (1-337aa)
1 (START)
atggcgcccccgggaatgcgcctgaggtcgggacggagcaccggcgcgcccttaacgagag
gaagttgtaggaaacgaaacaggtctccggaaagatgtgaccttggcgatgacctacatctaca
accgcgaaggaagcatgtcgccgactccgtcgacggccgggaatgtggaccccacaccttgc
ctataccaggaagtcccacagtgttcacatccgggctgccagcatttgtgtctagtcctactttacc
ggtggctcccattccttcacccgctcccgcaacacctttacctccaccggcactcttaccccccgt
aaccacgtcttcctccccaatccctccatcccatcctgtgtctccggggaccacggatactcattct
ccatctcctgcattgccacccacgcagtctccagagtcttctcaaaggccaccgctttcaagtcct
acaggaaggccagactcttcaacacctatgcgtccgccaccctcgcagcagactacacctcca
cactcacccacgactcctccacccgagcctccctccaagtcgtcaccagactctttagctccgtct
accctgcgtagcctgagaaaaagaaggctatcgtccccccaaggtccctctacactaaaccca
atatgtcagtcgcccccagtctctccccctagatgtgacttcgccaaccgtagtgtgtaccccccat
gggccacagagtccccgatctacgtgggatcatccagcgatggcgatactccgccacgccaa
ccgcctacatctcccatctccataggatcatcatccccgtctgagggatcctggggtgatgacac
agccatgttggtgctccttgcggagattgcagaagaagcatccaagaatgaaaaagaatgttcc
gaaaataatcaggctggcgaggataatggggacaacgagattagcaaggaaagtcaggttga
caaggatgacaatgacaataaggatgatgaggaggagcaggagaca
337
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Fig 2.1 B LANA1 carboxyl termini sequences used for Hybrigenics
yeast two-hybrid screening
ORF 73 C-terminus (as DNA sequence): GAA (2677) to 3390 (TAA) 
>Expected PCR DNA: 714bp
>Expected protein: 237aa (893-1129aa) (excluding STOP 
codon)
893
gaacagcaggagcaggagacggtggaagagcccataatcttgcacgggtcgtcatccgagg
acgaaatggaagtggattaccctgttgttagcacacatgaacaaattgccagtagcccaccagg
agataatacaccagacgatgacccacaacctggcccatctcgcgaataccgctatgtactcag
aacatcaccaccccacagacctggagttcgtatgaggcgcgttccagttacccacccaaaaaa
gccacatccaagataccaacaaccaccggtcccttacagacagatagatgattgtcctgcgaa
agctaggccacaacacatcttttatagacgctttttgggaaaggatggaagacgagatccaaag
tgtcaatggaagtttgcagtgattttttggggcaatgacccatacggacttaaaaaattatctcagg
ccttccagtttggaggagtaaaggcaggccccgtgtcctgcttgccccaccctggaccagacca
gtcgcccataacttattgtgtatatgtgtattgtcagaacaaagacacaagtaagaaagtacaaat
ggcccgcctagcctgggaagctagtcaccccctggcaggaaacctacaatcttccatagttaag
tttaaaaagcccctgccattaacccagccaggggaaaaccaaggtcctggggactctccacag
gaaatgacataa
1130 (STOP)
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Table 2.1 Antibodies used in this thesis
Primary
Protein
Target
Antibody
name/Ref
Species Type Source Academic
reference
LANA1 LN53 Rat Mono P.Kellam (Kellam et 
al. 1999)
LANA1 LN72 Rat Mono P.Kellam (Kellam et 
al. 1999)
hnRNPAI 2D32 Mouse Mono S.Murakami -
hnRNPAI 4B10 Mouse Mono G.Dreyfuss -
PABP1 - Mouse Mono G.Dreyfuss -
hTERT so-7212 Rabbit Poly Santa Cruz -
GST sc-459 Rabbit Poly Santa Cruz -
CD31 - Mouse Mono Chemicon -
Secondary
Protein Target Antibody 
Ref Code
Species Conjugate Source
Anti-rat IgG F0234 Rabbit FITC DAKO
Anti-mouse IgG R0480 Goat RPE DAKO
Anti-rabbit IgG sc-2054 Goat HRP Santa Cruz
Anti-rat IgG sc-2006 Rabbit HRP Santa Cruz
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Table 2.2 Cell line information
Cell
line
Source Cell type Features Adherent/
suspension
DG75 Burkitt’s
lymphoma
B-cell EBV
transformed
(EBV-negative)
Suspension
BCP-1 PEL B-cell KSHV positive Suspension
BC-3 PEL B-cell KSHV positive Suspension
HEK-
293
Human
embryonic kidney
Fibroblast Adenovirus E1A 
&E1B
Adherent
HEK-
293T
Human
embryonic kidney
Fibroblast Adenovirus E1A 
& E1B & SV40 
large T antigen
Adherent
HeLa Cervical Epithelial HPV E6 & E7 Adherent
CB3 Mouse
erythroleukaemia
Erythrocyte
progenitor
Retrovirus
insertion
Suspension
CB7 Mouse
erythroleukaemia
Erythrocyte
progenitor
Suspension
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Table 2.3 Primers used for PCR/RT-PCR
Target 573’ Oligo sequence
LANA1 aa 1-282 5’ aaagtacttgatatcgccaccatggcacccccgggaatgcgc
LANA1 aa 1-282 3* catggctgtgtcatcacccca
hnRNP A1 5’ cgagaggagctgggatccggtatgtctaagtcagagtctcctaaa
hnRNPAI 3* gctgccctcgagtccttaaaatcttctgccactgccatagct
UP1 5* cgagaggagctgggatccggtatgtctaagtcagagtctcctaaa
UP1 3’ cgcctcgagctaagcgtagtctgggacgtcgtatgggtatcgacct
ctttggctggatga
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Chapter 3 Results
HIV-1 based lentivirus infection of human primary endothelial 
cells
Chapter aims: The aim of this chapter was to develop an HIV-1 based 
lentivirus vector carrying KSHV LANA1 and demonstrate its use in 
both primary cells and cell lines.
3.1 Phenotypic analysis of primary endothelial cells
Primary endothelial cells were obtained from a donor and sorted by Dr 
Mike O’Hare, UCL. Prior to use in gene delivery and gene expression 
microarray experiments cells were checked for phenotype and 
viability. Staining with anti-CD31 antibody, observation of cells in
continuous culture and functional activity in a tube formation assay
were used to achieve this. Cells maintained the characteristic ‘cobble 
stone’ phenotype up to passage 15, at which point culture of cells was 
stopped (senescence usually occurs between passages 15-20).
Staining of cells in culture with anti-CD31 antibody showed
characteristic expression of CD31 at cell-to-cell contact (Fig 3.1 A). 
The functional ability of the endothelial cells to form artificial blood 
vessels in a tube formation assay was tested. This assay allows the 
‘health’ of the cells to be judged as low passage endothelial form 
tubes very quickly after seeding on Matrigel. Cells began forming 
tubes at 2hrs post seeding and this continued until the assay was 
stopped at 24hrs (Fig 3.1B). The formation of correct junctions is 
observable. While fibroblasts may possess tube formation activity and 
express CD31, they have a very different phenotype in culture and are 
easily distinguishable from primary endothelial cells. Fibroblasts have 
an elongated, streaming phenotype as compared to a cobblestone 
phenotype for endothelial cells. From these data I concluded that the 
cells obtained were of endothelial origin and were suitable for further 
experiments.
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Fig 3.1 -  Phenotypic analysis of primary HMVEC.
A, CD31 staining of primary endothelial cells. Primary human 
microvascular endothelial cells (HMVEC) were seeded onto glass 
slides as described in Material and Methods. Cells were fixed and 
permeabilised and incubated with anti-CD31 primary antibody and 
anti-mouse-RPE conjugated secondary antibody. Secondary antibody 
only controls were included which showed no staining. Cells were 
visualized and images obtained from a Leica microscope. CD31 can 
be seen at cell-cell junctions as is typical for healthy primary 
endothelial cells.
B, Tube formation assay on primary endothelial cells. Cells were 
seeded into 24 well plates previously coated with Matrigel. Cell 
morphology was observed at various times post-seeding and 
photographed using a Nikon microscope and digital camera.
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Fig 3.1 
A  ___
B
1 hr post-seeding:
Limited pre-tubule formation 
is observed (most cells are still 
round after attachment)
2hr post-seeding:
More advanced pre-tubule 
formation is observed (most 
cells are now tubular)
16hr post-seeding: 
Mature tube formation is 
observed
24hr post-seeding: 
Mature tube formation is 
complete
3.2 pHR CMV GFP infects cell lines
The pHR CMV-based virus system was selected to achieve my aim 
(Naldini et al. 1996). Initial testing of the pHR CMV-based lentivirus 
system concentrated on the infection of cell lines. If successful, 
further work would be undertaken of infection of primary cell lines with 
GFP and cloning of LANA1 into the system to allow delivery of LANA1 
to cells. Virus was produced by the three plasmid transient 
transfection of HEK-293T cells (Naldini et al. 1996). HEK-293T cells 
(abbreviated to 293T from here on) are derived from human 
embryonic kidney cells but have been infected with adenovirus and 
SV40. They therefore express adenovirus E1A, E1B and SV40 large- 
T antigen. They are commonly used as packaging cells for the pHR 
CMV-based system as they are simple to grow, easy to transfect and 
the pHR CMV plasmids contain an SV40 origin of replication. Virus 
supernatant produced from these cells was concentrated by 
ultracentrifugation and used to infect DG75 (EBV negative Burkitts 
lymphoma cell line), BCP-1 (KSHV positive PEL cell line) and HEK- 
293. Control virus was produced by replacing the p8.91 plasmid with 
a plasmid expressing CRE. This was done to control for non-specific 
uptake and expression of GFP protein. As GFP protein is produced 
and released into the viral supernatant, this is a concern. Cells mock- 
infected with these controls should therefore not show expression of 
GFP. A high level of infection and good expression of GFP was seen 
in all cells tested (except primary B cells -  see section 3.3) (Fig 3.2). 
This initial data showed that the lentivirus system was producing 
viable HIV-1 based viruses carrying the GFP transgene and was 
suitable for use in several types of cell line. The expression of any 
introduced gene can have aberrant effects on cells. I therefore tested 
the stability of GFP expression in cells up to 8 days/3 passages post­
infection. HeLa cells were seeded at 5x105 and infected the following 
day with 100pl of ultracentrifuge concentrated GFP virus and control 
(CRE transfected packaging cells). Cells were examined by FACS 
analysis for percentage of GFP expression at 48hrs, 120hrs
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Fig 3.2 - pHR CMV GFP lentivirus infections of various cell types (72 
hrs post infection). pHR CMV GFP virus was prepared in parallel with 
a GFP-CRE packaging control. Various cell types were infected with 
virus or control, and GFP was visualized at 72hrs post-infection using 
a confocal microscope.
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Fig 3.2
Fluorescent Phase Fluorescent Phase
microscopy contrast microscopy contrast
BCP-1 + virus CRE control BCP-1 + pHR CMV GFP
DG75 + virus CRE control DG75 + pHR CMV GFP
Primary B cells + virus CRE control Primary B cells + pHR CMV GFP
293 + virus CRE control 293 + pHR CMV GFP
and 192hrs post-infection (Fig 3.3). Percentage of infected cells was 
determined by comparison with the CRE control. Percentage of 
infection was calculated as around 82% at 48hrs and throughout 
subsequent passages. These data show that the expression of GFP 
is stable and has no effect on the health of the cells. From this I also 
concluded that the GFP expression seen was due to infection and not 
short-term non-specific uptake of GFP protein.
3.3 Infection and stability of GFP expressing virus in primary 
endothelial cells
The lentiviral system, driven by the cytomegalovirus (CMV) promoter 
is capable of infection and driving GFP expression in several different 
types of primary and transformed cells lines, both adherent and 
suspension (Fig 3.2). The results show, however, that the system or 
this particular promoter is not suitable for infection of primary B-cells. 
Initial work concentrated on optimization of the lentiviral system in 
endothelial cells using GFP virus. The experiments for expression of 
GFP virus were controlled by a negative packaging control. In parallel 
with the production of virus using VSVg, p8.91 and pHR CMV GFP, 
flasks were transfected with VSVg, CRE plasmid and pHR CMV GFP. 
This control was needed, as it is possible for GFP protein to be 
endocytosed by cells. This is potentially a problem with primary 
endothelial cells as under certain conditions endothelial cells can act 
as professional antigen presentation cells and display proteins via the 
MHC-II pathway. GFP expression was never seen either by 
fluorescent microscopy or by FACS in CRE packaged controls during 
normal infections. However, the addition of polybrene as a reagent 
leads to an increased background in GFP-CRE controls (Fig 3.4). 
Due to this increased background and high levels of infection without 
the addition of polybrene, its use in subsequent infections was 
stopped. Primary endothelial cells were infected with a titration of 
GFP virus to determine the maximum percentage of
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Fig 3.3 - Stability of GFP virus expression in HeLa cells. HeLa cells 
were seeded at 5x105 and infected the following day with 100pl of 
ultracentrifuge concentrated GFP virus and control (CRE transfected 
packaging cells). Cells were examined by FACS analysis for 
percentage of GFP expression at 48hrs, 120hrs and 192hrs post­
infection (Fig 3.3). Percentage of infection was determined by 
comparison with the CRE control. Percentage of infection was 
calculated as around 82% at 48hrs and throughout subsequent 
passages.
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Fig 3.4 - The effects of polybrene on pHR CMV GFP infection of 
primary endothelial cells. pHR CMV GFP virus was prepared in 
parallel with a GFP-CRE packaging control. Virus supernatant was 
centrifuged at 25,000rpm for 11/2 hrs at 4°C. Concentrated virus was 
resuspended in 500jul of EGM-2 (per 20ml supernatant) and stored at 
-80°C. Primary endothelial cells were seeded at 2x104 per well (6 well 
plate) and infected 4 days later. 10Ojil of virus or control was added 
per well. 72hrs later cells were observed using a confocal 
microscope. Polybrene was added to 3 wells, with 1jil of EGM-2 
added to the other 3 wells.
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Fig 3.4
polybrene +polybrene (1pl)
Primary HMVEC
Primary HMVEC + GFP CRE control
Primary HMVEC + pHR CMV GFP
endothelial cells that were infectable. 1x104 HMVEC were seeded in a 
24well plate and infected the following day with a titration (1 jlaI, 10pl, 
100jnl, 1000pl and 1000pl CRE control) of unconcentrated GFP virus. 
Infected cells were infected and examined by FACS analysis at 10 
days post-infection after 3 passages. Overall, unconcentrated pHR 
CMV GFP virus is capable of high levels of infection in primary 
endothelial cells. >90% is practically possible, and the infection is 
stable over passaging as shown by FACs on 3rd passage HMVEC (Fig 
3.5). Furthermore the data suggest correct integration of pHR CMV 
GFP allowing long-term expression and no aberrant effects on 
infected cells (Fig 3.5).
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Fig 3.5 - The stability of pHR CMV GFP lentivirus in primary HMVEC. 
Primary human male microvascular endothelial cells (HMVEC) at 
passage 6 were seeded at 1x104 in 24 well plate (1ml per well) in 
EGM-2 media 12 hours prior to infection. Media were removed from 
the cells and virus was added in amounts of 10OOpil unconcentrated 
pHR CMV GFP-CRE (negative control), 1 jlxI, IOjliI, IOOjliI and 10OOjLtl 
unconcentrated pHR CMV GFP. All infections were adjusted to 
1000pl with DMEM + 10% FCS + antibiotics if necessary. Virus was 
left on cells for 5hrs then replaced with fresh EGM-2. At passage 8, 
cells were trypsinised and washed twice in PBS for FACS. FACS data 
were gated against pHR CMV GFP-CRE.
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3.4 pHR-CMV-LANA1 lentivirus infects cell lines
LANA1 was introduced into the pHR CMV LacZ vector as detailed in 
Materials and Methods. Briefly, LANA1 amino terminus was amplified 
by PCR and the carboxyl terminus was created by restriction digest of 
the parental vector IgH P/E 73cycK13, followed by three way cloning 
into the pHR CMV backbone from which LacZ had been removed. 
LANA1 is a large protein with a predicted molecular weight of 160kDa, 
but LANA1 actually runs during electrophoresis as a doublet at around 
222/234 (Rainbow et al. 1997) or 220/235kDa (Kellam et al. 1997). 
The cloned pHR CMV LANA1 was confirmed by restriction mapping 
and DNA sequencing. For the production of LANA1 carrying HIV-1 
based lentiviruses, 293T cells were transiently transfected with the 
pHR CMV LANA1 plasmid or an empty vector (pHR CMV emp), VSVg 
and p8.91. Supernatants were collected at 48hrs post transfection 
and stored at -80°C. The 293T cells were lysed in RIPA and 
subjected to western blotting using an anti-LANA1 antibody (Fig 3.6A). 
The cells showed good expression of LANA1 at 48hrs post­
transfection indicating that the cloning and expression of LANA1 had 
been successful (Fig 3.6A). Syncytial formation is observed in cells 
transfected to produce LANA1 virus, indicating the expression of the 
VSVg construct (Fig 3.6B).
The kinetics of LANA1 expression at 24, 48 and 72hrs post-infection 
was observed by western blotting of infected DG75 cells (Fig 3.6C). 
LANA1 expression was detected at 48 and 72hrs post-infection, but 
was either low or not expressed at 24hrs (Fig 3.6C). These data 
indicated that the best time points for LANA1 expression is 48 and 
72hrs post-infection. It is possible that the low expression of LANA1 
at 24hrs is due to the time required for infection, integration and 
expression of the pHR CMV-based viruses.
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Fig 3.6 - LANA1 lentivirus production and testing. A, WB on 293T 
cells for LANA1. HEK-293T cells were transiently transfected with 15 
jLxg of pHR CMV LANA1 or pHR CMV emp, 10pg of p8.91 and 5pg of 
VSVg. Cells were lysed in RIPA buffer at 48hrs post-transfection and 
protein was separated on a 6-12% SDS-PAGE gel. Proteins were 
transferred to nitrocellulose membranes and blotted with anti-LANA1 
antibody followed by anti-Rat HRP. Bands were visualized using 
ECL+ and ECL film. B , Formation of VSVg induced syncytia at 48hrs 
post transfection. Post-transfection 293T show the formation of 
syncytia due to the expression of VSVg. C , Kinetics of LANA1 
expression 24-72hrs post infection. DG75 cells were infected with 
LANA1 lentivirus or CRE packaging control supernatant. Cells were 
lysed at 24, 48 and 72hrs post-infection. Expression of LANA1 post­
infection is observed at 48 and 72hrs.
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Fig 3.6 
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The expression pattern of LANA1 in cell lines post-infection was 
tested using HeLa cells. LANA1 carrying virus, along with a CRE 
packaging control was used to infect cells. The pattern of LANA1 by 
western blotting was compared to endogenous LANA1 in BC-3 cells to 
ensure correct processing of LANA1 expressed from the lentiviral 
construct. BC-3 and HeLa-LANA1 cells were lysed in RIPA buffer and 
a titration of cell number was used for western blotting. LANA1 
expressed from infected HeLa cells shows the same pattern by 
western blotting as endogenous LANA1 from BC-3 cells (Fig 3.7A). 
These data showed that LANA1 was being processed correctly.
As mentioned earlier, LANA1 is a large protein that acts as both a 
transcriptional activator and repressor. To test that over expression of 
LANA1 was not having an aberrant effect on cells, the stability of 
LANA1 in HeLa cells was observed over time by western blotting. 
HeLa cells at passage 1,2 and 3 post-infection with pHR CMV LANA1 
or CRE control were lysed and LANA1 was detected by western 
blotting. LANA1 expression is seen at 3 passages post-infection 
indicating stability of the transgene (Fig 3.7B).
For initial experiments viruses were produced in parallel with a 
packaging control, in which the p8.91 plasmid was substituted with a 
CRE expressing plasmid. The data in this section show that no 
specific uptake and expression of LANA1 was seen in control 
infections. For later use [in gene expression microarray experiments], 
a pHR CMV empty plasmid was packaged as a negative, to control for 
the effects of viral infection on primary endothelial cells.
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Fig 3.7 - LANA1 expression and stability in Hela and primary 
endothelial cells. A, LANA1 patterning by Western blot in HeLa cells. 
BC-3 and pHR CMV LANA1 /LANA1-CRE control virus infected HeLa 
cells were lysed in RIPA buffer. Various amounts of protein were 
separated on a 6-12% SDS-PAGE at 120V. Proteins were transferred 
to a Hybond-P membrane over night at 0.1 A in MeOH transfer buffer 
Membranes were blocked in PBS+Tween+milk powder and probed 
with anti-LANA1 LN72 rat monoclonal diluted 1:1000 in 10% blocking 
buffer for 2hrs. After washing anti-Rat HRP (Santa Cruz) was 
incubated with the membranes for 1 hr and bands were visualized after 
incubation with ECL+ (Amersham Pharmacia Biotech) and exposure 
to ECL film (Amersham Pharmacia Biotech). The patterning of LANA1 
expressed from the lentivirus matches that seen in BC-3, indicating 
that the virus is expressing correctly. B, LANA1 expression in Hela 
cells is stable over 3 passages. 5x105 HeLa cells were infected with 
concentrated LANA1 lentivirus and CRE packaging control. Cells 
were maintained in culture over three passages and a proportion lysed 
in RIPA buffer for analysis by western blotting. Proteins were 
separated on 6-12% gradient SDS-PAGE gel and detected by anti- 
LANA1 monoclonal antibody. Expression of LANA1 is evident up to 
passage three. C, LANA1 expression in primary HMVEC is stable 
over 4 passages. 8x104 primary HMVEC at passage 5 were infected 
with 1 OjliI, 10Ojul or 1000pl of unconcentrated LANA1 lentivirus. Cells 
were maintained in culture until passage 9 and lysates were prepared 
in RIPA buffer at each passage. Protein was separated on a 6-12% 
SDS-PAGE gradient gel and LANA1 was detected using anti-LANA1 
monoclonal antibody. Expression of LANA1 is evident up to passage 
9 (4 passages post-infection).
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Fig 3.7  
A
B
BC-3 Hela +/- LANA1
I r
M (kDa)
1 2 3 4 5 6 7 8
2 5 0 -
1 5 0 -
100 -
Cell counts per well
1 - 3,500 BC-3 5 -  20,000 CRE control
2 -  17,500 BC-3 6 -  5,000 Hela LNA-1
3 -  35,000 BC-3 7 -  10,000 Hela LNA-1
4 -  70,000 BC-3 8 -  20,000 Hela LNA-1
Passage after infection
' 1  2 3 1
BC-3 LANA1 CRE LANA1 CRE LANA1 CRE
___
LANA1
LANA1
Passage after infection
Virus (10,100,1000^1) +
H
• • LANA1
3.5 pHR-CMV-LANA1 lentivirus infects primary HMVEC
LANA1 shows characteristic patterning by western blot (Fig 3.7A) of a 
doublet at 220-235kDa, similar to endogenous expression of LANA1 in 
KSHV-infected PEL cells (BC-3). I next tested the infection of primary 
endothelial cells with the LANA1 virus. Endothelial cells were infected 
and expression of LANA1 was monitored by western blotting over 
several passages. The expression of LANA1 is high and LANA1 is 
stable over at least 4 passages (Fig 3.7C). This data indicated that 
the infection of primary cells was possible, LANA1 was expressing and 
the expression was stable over time indicating no growth 
disadvantage for cells expressing LANA1.
KSHV LANA1 has previously been shown to be a nuclear protein that 
associates with heterochromatin-nuclear bodies and shows a 
characteristic nuclear stippling by immunofluoresence assay (Szekely 
et al. 1999). Although my data showed that the system was 
expressing LANA1, I also wanted to confirm the cellular localization of 
LANA1 after infection with this virus. To achieve this I used 
immunofluoresence assay with an anti-LANA1 antibody. Primary 
endothelial cells were grown on pre-sterilised glass cover slips in 6- 
well plates. After infection, cells were incubated with anti-LANA1 
antibody and visualized using fluorescent microscopy. The results of 
LANA1 staining in endothelial cells are seen in Fig 3.8. Detection of 
pHR CMV LANA1 in primary HMVEC 72hrs after infection reveals the 
characteristic nuclear localization and stippling (Fig 3.8A) and 
association with cellular DNA during mitosis (Fig 3.8B). Co-staining of 
LANA1 and CD31, an endothelial cell marker, was also undertaken 
(Fig 3.8C). Overall, these data showed that good infection of 
endothelial cells was possible with the LANA1 virus and that LANA1 
behaved in a phenotypically correct manner.
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Fig 3.8 -  Cellular localization of LANA1. A, Primary microvascular 
endothelial cells were plated in 6 well plates containing glass cover 
slips. Cells were seeded at 8 x104 per well the evening before 
infection with virus. Cells were infected either with 1ml of pHR CMV 
LANA1 (LANA1+) or 1ml of LANA1 CRE (LANA1-) control. 48hrs p.i. 
cells were subjected to I FA protocol using LN53 as the primary and 
anti-Rat FITC (DAKO) as the secondary antibody. Cells were 
visualized and photographed on a Nikon fluorescent microscope. B, 
LANA1 associates with condensed chromatin during mitosis. C, 
Primary endothelial cells were grown on glass cover slips and infected 
with LANA1 lentivirus. Cells were fixed, permeabilised and co-stained 
with anti-LANA1 rat monoclonal (1:1000) and anti-CD31 mouse 
monoclonal (1:500). Secondary antibodies used were anti-rat FITC 
(1:120) and anti-mouse RPE (1:100).
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3.6 Discussion and conclusion
In this chapter I have developed a reliable method for the delivery of 
viral genes to transformed cell lines and to primary endothelial cells. 
Other groups have utilized the system for delivery of transgenes to 
endothelial cells, including LacZ (Totsugawa et al. 2002), eGFP 
(Wang et al. 2000) and the non-catalytic fragment of matrix 
metalloproteinase 2 (PEX) (Pfeifer et al. 2000). The pHR CMV GFP 
system has been used to infect a range of cells including CD34+ 
CD38- human hematopoietic cells (Case et al. 1999). The data 
contained in this chapter represent the first study to use a lentiviral 
system for the delivery of a viral oncogene to primary endothelial cells.
The lentiviral system, although eventually reliable and robust, was 
initially problematic. Careful considerations when using the system 
include the preparation of plasmid DNA, the density and age of 
packaging cells and the transfection of packaging cells. Together, 
these areas represent the main reasons for either sub-optimal results 
or failure of the lentiviral systems. In the whole however, once these 
technical aspects have been learnt, the lentivirus system is a powerful 
and flexible tool that will no doubt continued to be developed and used 
in an increasing number of laboratories.
The delivery of LANA1 to primary endothelial cells using the lentiviral 
system resulted in a characteristic phenotype and localization of 
LANA1 protein. This is important in any system, allowing results 
obtained to be interpreted as being directly relevant to disease state. 
LANA1 and the viral episomes accumulate in heterochromatin- 
associated nuclear bodies ensuring the virus persists in daughter cells 
(Ballestas et al. 1999;Cotter and Robertson 1999) and show a 
characteristic nuclear stippling pattern in all KSHV infected tumour 
cells (Dupin et al. 1999;Mattsson et al. 2002a;Szekely et al. 1999). 
The characteristic nuclear stippling and association of LANA1 with
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DNA in dividing cells were observed by I FA on LANA1 virus infected 
endothelial cells.
Overall, the data in this chapter show that LANA1 can be delivered 
effectively to primary cells and cell lines using a lentiviral based 
system and no aberrant effects are seen as a result. The expression 
of LANA1 is high, phenotypically correct and stable. The results show 
that the lentiviral system is a robust tool that could be applied to 
several different technical problems in modem biological research. 
The system was developed specifically for the delivery of LANA1 to 
primary endothelial cells but could be adapted for other viral genes. 
Areas include the delivery of viral genes to stem cells and the delivery 
of small interfering RNA (siRNA) to primary cells. This would be of 
particular interest in silencing KSHV genes from infected primary cell 
lines to study the effects of viral genes in a more relevant context. In 
the context of primary endothelial, the lentiviral delivery system may 
be an excellent way of delivering genes to cells for screening by 
chorioallantoic membrane assay (CAM) in which the cell growth and 
invasion potential of cells can be assessed.
In the next chapter I describe the use of the lentivirus system to study 
the effects of LANA1 on primary endothelial cells using gene 
expression microarrays.
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Chapter 4 Results
Effects of LANA1 on primary endothelial cells determined by 
gene expression microarray
Chapter aims: The aim of this chapter was to use the HIV-1 based 
lentivirus to determine the effects of LANA1 on the transcriptome of 
primary endothelial cells thereby identifying novel cellular 
transcriptional targets.
4.1 Optimization of cell culture and RNA extraction
Several considerations were important for the design of the microarray 
experiment. Firstly, primary endothelial cells are difficult to culture at a 
large scale, therefore the required amount of material for the 
microarray experiments (RNA) had to be calculated. Secondly, 
primary endothelial cells express a different array of genes depending 
on their cell density. It was decided that array analysis should take 
place on cells infected with lentivirus that had not yet reached 
confluent culture. It is known that upon confluence endothelial cells 
change their expression pattern from angiogenic to vascular 
homeostasis. I therefore designed experiments to determine suitable 
seeding conditions that would provide a sufficient amount of RNA, 
without the cells reaching confluence after infection. Primary 
endothelial cells were seeded in varying concentrations in 25cm2 
flasks. Cell populations were examined at 24hrs and 72hrs post 
seeding (Fig 4.1). In the previous chapter I showed that expression of 
LANA1 was strong at 48hrs post-infection. Based on this, infection 
with lentivirus would be carried out at 24hrs post seeding and RNA 
extracted at 72hrs post seeding, the equivalent of 48hrs post infection. 
The data show that the best seeding conditions are 2x105 in 25cm2 
flask (Fig 4.1), as this allows good cell growth, but remain sub­
confluent at the equivalent of 48hrs post-infection. RNA test 
extractions were performed to ensure that sufficient quantities of RNA 
could be recovered (Fig 4.2). Cells seeded at 2x105 provided 14.4pg
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of high quality RNA (260/280 = 1.935). As microarrays would be 
performed in duplicates, these parameters were therefore deemed 
suitable.
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Fig 4.1
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Fig 4.1 Test seeding of primary endothelial cells
Primary microvascular endothelial cells were seeded at passage 8 at concentrations 
ranging from 5x104 to 4x105 in 25cm2 flasks suspended in EGM-2 media.
A, Photographs were taken on the next day post seeding (24hrs) and
B, at 72hrs post seeding. Percentages of confluence were calculated and are 
shown in brackets.
'Fig 4.2
A  Seeded Final RNA yield 260/280
5x104 1.14x10s 2.4|ag 5.5
1x105 1.98x10s 2.4ng 2.7
2x105 3.6x10s 14.4(j.g 1.935
4x10s 9.36x10s 12.72|j.g 1.827
B
_______
Fig 4.2 Endothelial test seeding RNA extraction
Total RNA was extracted from primary endothelial cells seeded at various 
cell densities. A, Total quantities of RNA obtained from each cell density 
at the equivalent of 48hrs post-infection. B, 1 % agarose gel of extracted 
total RNA.
4.2 Equalisation of viral infections and infection data at 48hrs 
post infection
During the course of virus preparations it became evident that different 
pHR CMV transgene inserts produced varying quantities of virus. This 
was considered a problem for the controls during the microarray 
analysis. As gene expression microarray technology is sensitive, 
unequal amounts of virus put onto cells in terms of LANA1 vs control 
may have quenched significantly up or down regulated transcripts. To 
solve this problem, virus preparations were quantified prior to infection 
of primary endothelial cells. The size of insert cloned into the pHR 
CMV backbone correlated with the yield of virus. Using GFP as a 
guide, viruses were equalised in terms of p24 quantity. A quantity of 
GFP virus that had previously given high levels of infection was 
selected and other viruses equalised to this figure. Quantities of p24 
for each virus produced were calculated using a p24 ELISA (Fig 4.3 
A). From the p24 ELISA results it was evident that there was an 
inverse relationship between the size of the insert cloned into the pHR 
CMV vector and the quantity of p24 protein in viral supernatants (Fig
4.3 B). A quantity of GFP virus was calculated from p24 values to 
achieve as close to 100% infection of cells as possible. 78 ng of p24 
for each virus was added to cells for RNA extraction for analysis by 
gene expression microarray. At 48hrs post-infection, GFP infected 
cells were analysed by FACS and showed greater than 97% infection 
(Fig 4.4 A). This indicated that the expression of LANA1 viruses 
should be high in the primary endothelial cells. To confirm this, 
LANA1 was detected by western blotting of cell lysates at 48hrs post­
infection. LANA1 expression was detected in only the LANA1 infected 
cells (Fig 4.4 B). RNA was extracted from the infected cells at 48hrs 
post-infection and quantity and quality were determined by UV 
spectrophotometry. Data are shown for total RNA yield and quality 
based on two extractions for each sample (Fig 4.5).
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Fig 4.3
Size of gene insert p24 ng/ml
Okb 115
1.1 kb 39.7
1.5kb 26.7
3.1kb 18.8
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Effect of insert size on viral production 
1000 --------------------------------------------------------------------
Okb 1.1 kb 1.5kb 3.1kb
Size of insert
Fig 4.3 Quantification of viruses using p24 ELISA
A, Viruses were produced by the transient transfection of 293T cells. 
Supernatants from the packaging cells, which contain released virus, 
were used in a p24 ELISA to determine the quantity of virus as protein 
quantity. Quantities of protein are shown for each of the viruses tested.
B, the relationship between insert size in kb and quantity of produced virus.
Fig 4.4  
A
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2 5 0 -
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100 -
LANA1
Fig 4.4 FACS data and LANA1 expression from primary endothelial 
cells for gene expression microarray analysis
A, FACS analysis was performed at 48hrs post-infection on 
pHR CMV GFP lentivirus infected primary endothelial cells. Percentage 
of infection was calculated as 97%. B, Cells infected with various viruses 
in parallel with gene expression microarray experiments were lysed in 
RIPA buffer, separated by SDS-PAGE and subjected to western blotting 
with anti-LANA1 antibody. Expression of LANA1 is clearly visible at 24 
and 48hrs post-infection.
Fig 4.5
RNA yield/quality 48hr p.l.
Lane # Sample Yield (pg) 260/280
1 Norm 1 12 1.142
2 Norm 2 18.6 2.480
3 Empty 1 33.24 1.928
4 Empty 2 4.5 0.000
5 LANA11 35.7 2.087
6 LANA1 2 3.6 6.000
B M 1 3 5 7 9 2 4 6 8  10
■
28S
18S
Fig 4.5 Total RNA extraction for gene expression microarrays
A, Total quantity and quality of total RNA obtained from lentivirus 
infected cellsat 48hrs post-infection. B, 1% agarose gel of extracted 
total RNA.
4.3 Analysis of GEM data
Data from duplicate microarray hybridisations were obtained from a 
Storm scanner (Amersham Pharmacia Biotech) as .gif files and were 
imported into Research Genetics Pathways software. Initially data 
analysis was attempted by using software derived normalisation. This 
however did not provide good distribution figures for the data, so the 
data were exported as raw intensity values into MS Excel. In MS 
Excel data were normalised by the average total array values. The 
normalised average intensities for each duplicate set of arrays was 
plotted and correlation between the normalised data were determined 
to be R2 = 0.9884.
A list of potential genes was generated with a cut-off fold change of +/-
1.4 for I.ANA1 vs Emp (control). This list was used to cross-reference 
back to array figures, in order to confirm that each data spot was 
correctly aligned and not a false positive. Many of the genes identified 
were of low signal intensity. Using this method over 90% of target 
genes that could be visualized on the Pathways software, were 
discounted as false positives. This most often occurred where 
Pathways software had misinterpreted ‘bleed’ from a strong spot 
signal in close proximity (Fig 4.6). The problem was determined not to 
be caused by misalignment during import of the array images. Due to 
this, the final list of genes includes only those that were able to be 
checked manually against images. Genes whose low signal was not 
visible for checking were excluded from the final list. All genes initially 
selected are in Appendix 1. A final list of up/down regulated genes 
was created from this manual selection and curation of data. Figure
4.7 B shows the final list of genes selected as having a good fold 
change, t-test value <0.05 and visible correctly aligned cDNA spot. 
Figure 4.7 A shows the Pathways™ images in a representative 
experiment for each spot.
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Fig 4.6
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Fig 4.6 Alignment of cDNA spots on GF211 research 
genetics microarrays
A, shows a correctly aligned data point. B, shows a misaligned 
false positive. Where spot intensities were sufficient for manual 
checking, approximately 90%+ software selected where false 
positives, often due to strong intensities of surrounding 
cDNA spots.
Fig 4.7  
A
LANA1
+
B
Gene name Ratio Fold ttest Accession
Prostacyclin-stimulating factor 0.644241 -1.55 0.044394 T53298
MIR-10 1.433614 +1.43 0.034453 H54023
Nidogen 0.722972 -1.38 0.049286 AA709414
Transducin-like 
enhancer of split
0.709209 -1.41 0.017366 AA704492
Prostaglandin E 
synthase (PIG12)
1.500 +1.5 AA436163
Fig 4.7 Gene expression microarray images and data for LANA1 
target genes
A, Images of cDNA spots were captured from PathwaysTM software.
B, Genes determined as true targets of LANA1 based on manual 
screening of PathwaysTM images, ttest and fold change.
&
•O'
X  <5-
/ < /  / /
< p
/ /
From the manually curated microarray data, few changes were 
observed in gene expression patterns due to LANA1 expression. 
Overall 5 genes could be confirmed by manual curation (real image) 
and had fold changes +/- 1.4 fold. Genes of particular interest in 
regard to endothelial cells are discussed below.
Prostacyclin-stimulating factor, as its name suggests, stimulates the 
synthesis of prostacyclin. It is a potent vasodilator, antithrombotic and 
antiplatelet agent (Smyth and Fitzgerald 2002). Research has shown 
that prostacyclin-stimulating factor produced by fibroblast cells can 
stimulate the synthesis of prostacyclin (PGI2) in endothelial cells 
(Masakado et al. 1994). PGI2 is released from healthy endothelial 
cells (Gryglewski et al. 2002). Prostacyclin-stimulating factor localizes 
in endothelial cells and smooth muscle cells and may play a role in 
vascular homeostasis (Umeda et al. 1996).
Prostaglandin E synthase (PGES), also designated PIG 12 and 
MGST1-L1 is a membrane associated protein. Although its change in 
expression is not statistically significant, it showed a good fold change 
and is possibly relevant to LANA1 induced gene expression changes 
in endothelial cells. It is part of a protein superfamily involved in 
eicosanoid and glutathione metabolism (MAPEG family)(Jakobsson et 
al. 1999). High expression of PIG 12 is detectable in lung carcinoma 
(A549) and human ovarian cancer (HeLa) cell lines(Jakobsson et al. 
1999). PGES converts cyclooyxgenase (COX)-derived prostaglandin 
(PG)H2 into PGE2 (Jakobsson et al. 1999). In common with 
prostacyclin-stimulating factor, prostaglandin E is released from 
healthy endothelial cells (Gryglewski et al. 2002).
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4.4 Discussion and conclusion
In this chapter, I attempted to use the ability of the lentivirus system to 
deliver LANA1 to primary cells, and interrogate the functions of LANA1 
on the cellular transcriptome using gene expression microarrays.
The results from the gene expression microarray analysis of the 
effects of LANA1 on primary endothelial cells were disappointing and 
show little change in the gene expression pattern. Post-infection, 
LANA1 positive cells gene expression appears to differ little as 
compared to normal primary endothelial cells or an infection control 
(pHR CMV emp). Previous work has been published that attempted 
to identify the cellular targets of LANA1 in transformed B-cells. Stable 
cell lines expressing LANA1 were created and the gene expression 
profile was compared with LANA1 negative cells (Renne et al. 2001). 
Findings from this work were limited as no significant changes in 
known genes were observed. LANA1 did however alter the 
expression of several ESTs (Renne et al. 2001). The study 
investigated the effects of LANA1 on the activity of several synthetic 
promoters and found that LANA1 activated synthetic constructs 
containing ATF, AP1, CAAT and SP1 sites but repressed HIV-LTR 
and NFkB-dependent reporter genes (Renne et al. 2001). Results 
from gene expression microarrays showed limited modulation of 
cellular genes, including upregulation of several interferon responsive 
genes (Renne et al. 2001).
Previously LANA1 has been shown to be a potent regulator of 
promoter activity, acting as both a transcriptional activator and 
repressor (An et al. 2002;Knight et al. 2001;Radkov et al. 2000). 
However, these results have been obtained from artificial systems 
such as promoter reporter assays which are several times more 
sensitive than detection of changes in cellular transcripts by methods 
such as RT-PCR or gene expression microarrays. The promoters 
known to be transcriptionally activated by LANA1 include E2F
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(Radkov et al. 2000), human telomerase reverse transcriptase 
(hTERT) (Knight et al. 2001) and the hlL-6 promoter via the AP1 site 
(An et al. 2002).
Other work undertaken in our laboratory also attempted to compare 
the gene expression profile of LANA1 transformed rat embryonic 
fibroblasts (S. Radkov, unpublished data)(Radkov et al. 2000) with 
control cells but this also showed no significant changes in gene 
expression profile due to LANA1 expression (S. Radkov, unpublished 
data).
I attempted to improve on work with LANA1 and gene expression 
microarrays by using several new methods. There was concern that 
the specific effects of LANA1, which may be quite subtle, were being 
lost in the large changes of gene expression in transformed cells. 
Also cell types used were not necessarily relevant to KS, and it has 
been noted previously that the transcriptional activity of LANA1 is cell 
type specific (Knight et al. 2001). To answer these concerns, I used 
disease relevant un-transformed primary endothelial cells. The levels 
of LANA1 gene expression were also a concern as low levels of 
transfection may have lead to a diluted effect of LANA1-mediated 
gene expression change. I employed a lentiviral gene delivery system 
to achieve infection of greater than 95% of cells. However, despite 
these changes, little data were derived from the GEM experiments. 
There are several possible reasons for this.
Firstly, the choice of the gene expression microarray system may not 
have been ideal. While gene expression microarrays are sensitive, 
the majority of LANA1 transcriptional activation/repression studies 
have been performed using promoter constructs that express reporter 
genes. This is a much more sensitive assay than the detection 
offered by cDNA GEM technology.
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The specific type of GEM used in these experiments, cDNA arrays, 
may also have not been suitable. Problems encountered with the 
work on microarrays were mainly concerned with the analysis of data 
and interpretation of array images with the Research Genetics 
software. False positives were common using the software resulting 
in the need for lengthy manual checking of data with primary images.
The field of gene expression microarray production has grown 
considerably and there are now new alternatives to the traditional 
methods of cDNA microarrays. Most promising appears to be the use 
of oligo based array technology such as that employed by the 
Affymetrix system. The improvements in technology result in not only 
greater sensitive and reproducibility, but also greater confidence in 
data due to extensive internal controls. Future work could involve the 
use of the existing delivery and expression methods used for this 
work, coupled to the use of the new generation of oligo microarray 
systems. This may allow better sensitivity of detecting LANA1 
mediated gene expression changes.
Secondly, it is possible that the endothelial cells are not suitable for 
such experiments. In the formation of KS and other associated KSHV 
malignancies, LANA1 may act in concert with other viral genes. 
Future work could study the effects of LANA1 when co-expressed with 
vcyclin and/or vFLIP, as occurs in KSHV infected cells. The 
transcriptional effects of LANA1 may also be due to subtle cellular 
changes, not present in the primary endothelial cells used here.
Overall, despite attempts to analyse the transcriptional effects of 
LANA1, my results have not shown any significant change in gene 
expression that could be attributed to LANA1. As few changes were 
seen, I could conclude that it is likely the main functions of LANA1 are 
not mediated through transcriptional regulation. However, I believe 
that further work is required before this conclusion should be reached.
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In the next chapter of this thesis I looked at another possible route of 
LANA1 function; protein-protein interactions.
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Chapter 5 Results 
Characterisation of a LANA1 complex
Chapter aims: The aim of this chapter was to develop methods for the 
capture of a LANA1 native complex from KSHV infected B-cells and 
identify the binding partners of LANA1 using mass spectrometry. In 
parallel, the yeast two-hybrid system was used to identify direct 
interaction partners allowing comparison of candidate proteins and 
protein interaction domains between the two methods.
5.1 Construction and testing of LN53 and control columns
Previous studies on the protein-protein interactions of KSHV LANA1 
have concentrated on the use of the yeast two-hybrid system to 
identify individual direct partners (Fujimoro et al. 2003;Fujimuro et al. 
2003;Fujimuro and Hayward 2003;Platt et al. 1999). Here I sought to 
study LANA1 at the protein complex level, therefore identifying both 
direct and indirect binding proteins.
Initial work on the purification of a LANA1 complex concentrated on 
the construction of a suitable LAN A 1-specific column. Several 
methods are available for the capture and purification of proteins from 
a cell lysate. One method is to produce the proteins as a fusion, often 
with a glutathione-s-transferase (GST) moiety and use an anti-GST 
column to capture the recombinant fusion protein from bacteria. 
Mammalian cell lysate is then circulated over this column and proteins 
that bind to the immoblilised fusion protein are rescued from the 
lysate. This method does however have its disadvantages. Fusion 
proteins produced in bacteria will often bind to bacterial proteins and 
these can interfere with later mass spectrometry identification. This 
can be improved by ectopically expressing the fusion protein in 
mammalian cells. However, the addition of a GST moiety may alter 
the biochemical or structural properties of a protein and therefore alter 
its binding partners. As a high level of non-specific interactions occur
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with this method, it is often necessary to construct several columns 
with increasing amounts of fusion protein immobilized on them. 
Proteins that are identified as increasing in yield with increasing 
amounts of fusion protein can therefore be identified as specific. This 
is time consuming and not very cost effective. In addition, this method 
often only captures directly interacting proteins and not a native 
protein complex.
A method that is more specific and captures not only direct but indirect 
interaction partners is antibody affinity chromatography. This uses 
protein specific antibodies to bind proteins from cells lysates. There 
are two methods normally used: If no specific antibody is available, 
the protein is tagged, commonly with an HA or MYC tag, and 
ectopically expressed in cells. An anti-HA or anti-MYC column is then 
used to bind the proteins from cell lysates. This method is more 
suitable as the proteins are captured from cells in vivo and all binding 
partners can be identified. It still has the disadvantage however that 
the tag may interfere or change the proteins’ binding characteristics.
When available, the second and preferential method for protein 
capture is to use either a monoclonal or polyclonal protein specific 
antibody to capture complexes in a native form. This is the method I 
developed for use in this study.
To enable the capture of a native protein complex from KSHV latently 
infected B-cells I employed affinity chromatography. Specific anti- 
LANA1 antibody was cross-linked to CNBr media, in parallel with a 
non-specific rat IgG control. While it is possible to bind antibody to, 
for example, protein G beads, this method is not permanent and loss 
of antibody occurs at the elution stage. By cross linking the antibody to 
CNBr beads I was able to reuse the antibody media (antibody + CNBr) 
repeatedly.
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During construction, both columns (LN53 & Rat IgG) bound over 98% 
of the antibody coupled to them. Loss of antibody was calculated from 
flowthrough after binding. The BCA protein assay was used for 
quantification against known standards (see Materials and Methods). 
The results show that both the rat IgG and LN53 columns contain 
greater than 4.9mg of control antibody or anti-LANA1 antibody, 
respectively (Fig 5.1). The anti-LANA1 and control CNBr beads were 
packed into columns.
Initial work with the columns concentrated on the conditions for 
optimum capture of LANA1 from cell lysates, while maintaining as high 
a degree of stringency as possible. Different methods of physical 
disruption (sonication, dounce homogenization or no mechanical 
disruption) were employed to release LANA1 from BC-3 cells. LANA1 
was immunoprecipitated using anti-LANA1 rat monoclonal and the 
captured immunocomplexes were examined by western blotting (Fig 
5.2). Results showed that cells in low salt buffer disrupted with 
sonication gave the best results (Fig 5.2). Low salt buffer and 
sonication were therefore initially employed to allow gentle lysis of 
cells for column work.
The elution of proteins from an affinity column is often as important as 
the method of capture. There are several methods available to elute 
proteins including an increase in salt (often used in combination with a 
step or gradient elution), the use of an antibody specific eluting 
peptide, or pH. For this study I used a low pH method: 100mM 
glycine (pH 2.7). This method is often used because it provides rapid 
elution with the majority of the protein eluting at once. This makes 
concentration of the samples easier and more convenient.
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Fig 5.1
A Rat IgG LN53
Rat IgG 
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0.285g
( lm l )
I
4.9mg/ml CNBr
B
CNBr
LN53 IgG 
5mg
0.285g
(lml)
I
>4.9mg/ml CNBr
F
Packing flow lml/min 
Usable range 0.2 - 0.7ml/min
C
At usual flow rate:0.5ml/min 
Linear flow: 0.5 x 60 x4/7t x 0.5 x0.5 
: 152.7cm/hr
Fig 5.1 - Affinity column statistics
LANA1 specific and non-specific control columns were constructed 
by cross-linking of purified antibodies to CNBr activated sepharose 
4B media. A & B - Media was packed into HR 5/5 columns at 1ml/min 
flowrate. The efficiency of coupling was calculated by BCA assay 
on concentration of unbound antibody C -  Usable flow rate was 
calculated.
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Fig 5.2 - Immunoprecipitation of LANA1 from low salt buffer 
lysed cell extracts
BC-3 cells were lysed in low salt buffer using various methods of 
physical disruption and immunoprecipitated with anti-LANA1 antibody. 
Cells were washed in PBS then resuspended in Low salt buffer at 
1x107/ml. Lysates were subjected to either sonication, Dounce 
homogenisation or no physical disruption. Lysates were precleared 
with 50(il of protein G beads for 1 hr at 4°C. Rat IgG or LN53 antibody 
(5pg) was added per IP for 2 !4 hrs at 4°C. 50pl of protein G beads 
were added and allowed to bind overnight at 4°C with rotation. Beads 
were washed 3 times with low salt buffer, resuspended in Lamelli 
loading buffer and boiled at 95°C for 5mins. Proteins were then 
separated on a 6-12% SDS-PAGE gel, transferred to Hybond-P 
membranes (Amersham Pharmacia Biotech) and proteins detected 
with 1:1000 LN72 antibody. The resulting western blot shows that the 
most efficient method for extracting LANA1 protein for immunoprecipitation 
is by sonication in low salt buffer.
5.2 Enrichment of LANA1 from BC-3 cells
The anti-LANA1 column was tested for an ability to capture LANA1 
from BC-3 cells lysate. I used an AKTA explorer FPLC system that 
allowed the development of chromatographic methods. Conditions for 
the running of the columns had previously been calculated to be 
between 0.5-0.7ml/min as determined by the type of media, the size of 
the columns and the packing conditions. Initially the columns were run 
at 0.7ml/min. BC-3 cells were lysed in low salt buffer with sonication 
and prior to binding were diluted with MilliQ dH20 and adjusted to pH 
7. Columns were pre-equilibrated in 10mM Tris-HCL pH 8. After 
binding, washing and elution, protein was detected by the AKTA 
system and aliquoted. The resulting chromatograph showed the 
elution of two distinct peaks (Fig 5.3A). The first peak may contain 
weakly associated non-specific proteins, perhaps bound to the column 
media, which were not removed by washing. Western blot analysis of 
fractions shows strong positive band at 220-235kDa for LANA1 using 
an anti-LANA1 antibody (Fig 5.3B). When compared to the positive 
control (BC-3 cells) despite a far higher BC-3 protein quantity the 
I.ANA1 signals in the purified fractions are higher, indicating 
enrichment i.e. 1.4pg vs 0.4^g (Fig 5.3B). The strongest LANA1 
signal correlated with the two protein peaks eluted from the column. 
The second peak may contain proteins associated with the antibody 
and may therefore be specific. It was decided in future experiments to 
attempt to separate the two peaks by decreasing the size of the 
fractions. Coomassie staining of column-eluted protein reveals a 
distinct pattern different to that seen in pre-bound extracts (Fig 5.3C). 
This patterning indicates the purification of certain proteins and a 
reduction in others. These data showed that LANA1 was purified from 
BC-3 cells by the column. Although preliminary, the Coomassie blue 
banding pattern also suggested co-purification of associated proteins. 
LANA1 is purified from BC-3 extracts by the CNBr LN53 column. To 
further investigate column specificity, a negative control column (rat 
IgG) was used to perform a control purification.
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Fig 5.3 -  LANA1 is purified from BC-3 extracts by the CNBr LN53 
column. A, Binding and elution of LANA1 from CNBr LANA1 column 
2.3x108 BC-3 cells were lysed in low salt buffer as described in 
materials and methods. After column equilibration, lysate was bound 
for 3 1/2hrs at 0.7ml/min. After washing, bound proteins were eluted 
in 10OmM glycine pH 2.7 and neutralised with 1M Tris pH 8.0. An 
example chromatograph is shown, demonstrating the presence of two 
distinct protein peaks. Samples were desalted on PD-10 columns, 
concentrated by spin-vac and resuspended in low salt buffer. B, 
Detection of LANA1 in CNBr-LN53 column fractions using anti-LANA1 
rat monoclonal antibody. 5jnl from each fraction (1 OOjj.1 total per 
fraction) was separated on a 6-12% SDS-PAGE gel and run for 2hrs 
at 120V. 5jnl of pre-bound BC-3 lysate was used as a positive control. 
Proteins were transferred to a Hybond-P membrane over night at 0.1 A 
in MeOH transfer buffer. Membranes were blocked in 
PBS+Tween+milk powder and probed with anti-LANA1 LN72 rat 
monoclonal diluted 1:1000 in 10% blocking buffer for 2hrs. After 
washing, anti-Rat Hrp (Santa Cruz) was incubated with the 
membranes for 1 hr and bands were visualised after further washing 
with ECL+ (Amersham Pharmacia Biotech) and ECL film (Amersham 
Pharmacia Biotech). Membranes were stained with coomassie blue 
and air-dried at 22°C. C, A distinct protein pattern is revealed by 
coomassie staining on column elutes. 8pl of each column fraction and 
pre-bound BC-3 were run on a 6-12% SDS PAGE gel. Protein was 
visualised by staining with coomassie blue. A distinct banding pattern 
is seen in column elutes when compared with pre-bound BC-3 lysate.
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This was important as the peaks may have been non-specific and 
resulted from retardation of protein after passage over the column. A 
control of CNBr beads alone could have been used, but it was decided 
that an antibody control was preferable. Ideally, the antibody would 
have been an isotype control, but this was not available at the time. 
Fig 5.4 shows the results of this control column as compared to a new 
purification on the anti-LANA1 column. This experiment achieved 
separation of the two peaks into separate fractions. Two peaks are 
again seen in the anti-LANA1 column (LN53) elutes (Fig 5.4B) 
whereas only one peak is seen in elutes from the control column (rat 
IgG) (Fig 5.4A). Western blot analysis showed that strong LANA1 
signal was associated with the second smaller eluted peak (Fig 
5.4B). This further reinforces the previous result showing specific 
elution of enriched LANA1 from the LN53 column. The rat IgG column 
shows little enrichment of LANA1, although some may be present due 
to the low salt and non-stringent conditions used.
The above data provide evidence that the second peak is specific and 
contains LANA1. At this point it was unclear if LANA1 elutes prior to 
its interacting proteins, or after the proteins bound to it. On this basis 
fractions 8, 9 and 10 were analysed by SDS-PAGE and coomassie 
blue staining, to identify unique proteins. Any unique proteins, found 
in the anti-LANA1 column but not the control column would be 
selected for identification by MALDI-TOF MS. Unfortunately, the gel 
revealed no specific bands (data not shown).
Western blot analysis of concentrated fractions from the columns 
showed good recovery of LANA1 from cells. These data, in 
combination with the observation that the negative column does 
appear to recover a small amount of BC-3 from cells (Fig 5.4B), lead 
to the conclusion that the experimental conditions may not be optimal. 
The protein eluted from the LN53 and Rat IgG columns was high for 
the purification of a protein that probably represents >0.01% of total 
cell protein.
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Fig 5.4 - Purification of LANA1 complex from BC-3 cells using a 
CNBr-LN53 column and a control CNBr-Rat IgG column. A & B, BC- 
3 cells (c.4x108) were lysed in low salt lysis buffer (50mM Tris, 50mM 
NaCI, 1% IEGAL-CA 630, 1mM PMSF, 0.5% protease inhibitor 
[Sigma]) and disrupted by sonication. Lysates were rotated for 1 hr at 
4°C, diluted 1:5 in MilliQ dH20 and adjusted to pH 7 prior to binding. 
Rat IgG (A) and LN53 (B) and columns (stored in 20% EtOH) were 
equilibrated in 10mM Tris pH 8.0 on an AKTA FPLC Explorer system. 
Lysates were bound overnight by circulation at 0.5ml/min. Columns 
were washed in 10mM Tris pH 8.0 until baselines were at OmAu. 
Protein was then eluted from the columns using 100mM glycine pH 2.7 
over a 5 column volume 100% gradient. 1 ml fractions were collected 
and neutralised with 10Ojul of 1M Tris pH 8.0. After elution Rat IgG 
column (A) has 1 peak, whereas LN53 column (B) shows 2 peaks. 
Protein eluted from each column was desalted, dried by centrifugation 
and resuspended in modified RIPA buffer. Protein was separated on 
a 6% SDS-PAGE gel and LANA1 was detected by western blotting 
with anti-LANA1 rat monoclonal (LN53) (shown beneath 
chromatographs). LANA1 was enriched in fraction 8 which 
corresponds to peak 2 on the chromatographs (Fig 5.4B).
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This result calls into question the stringency of the purification. A 
possible criticism of any protein complex purification strategy is 
specificity. How can it be certain that proteins eluted from the 
columns are actually part of the complex? Initial purifications have 
been undertaken with BC-3 cells lysed and disrupted in non-stringent 
conditions. Low salt buffer was used with sonication possibly resulting 
in non-specific interactions. The columns were run at low salt levels 
(10mM Tris pH 8.0), which may have possibly lead to non-specific 
protein interactions with the columns/captured LANA1. The 
adjustment of cell lysates to pH 7 may have also been a factor.
The purification was repeated using more stringent conditions in which 
a modified RIPA buffer (150mM NaCI, 50mM Tris pH 8.0, 0.1% SDS, 
1mM PMSF, protease inhibitors) was used to lyse cells. RIPA buffer 
is commonly used for such experiments as its composition closely 
matches the cytoplasm of a mammalian cell. The affinity columns 
were then equalised in Buffer A (75mM NaCI, 25mM Tris pH 8.0 
0.5mM PMSF) and lysates were diluted to 50% RIPA prior to binding. 
For these experiments cell lysates were not pH adjusted.
Columns were again run on AKTA FPLC systems. Results were 
significantly different from those obtained with the low salt buffer. The 
chromatographs showed elution of a specific peak relating in position 
post-elution to the second peak on the low salt lysate columns (Fig 
5.5A & B). Under these more stringent conditions (50% RIPA) the first 
peak containing a large quantity of protein was markedly absent, 
despite a similar number of cells being used. This indicated a more 
selective capture of proteins. As the eluted protein levels were so low, 
there was concern that proteins had simply not bound to the columns. 
To investigate this immunodepletion of LANA1 was demonstrated by 
western blotting of lysates both pre and post circulation over the 
columns (Fig 5.5C). LANA1 was absent from the lysates passed over 
the LN53 column, but the quantity of LANA1 as compared to pre­
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bound lysates did not change after circulation over the control rat IgG 
column. Overall, these data provided evidence for the total depletion 
of LANA1 from cell lysates by a specific method. By increasing the 
stringency of binding and washing on the columns I had reduced 
background and efficiently removed LANA1 from BC-3 cell lysates.
The post-elution 1ml fractions from the LN53 column (fractions 15-26) 
(Fig 5.5A & B) were pooled, desalted, vacuum centrifuged and 
resuspended in 100% modified RIPA. The corresponding fractions 
from the rat IgG column were processed in parallel. Unfortunately 
insufficient protein was eluted for western blot analysis. Protein was 
diluted in loading buffer and loaded onto a 10% SDS-PAGE gel and 
separated overnight. Following staining and destaining, the gel was 
scanned and specific bands observed (Fig 5.6). A total of 3 bands in 
the rat IgG column elutes and 27 bands in the LN53 column elutes 
were observed. Bands 1-27 from the LN53 column elutes were 
selected for identification by MALDI-TOF MS (Fig 5.6).
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Fig 5.5 - Capture of LANA1 from 50% RIPA BC-3 cell lysates using 
affinity columns. A & B, 6x108 BC-3 cells were lysed in modified RIPA 
buffer and diluted to 50% RIPA in dH20. Columns were equilibrated in 
25mM Tris, 75mM NaCI and 0.5mM PMSF. Lysates were circulated 
O/N, washed and eluted in low pH glycine (pH 2.7). Aliquots 15-26 
were pooled, desalted, concentrated and resuspended in RIPA buffer. 
Equal quantities for BC-3 cell lysates were circulated over a Rat-IgG 
control column (A) and an anti-LANAl (LN53) column (B). Fig 5.5 
shows the presence of a greater reduced peak in the same area as 
the second peak on Fig 5.4, indicating greater specificity of 
purification. As these peaks correspond in terms of time after elution, 
they are comparable. The proteins were used to run an SDS-PAGE 
gel for identification of proteins by MALDI-TOF MS. C, 
Immunodepletion of LANA1 from pre- and post-affinity lysates. Cell 
lysates before and after circulation over affinity columns were tested 
for the presence of LANA1 by western blotting. LANA1 is completely 
removed by passage over the anti-LANA1 affinity column, but not by 
passage over the control (Rat IgG) column.
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Fig 5.5  
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Fig 5.6 - SDS-PAGE of affinity captured LANA1 complex. Proteins 
eluted from anti-LANA1 and rat IgG columns under 50% RIPA binding 
conditions were separated by SDS-PAGE electrophoresis on a 10% 
gel. Proteins from affinity chromatography experiments (Fig 5.5 A&B) 
were separated on a 10% SDS-PAGE gel and run until the dye front 
was lost. The gel was then stained with Coomassie Brilliant Blue and 
destained over several days. Protein bands were excised and 
identified by mass spectrometry (see Materials and Methods).
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5.3 Identification of LANA1 complex members
After excision and tryptic digestion polypeptides were identified by 
MALDI-TOF MS, MALDI-PSD/LIFT MS/MS and nano-HPLC-ESI-CID 
MS/MS. The proteins identified as interacting with the LANA1 column 
from the affinity chromatography method are listed in Table 5.1. The 
table shows data from both MALDI-TOF and protein MS/MS 
identification methods. From this initial data, novel interaction 
partners of LANA1 were identified. These included polyadenylate 
binding protein 1 (PABP1), heterogeneous nuclear ribonucleoprotein 
A1 (hnRNP A1), galectin-3, HSP73 and histone H1. The presence of 
keratin was assumed to be due to contamination. Rat IgG antibody 
was also identified having co-eluted with proteins from the column.
When identifying gel bands from 1-D gels it is possible that there is a 
mixed population that is difficult to identify using MALDI-TOF MS. In 
these cases the use of protein sequencing allows the identification of 
mixed protein populations. Several of the most abundant polypeptides 
were identified by Nano-HPLC ESI MS/MS (Table 5.1). Several 
members of histone H1 were found to co-migrate in bands with other 
proteins and therefore share the same polypeptide number (Table 
5.1). LANA1 has been previously shown to bind histone H1, and via 
this interaction maintain the KSHV viral episome (Ballestas et al. 
1999;Cotter and Robertson 1999). Histone H1 family members 4 and 
5 were identified, but no other histones i.e. H2A, H2B, H3, H4 were 
immunoprecipitated. Previously it has been shown that LANA1 can be 
co-immunoprecipitated with histone H1 but not histones 3 or 4 (Cotter 
and Robertson 1999).
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Table 5.1
Polypeptide
number
Protein Name NCBI
Accession
Identification method
MALDI-
TOF
MALDI
LIFT
/PSD
MS/MS
CID
ESI
MS/MS
Nano-
HPLC
ESI
MS/MS
pp24.5 Cleavage and polyadenylation 
specific factor 5, 25kDa subunit
X
PP27 Galactose-specific lectin AAA88086 X
pp27.5 Galactose-specific lectin AAA88086 X
pp27.5 Histone H1 family, member 4 NP_005312 X
PP28 Small nuclear ribonuclear 
nucleoprotein polypeptide A
NP_004587 X X
PP28 Histone H1 family, member 5 NP_005313 X
pp29.5 Heterogeneous nuclear 
ribonucleoprotein A1
NP_002127 X X
pp30 Heterogeneous nuclear 
ribonucleoprotein A1
NP_002127 X X
pp49 lgG-2C Chain C region (rat) P20762 X X
pp65 Keratin contamination X
PP72 Polyadenylate-binding protein 1 
(PABP1)
P11940* X
PP74 HSP73 NP 006588 X
Table 5.1 LANA1 column interacting proteins captured by affinity 
chromatography and identified by MALDI-TOF mass spectrometry 
(MS) and/or nano-HPLC-ESI-CID MS/MS. Proteins are referenced by 
their polypeptide size (pp) as compared with molecular weight size 
markers and by NCBI accession numbers. Proteins identified were of 
human origin unless otherwise stated.
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The data at this point provided the identifications of 9 LANA1 column 
interacting proteins. I was able to discount the identification of rat IgG 
as contamination from the experimental method, as well as keratin, 
which is a common contamination of mass spectrometry gels. At this 
point a general trend in the types of protein identified became 
apparent. Of the remaining 7 proteins, 6 have roles in cellular 
splicing/transport of mRNA. One of these proteins (hnRNP A1), also 
has a role in telomere biogenesis. Furthermore, a large proportion of 
the identified proteins have either a nuclear localization, or are known 
to shuttle between the cytoplasm and the nucleus. As LANA1 is 
known to have a nuclear localization this data reinforces the likelihood 
of a real interaction. I will give a brief overview of the most interesting 
proteins in regard to LANA1:
Cleavage and polyadenylation specific factor 5 (CPSF-5) is a member 
of a complex required for 3’ cleavage and subsequent polyadenylation 
of RNA. It is also commonly termed the “pre-mRNA cleavage factor 
Im (25kDa) and was identified as a co-purifying polypeptide with CF lm 
activity (Ruegsegger et al. 1996). Subsequently it was cloned and 
characterised as possessing no known structural motifs (Ruegsegger 
et al. 1998). Recently, the purification and characterization of the 
human spliceosome using proteomics has revealed many interesting 
new interactions (Zhou et al. 2002). Among these was the presence 
of cleavage factor Im, 25kDa subunit (CPSF-5) (Zhou et al. 2002).
Galactose-specific lectin is also termed Galectin-3 and as its name 
suggests is a galactose-specific lectin which binds IgE antibody. Its 
localization is normally nuclear, but changes to cytoplasmic in 
malignancies such as carcinomas. Galectin-3 has been characterised 
as interacting with several important cellular proteins including bcl-2 
(Akahani et al. 1997;Yang et al. 1996) and Gemini4 (Park et al. 2001). 
Galectin-3 has been shown to be present in SMN-containing 
complexes which complement the H/E splicing complex by the 
addition of functional snRNPs (Pellizzoni etal. 1998).
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Polyadenylate binding protein (PABP1) is a 72kDa protein that 
contains four RNA-binding domains (RRM). PABP1 is a versatile and 
important protein involved in cellular activities including translation 
initiation, mRNA deadenylation, mRNP maturation, and RNA stability. 
It is also known to shuttle between the nucleus and the cytoplasm, 
aiding in the formation and transport of mRNPs (Afonia et al. 1998).
Heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) is an 
abundant member of the H-complex. Its functions include mRNA 
splicing, mRNA transport and a role in the biogenesis of telomeres.
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5.4 Immunoaffinity purification
While the methods for LANA1 purification using affinity 
chromatography had proved successful, it was decided to attempt a 
different method of purification. The AKTA FPLC system was 
originally used as it was predicted that the purification of a LANA1 
complex would require several steps, including affinity 
chromatography, ion-exchange and gel filtration. This type of method 
had been used successfully by other groups to purify a native protein 
complex. It was evident, however, from the affinity chromatography 
experiments that the capture of LANA1 by a single step was sufficient. 
This was judged by the percentage of LANA1 captured (100%) and 
the difference between specific and control columns protein bands 
(9:1 respectively). This one step allowed a lower quantity of starting 
material (cell lysate) to be used, therefore making the system 
convenient in terms of cell culture. Subsequently purification 
experiments were undertaken using the media from the columns 
(LN53 & ratlgG antibodies). This new method was termed large-scale 
immunoaffinity purification. This employed the same reagents as the 
affinity chromatography, but the experiment took the form of a large- 
scale immunoprecipitation, not involving the use of an FPLC system. 
In brief, cell lysates were circulated over the antibody media, 
immunocomplexes were washed and bound protein eluted using the 
same buffers as previously. As elution was in one tube, no pooling of 
samples was required. Eluted protein was desalted and concentrated 
as before. As this was a change in protocol from the affinity 
chromatography method, the capture of LANA1 from cell lysates was 
again checked. This was done by western blotting on both pre and 
post-bound fractions and on washed beads, which should contain 
bound LANA1 immunocomplexes (Fig 5.7). Equal amounts of pre­
circulated BC-3 lysate and BC-3 lysates passed over both the positive 
and negative beads were subjected to western blotting with anti- 
LANA1 antibody to confirm immunodepletion and immunoprecipitation 
(sampled prior to elution) of LANA1 (Fig 5.7A & B).
145
Fig 5.7 - Immunoprecipitation/lmmunodepletion of LANA1 from BC-3 
extract by large scale immunoaffinity. A, Western blotting on pre- and 
post-binding lysates shows that LANA1 was removed completely from 
cell lysates by the anti-LANA1 CNBr beads. B, Eluted proteins from 
either the anti-l_ANA1 or control rat IgG were subjected to western 
blotting. LANA1 was detected in proteins eluted from the anti-LANA1 
large-scale immunoaffinity purification only.
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LANA1 is immunoprecipitated only by the anti-LANA1 beads (Fig 
5.7B) and the efficiency of the large-scale immunoprecipitation was 
high as all LANA1 was efficiently removed from circulated lysates (Fig 
5.7A). From these data I was confident that the native complex of 
LANA1 had been purified. The percentage of LANA1 removed from 
cell lysates was again 100% showing a high level of efficiency. The 
ratio of proteins that co-purified with LANA1 as compared to the 
negative control was acceptable and the system was therefore 
suitable for the identification of proteins interacting directly/indirectly 
with LANA1.
During these experiments hnRNP A1 was used a control for the 
immunoprecipitation of the LANA1 complex as it had been identified 
as an interaction partner by affinity chromatography. High levels of 
immunoprecipitation of LANA1 and hnRNP A1 are observed by the 
LN53 columns whereas the Rat IgG column does not 
immunoprecipitate LANA1 and subsequently hnRNP A1 (Fig 5.7B). 
Western blotting for immunodepletion shows that although 100% of 
I.ANA1 is captured from 3x108 BC-3 cells a more subtle decrease in 
levels of hnRNP A1 are observed (Fig 5.7A). This is likely due to the 
relative abundance of each protein. hnRNP A1 is one of the most 
abundant nuclear proteins in cells, whereas LANA1 is a virally 
encoded protein with relatively low levels of expression. Proteins for 
identification by mass spectrometry were again separated on a 10% 
SDS-PAGE gel and bands visualised by Coomassie brilliant blue 
staining (Fig 5.8). Improvements in the processing methods for the 
samples resulted in an increased number of identified interaction 
partners. Table 5.2 lists the proteins identified. Positive identification 
was again obtained for Histone H1, hnRNP A1 and PABP1. Further 
proteins identified included human p32, several other hnRNP proteins, 
cyclophilin and galactose-specific lectin. As with the affinity 
chromatography method, several proteins co-migrated on the gels and 
required identification by MS/MS. Overall, 25 proteins (excluding rat
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Ig protein and keratin) were identified using immunoaffinity purification, 
of which 6 were confirmed by earlier data from my affinity 
chromatography experiments. The functions for each of the 25 
identified proteins, where known, are shown in Table 5.3.
hnRNP proteins
The data obtained from the affinity chromatography experiments 
showed hnRNP A1 was a LANA1 binding protein. The immuno affinity 
purification data replicates these data, but also identifies hnRNP AB, 
hnRNP A2/B1, hnRNP D and hnRNP I (polypyrimidine tract binding 
protein). Some of these proteins are members of the H-complex 
present within mammalian cells (Table 5.4). As evident from the table, 
HSP73, also identified as a LANA1 column interacting protein, is a 
further member of the complex.
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Fig. 5.8 - Large-scale immunoaffinity purification of a native LANA1 
complex. 3x108 BC-3 cells were lysed in RIPA, diluted to 50% and 
passed over either an anti-LANA1 (LN53) or control IgG CNBr beads. 
Immune complexes were washed and protein was eluted with 100mM 
glycine pH 2.7. Eluted proteins were pooled, desalted, vacuum dried 
and resuspended in RIPA buffer. Protein was separated on a 10% 
SDS-PAGE gel and stained with coomassie brilliant blue. Molecular 
markers are shown on each side of the gel. Bands were excised, 
subjected to tryptic digestion and identified by mass spectrometry.
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Table 5.2. LANA1 column interacting proteins captured by 
immunoaffinity purification and identified by MALDI-TOF mass 
spectrometry (MS), MALDI-PSD/LIFT tandem mass spectrometry 
(MS/MS) and nano-HPLC-ESI-CID MS/MS. Proteins are referenced 
by their polypeptide size (pp) as compared with molecular weight size 
markers and by NCBI accession numbers. Where homology lead to 
more than one protein entry match from the database search, a 
representative NCBI accession number is given and marked (*). 
Proteins identified were of human origin unless otherwise stated.
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Table 5.2
Polypeptide
number
Protein Name NCBI
Accession
Identification method
MALDI-
TOF
MALDI 
LIFT/PSD 
MS/MS
CID
ESI
MS/MS
pp15 Cyclophilin AAA35733* X X
pp20 Stromal cell derived factor 2-like 1 XP 096152 X
PP20 Ribosomal protein AAB00969* X
PP25 Ig kappa chain (rat) AAA41395* X
PP27 Galactose-specific lectin AAA88086* X X
PP27 Endoplasmic reticulum lumenal 
protein 28
NP_06808 X
PP27 Heterogeneous nuclear 
ribonucleoprotein A2/B1
NP_112533* X X
PP27 PYM protein NP 115721* X X
PP27.5 Galactose-specific lectin AAA88086* X
pp27.5 Heterogeneous nuclear 
ribonucleoprotein A2/B1
N P J12533* X
PP28 FK-506-binding protein 3 NP 002004 X
PP28 Galactose-specific lectin AAA88086* X X
pp31.5 Transcriptional activator ALY AAD096608* X
PP32 Small nuclear ribonuclear 
nucleoprotein polypeptide A
NP_004587 X
PP32 Similar to heterogeneous nuclear 
ribonucleoprotein A1
XP_015697* X
PP32 bZIP enhancing factor NP 005773 X
PP32 Complement component 1, p32 
splicing factor S
NP_001203* X
PP32 Histone H1 JX0087* X
PP32 Ig gamma-2c chain C region (rat) 121056 X
pp34.5 Heterogeneous nuclear 
ribonucleoprotein A1
NP_002127 X
pp35 Heterogeneous nuclear 
ribonucleoprotein A1
NP_002127* X
pp36 Annexin A2 AAH23990* X
pp36 Apex nuclease S47521* X
PP37 Heterogeneous nuclear 
ribonucleoprotein A/B
XP_038946 X
pp39 Heterogeneous nuclear 
ribonucleoprotein D
NP_002129* X
pp41 Heterogeneous nuclear 
ribonucleoprotein D
NP_002129* X
pp50 lgG-2C Chain C region (rat) P20762 X
PP52 lgG-2C Chain C region (rat) P20762 X
PP52 Similar to DKFZP564M2423 AAH03049 X
pp54 Polypyrimidine tract binding 
protein (PTB) 
(Heterogeneous nuclear 
ribonucleoprotein I)
NPJ 14368* X
PP54 lgG-2C Chain C region (rat) P20762 X
PP62 Splicing factor 3a, subunit 2, 
66kDa
NP_009096* X
PP74 HSP73 NP 006588 X
PP75 Polyadenylate-binding protein 1 
(PABP1)
P11940* X
PP76 Keratin contamination X
PP24 Nuclear RNA helicase, DECD 
variant of DEAD box family
XP_031276* X
PP24 Ig kappa chain AAA41395* X
PP24 PDGF associated protein NP 055706 X
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PP26 Heterogeneous nuclear 
ribonucleoprotein A2/B1
NP__002128* X
PP26 Galactose-specific lectin AAA88086 X
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Table 5.3
Protein Name NCBI
Accession
Function Localisation
Cyclophilin AAA35733 peptidyl-prolyl cis-trans isomerase ER
Stromal cell-derived factor 
2-like1
XP 096152 - -
Ribosomal protein AAB00969 Cellular ribosomes ER
Galactose-specific Lectin AAA88086 Galactose-specific lectin which binds 
IgE.
Nuclear, 
(Cytoplasmic in 
adenomas and 
carcinomas)
Heterogeneous nuclear 
ribonucleoprotein A2
NP 002128 Involved in pre-mRNA processing. 
Member of ribonucleosomal 
complexes
Nuclear 
Component of 
ribonucleosomes
Hypothetical protein 
MGC13064
NP 115721 - -
FK506-binding protein 3 NP 002004 FK506/Rapamycin binding protein
Transcriptional coactivator 
ALY
AAD09608 Mediator of the TCRalpha enhancer 
complex
Nuclear
Heterogeneous nuclear 
ribonuclearprotein A1
NP 002127 Member of ribonucleosomal 
complexes. Modulation of splice site 
selection. Packages pre-mRNA into 
hnRNP complexes Transport of poly 
A+ mRNA from the nucleus to the 
cytoplasm.
Nuclear;
Nuclear/cytoplasmic 
shuttling protein
Annexin A2 AAH23990 Plasminogen receptor Cell surface
bZIP enhancing factor NP 005773 Transcriptional co-activator Nuclear
Apex nuclease S47521 - -
Heterogeneous nuclear 
riboncleoprotein A/B
XP 038946 RNA splicing Nuclear/Cytoplasmic
Nuclear ribonucleoprotein D
NP 002129
Binds to RNA containing AU-rich 
elements.
Nuclear; Member of
ribonucleosomal
complexes.
Similar to DKFZP564M2423 AAH03049
Polypyrimidine tract binding 
protein (PTB) (also hnRNP 
I)
NP 114368
Involved in pre-mRNA splicing. Binds 
to the polypyrimidine tract of introns. 
May promote the binding of U2 snRNP 
to pre-mRNA.
Nuclear
Splicing Factor 3a, subunit 
2, 66kD (SAP62)
NP 009096 Subunit of the splicing factor SF3a 
required for 'A’ complex formation. 
May anchor U2 snRNP to the pre- 
mRNA. Possibly also involved in the 
‘E’ complex assembly.
Nuclear; A main 
component of the 
SF3A complex 
(SF3A3/SAP61, 
SF3A2/SAP62, 
SF3A1/SAP114). The 
U2 snRNP 
ribonucleoprotein 
complex is formed by 
the binding of SF3A 
to SF3B and a 12S 
RNA unit.
HSP73
Identical to HSP71 
(P11142)
NP 006588 Heat shock protein involved in protein 
folding. May also act as an ATPase
Polyadenylate-binding
protein
P11940 Binds mRNA at the polyA tail Cytoplasmic; 
Nuclear/cytoplasmic 
shuttling protein
Nuclear RNA helicase, 
DECD variant of DEAD box
XP 031276 - -
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family
PDGF associated protein NP 055706 Signal transduction/cell proliferation
snRNP U1A NP 004587 Member of the spliceosome complex Nuclear
PYM protein NP 115721 - -
Histone H1 JX0087 Essential for the condensation of 
nucleosome chains into higher order 
structures
Nuclear
Human p32 NP 001203 RNA splicing, binds SF2 Mitochondrial/Nuclear
Table 5.3
Pooled functional annotation data for all proteins identified as 
interacting directly/indirectly with LANA1 by affinity chromatography 
and immunoaffinity purification.
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Table 5.4
Spliceosome proteins Identification method
U1 specific proteins
U1 A Immunoaffinity purification
Cyclophilin Immunoaffinity purification
Cleavage factor Im, 25kDa subunit Immunoaffinity purification
H-complex components Identification method
hnRNP A1 Immunoaffinity purification
hnRNP A2/B1 Immunoaffinity purification
hnRNP D Immunoaffinity purification
hnRNP l/PTB Immunoaffinity purification
HSP73 Immunoaffinity purification
Table 5.4 -  Spliceosome and H-complex members identified as 
interacting directly/indirectly with LANA1.
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5.5 LANA1 interactions identified by yeast two-hybrid screening
To complement the immunoaffinity purification data I sought to confirm 
and identify further direct protein-protein interaction partners of 
LANA1, using a yeast two-hybrid screening system. Two areas of 
LANA1 were selected as bait -  amino acids 1-337 and 893-1130. 
Unfortunately, the carboxyl terminus of LANA1, aa893-1130, were 
toxic in yeast. Screens with the amino terminus of LANA1, aa1-337, 
identified interactions with several novel proteins (Appendix II). One 
of these proteins, SAF-B, contains a RRM domain in common with 
many other proteins identified by immunoaffinity purification and mass 
spectrometry.
SAF-B, also termed HAP, heat-shock protein (HSP27) estrogen 
response element and tata box-binding protein (HSP27 ERE-TATA- 
binding protein) is a 849 amino acid with a predicted molecular weight 
of 96,696 Da (Renz and Fackelmayer 1996). Purified SAF-B migrates 
at 150kDa on denaturing SDS-PAGE due to a high number of charged 
amino acids (Renz and Fackelmayer 1996). SAF-B binds to S/MAR- 
DNA, which are regions of DNA that are A T rich sequences. Several 
proteins have been identified as S/MAR-DNA binding proteins, 
including SAF-A (hnRNP U) (Fackelmayer et al. 1994) and Histone H1 
(Izaurralde et al. 1989). The relevance of an interaction between 
SAF-B and LANA1, in the context of the large-scale 
immunopurification data are discussed later.
The raw data and summary data for SAF-B are shown in Table 5.5 
and Fig 5.9A, respectively. Two clones of SAF-B were identified by 
yeast two-hybrid screening and corresponded to aa341-825 and 
aa357-777. Both of the clones sequences overlapped with the RRM 
domain of SAF-B, which is located at aa409-480 (Fig 5.9A).
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Table 5.5
Contig
number member Se«uence' D
Percentage Protein Function 
match vs name 
Genbank 
sequence
Contig918363 2
gi|4506778|ref|NM_002967.1| 
Homo sapiens scaffold 
attachment factor B (SAFB), 
mRNA
97.9
SAF-B
Hsp27
ERE-
TATA-
binding
protein
(HET)
Scaffold
attachment
Contig918358 2
gi|4506778|ref|NM_002967.1| 
Homo sapiens scaffold 
attachment factor B (SAFB), 
mRNA
99.5
SAF-B Scaffold
attachment
Table 5.5 - Identification of SAF-B as a LANA1 interacting protein 
using yeast two-hybrid analysis. LANA1 (aa1-337) was used as bait 
for a yeast two-hybrid screen. Several interacting partners were 
identified and are listed in appendix II. Details of SAF-B are shown.
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Fig. 5.9 - LANA1 protein-protein interaction domains. A, SAF-B was 
identified as binding to the amino terminus of LANA1 (aa1-337) by 
yeast two-hybrid analysis. Data show independent clones rescued. 
B, Several proteins identified as directly/indirectly interacting with 
LANA1 share common RNA-binding domains (RRM/RBD domains). 
Domain data were obtained from the NCBI.
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Fig 5.9
Clone
A
B
1
A.acid
341-825
357-777
RRM SAF-B409 480 OMr D 915
B Size (amino acid) Interaction
Protein
p 2p0 4p0 6p0 - ^ J O O O  lp/MS Y-2-H In vitro
hnRNP A1 + - +
UP1 - - +
hnRNPA2 + - NT
hnRNP AB + KIT
hnRNP D + -
IN I
NT
hnRNPI + - NT
PABP1 + - NT
snRNP poly A — -------------------- + - NT
bZIP enhancing + - NT
factor
SAF-B NT
H H  RRM/RBD RNA binding domain 
NT = Not tested
Protein-protein interaction domain: RRM domain 
SAF-B contains an RNA binding domain in common with many of the 
other novel LANA1 interaction proteins, which are summarized in Fig 
5.9B. The RNA-recognition motif (RRM), also termed RNA binding 
domain (RBD) and ribonucleoprotein consensus sequence (RCS), is 
common among many hnRNPs and proteins involved in splicing (Xu et 
al. 1997).
Overall the data obtained by both methods of interaction screening 
revealed the RRM domain as a common target for LANA1. From the 
pooled data 9 novel interaction partners of LANA1 were identified 
which had at least one RRM domain. However, the proteins hnRNP 
A1, hnRNP A2/B1 and hnRNP D all also contain an RGG site, located 
in the carboxyl terminus. The interaction between LANA1 and the 
RRM sites will be developed in Chapter 6.
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5.6 Discussion and conclusion
Biological experiments are becoming increasingly global in cellular 
scale. Previously protein-protein interactions were often studied at a 
one-to-one scale. Techniques that fall under the recently popular field 
of proteomics were successfully used to obtain and characterise the 
native LANA1 complex.
KSHV is an infectious agent directly implicated in the etiopathogenesis 
of several important human malignancies including KS, MCD and PEL 
(Cesarman et al. 1995;Chang et al. 1994;Soulier et al. 1995). Of all 
KSHV proteins, LANA1 is one of the few proteins expressed in all 
tumor cells, interacts with a broad spectrum of important cellular 
proteins and acts as both a transcriptional activator and repressor. In 
this work I sought to identify further novel interactions of LANA1 that 
may have direct relevance to pathology. By employing a protein 
complex capture method and a yeast two-hybrid system I identified 
several novel LANA1 complex proteins.
The work presented in this chapter represents the first attempt to 
purify a native LANA1 complex. When employing a novel method it is 
important to obtain data that overlaps with previous knowledge in the 
field. As techniques differ from group to group and lab to lab it is not 
possible to recreate the conditions for several experiments in one. In 
the case of LANA1, more than 10 groups have reported LANA1 
interacting proteins often using different methods. In this chapter I 
report the confirmation of data from two such groups publishing on two 
ORF73 interacting proteins; Histone H1 and cellular p32 (the latter 
was identified as an HVS ORF73 interacting protein)(Hall et al. 2002). 
These results not only show that the techniques employed for the 
capture and analysis of the LANA1 complex in this chapter were 
sound, but that greater confidence can be placed on the identification 
of novel LANA1 complex proteins.
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Recently the publication of an extensive characterisation of the human 
spliceosome was achieved (Zhou et al. 2002). This paper identified all 
previously known spliceosome components and also identified 58 new 
proteins. Among these proteins were several members identified as 
binding to LANA1, both by the Hybrigenics data and complex 
purification.
Coupled with yeast two-hybrid data I have identified not only several 
new interaction partners of LANA1, but also novel interaction domains. 
The RRM domain was identified by as an interaction domain by both 
yeast two-hybrid and the immunoaffinity purification work. The large 
proportion of the novel interaction partners of LANA1 described here 
have common protein domains. The hnRNPs, PABP1 and several 
others all contain RRM motifs (also termed RBD), protein domains 
required for RNA binding (Fig 5.9B).
As mentioned earlier, SAF-B was identified as interacting with LANA1 
by yeast two-hybrid. Identification of SAF-B as a direct protein-protein 
interaction partner was interesting as literature searches on SAF-B 
revealed further interaction partners. SAF-B is known to bind directly 
to two proteins I identified here, by immunoaffinity purification, as 
interacting with a LANA1 complex; hnRNP A1 and hnRNP D (Arao et 
al. 2000;Weighardt et al. 1999). The specificity of this interaction and 
the confirmation of direct protein-protein interactions with this domain 
are explored further in Chapter 6.
More recently evidence has emerged of an important role for several 
hnRNPs at the telomeres of mammalian cells (Ford et al. 2002). The 
telomerase complex whose components include hTR, telomerase 
reverse transcriptase (hTERT) and several associated 
ribonucleoproteins including hnRNP A1, C1/C2 and D, maintains 
mammalian telomeres. Telomerase activity is frequently upregulated 
in human tumors and extended telomeres are associated with lifespan
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extension (Hahn and Weinberg 2002). Both hnRNP A1 and its 
proteolytic derivative, UP1, were found to bind telomere sequences 
and UP1 was found to be sufficient for the maintenance of mammalian 
telomeres in vivo (LaBranche et al. 1998). hnRNP A1 and UP1 also 
protect mammalian telomeres from degradation by endonucleases and 
exonucleases (Dallaire et al. 2000). I identified here hnRNP A1, 
A2/B1 and D as LANA1 complex proteins (Fig 5.9). Telomere related 
protein Interactions identified by yeast two-hybrid and proteomics 
techniques, and their novelty, are highlighted in Fig 5.10. This 
suggests a role for LANA1 in the biogenesis of telomeres and is 
expanded upon in Chapter 6. The interaction of LANA1 with several 
hnRNPs and splicing factors suggests a role for LANA1 in the 
modulation of cellular and viral RNA splicing. The herpesviruses 
interact with a wide range of proteins involved in splicing and RNA 
metabolism. Human cytomegalovirus (CMV) immediate early protein 2 
(IE2) has been reported to bind hnRNP A1 (Wang et al. 1997) and in 
common with LANA1, IE2 has also been shown to bind pRB and p53 
(Hagemeier et al. 1994;Speir et al. 1994). SAP62, a subunit of the 
splicing factor SAF3a and a member of the U2 snRNP complex was 
identified here as a LANA1 complex protein. In herpes simplex virus 
(HSV-1) the multifunctional protein ICP27 (also termed IE63) binds to 
SAP 145, another member of the SAF3a splicing complex (Bryant et al. 
2001). Via this interaction, ICP27 has been shown to inhibit cellular 
RNA splicing. A further interaction partner of ICP27, the cellular 
protein p32 (Bryant et al. 2000) was also identified here as a KSHV 
LANA1 complex protein (Table 5.3). As p32 plays a role in cellular 
splicing and as it is targeted by ICP27, HSV-1 can further deregulate 
normal splicing functions. Herpesvirus saimiri (HVS) ORF73, a 
homologue of KSHV LANA1, was recently shown to interact with p32 
by yeast two-hybrid (Hall et al. 2002).
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Fig. 5.10 Interactions identified and/or confirmed in this thesis. By 
using two independent methods of interaction screening (yeast two- 
hybrid and large scale immunoaffinity purification) I identified several 
novel binding partners of LANA1. Proteins shown are either related to 
telomere biogenesis or share common RRM domains. Published 
interactions between proteins and/or telomeres and telomerase are 
shown.
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It is tempting to propose that interactions with cellular splicing factors 
may allow LANA1 to modulate KSHV transcripts and perhaps its own 
post-transcriptional modification. This is particularly relevant as 
LANA1 mRNA levels appear to be tightly regulated. LANA1 is 
transcribed with vcyclin and vFLIP on a polycistronic transcript (Talbot 
et al. 1999). Two forms of the transcript exist as 1.7kb and 5.32kb 
transcripts, the former of which is a splice variant that lacks LANA1 
and is increased by n-butyrate treatment (Talbot et al. 1999). Talbot 
et al suggest that changes in the relative levels of each transcript after 
n-butyrate treatment may be due to levels of hnRNP A1 and SF2. As 
LANA1 is located at the viral episome in KSHV-infected cells, the 
recruitment of hnRNP A1 by LANA1 may favour the selection of the 
distal splice site and increase the relative levels of the 1.7kb 
transcript. This presents a novel post-transcriptional mechanism for 
the control of LANA1 protein levels within KSHV infected cells.
A possible criticism of this work is that several proteins previously 
identified as interacting with LANA1 were not confirmed, for example 
p53 and pRB. While this is disappointing, it is perhaps not 
unexpected. During different phases in the cell cycle and stages in 
cell proliferation, interactions often change. Depending on which 
stage the cells are lysed at will identify interactions at that particular 
time-point. This was a consideration during the planning of this work 
and it was decided to use a heterogeneous population of cells. I have 
successfully identified many proteins using this method. It is possible 
that interactions with p53 and pRB are cell-cycle dependent and so 
would need more detailed protocols for capture of the complex 
containing them. Future work could aim to identify cell-cycle specific 
LANA1 -related complexes, using synchronised cells lysed at various 
times after induction of the cell cycle.
Several of the proteins identified using this method are highly 
abundant in mammalian cells, including hnRNP A1 and PABP1. In
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Hela cells, hnRNPAI is present at 70 x 106 molecules per cell 
(Kiledjian et al. 1994). The techniques used in the chapter to identify 
protein-protein interactions may have been limited by the level of 
starting material.
A further possibility is the stringency of the purification step. Initial 
work concentrated on the use of a low salt buffer to capture the 
LANA1 complex, but this buffer proved difficult to use as too many 
proteins co-purified with LANA1. Using this buffer it would not have 
been possible to identify specific LANA1 complex proteins. Therefore, 
the loss of some weakly interacting proteins may have been the price 
for the identification of strong and specific interacting proteins.
It was also interesting that LANA1 was not identified as an eluting 
protein from the columns. This could be due to several different 
factors. Firstly, the low abundance of LANA1 in BC-3 cells, in relation 
to other identified proteins (the hnRNPs and histones), may have 
resulted in insufficient material for identification. Secondly, the high 
molecular weight and unusual biochemical structure of LANA1 may 
have resulted in LANA1 precipitating out of solution during the elution 
(due to low pH) or protein concentrating steps (due to vacuum drying). 
When beads were tested prior to elution and concentration of protein, 
high levels of LANA1 were detectable. The lack of LANA1 
identification by MS is therefore likely to be due to the nature of 
LANA1.
Overall, I have identified many new interaction partners of LANA1 
using proteomic analysis. The majority of these new interaction 
partners have a role in cellular splicing. Proteins are either involved in 
the formation of the human spliceosome (CPSF-5, cyclophilin) or form 
part of the H-complex (hnRNPAI, A2/B1, D, I and HSP73). It is 
possible that by interacting with a broad range of proteins involved in 
spliceosome formation, RNA splicing and RNA transport, LANA1 may
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modulate cellular splicing. Alternatively, the formation and recruitment 
of such factors to the viral episome would be beneficial to the life-cycle 
of the virus, enabling the preferential processing of viral transcripts. 
Further studies will elucidate these putative functions of LANA1.
170
Chapter 6 Results
hnRNP A1 is part of a native LANA1 complex
Chapter aims: The aim of this chapter was to further confirm and 
investigate the protein-protein interaction data for LANAI Further 
experiments were undertaken in an attempt to understand the 
functional implications of the interaction data.
6.1 Conformation of interacting proteins
To confirm interactions identified from the columns, 
immunoprecipitations, GST-pulldown assays and for some interacting 
proteins, functional assays were performed. From the combined 
Hybrigenics (Paris, France) and IP/MALDI results common interaction 
domains became obvious. The majority of proteins interacting with 
LANA1 from the columns possessed at least one RNA binding domain 
(RRM/RBD), with several possessing multiple motifs up to a maximum 
of 4. A selected number of proteins were chosen for further analysis. 
These were hnRNP A1, PABP1 and galactose specific lectin 
(Galectin-3). A bank of GST-LANA1 constructs were used to screen 
for the interaction domains on LANA1.
Galectin-3, Galactose specific lectin, also termed Galectin-3 is a 
multi-functional protein with roles in several different areas of the 
cellular life cycle (Liu et al. 2002). Galectin-3 has been shown to 
protect cells from anoikis, cell death induced by loss of anchorage. 
Despite Galectin-3 being pulled down by the columns, no specific 
interaction was seen when BC-3 cell lysates were incubated with 
GST-LANA1 constructs. This may be due to the interaction domain 
for Galectin-3 being in the central region of LANA-1, an area which I 
was unable to successfully express as a GST- fusion protein, probably 
due to its highly repetitive nature. I also encountered difficulties when 
trying to confirm the interaction via small-scale immunoprecipitation, 
as Galectin-3 runs at the same size as the rat light chain (25kDa).
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Despite these problems, Galectin-3 was repeatedly identified by mass 
spectrometry and is therefore likely to be a true interaction partner.
PABP1, The polyadenylate binding protein 1 is a 70 kDa protein that 
functions in RNA metabolism by binding the polyA+ tail of mature 
mRNA. It has a predominately cytoplasmic distribution, although it 
shuttles between the cytoplasm and the nucleus. To confirm the 
interaction of PABP1 with LANA1, BC-3 cells and immunaffinity 
purification lysates performed as stated in Materials and Methods 
were subjected to western blotting with mouse anti-PABP1 antibody (a 
kind gift from Professor Gideon Dreyfuss). The western blot shows 
the specific co-immunoprecipitation of PABP1 with LANA1 in BC-3 
cells (Fig 6.1 A).
hnRNP A1 and UP1, The implication of hnRNP A1 as a regulator of 
telomere length was shown when both hnRNP A1 and its proteolytic 
N-terminal derivative UP1 were found to bind telomere sequences and 
found to be required for the maintenance of mammalian telomeres in 
vivo (LaBranche et al. 1998). hnRNP A1 and UP1 protect mammalian 
telomeres from degradation by endonucleases and exonucleases 
(Dallaire et al. 2000). To confirm the interaction between hnRNP A1 
and LANA1 as revealed by affinity chromatography, I used in vitro 
pulldown and in vivo co-immunoprecipitation assays.
6.2 hnRNP A1 co-im mu noprecipitates with LANA1 in vivo
To further characterise the interaction of LANA1 with hnRNPA1/UP1, 
co-immunoprecipitation assays were performed. BC-3 cells were 
lysed in RIPA buffer, diluted to 50% RIPA and bound to either 5jug of 
anti-LANA1 antibody or a control antibody. After washing, beads were 
resuspended in 2x Laemmli loading buffer, proteins were separated by 
SDS-PAGE and detected by Western blotting.
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Fig. 6.1 - Confirmatory small scale immunoprecipitations. A, PABP1 
co-immunoprecipitates from BC-3 lysates with LANA1. To detect 
PABP1, protein was eluted from CNBr beads used for the large-scale 
immunoaffinity purification and separated on a 6% SDS-PAGE gel. 
PABP1 was detected using anti-PABP1 (1:500). B, hnRNP A1 was 
detected by western blotting after small scale immunoprecipitation 
from BC-3 cells. Both PABP1 and hnRNP A1 co-immunoprecipitated 
with LANA1 confirming the large-scale immunoaffinity purification data. 
C, hnRNPAI co-immunoprecipitates with LANA1 from HEK-293 cells. 
HEK-293 cells were transfected with pHR CMV LANA1 or empty 
vector. Lysates were incubated with anti-LANA1 antibody and washed 
repeatedly. hnRNPAI was detected with anti-hnRNPA1 mouse 
monoclonal (1:500). hnRNPAI was immunoprecipitated only from 
HEK-293 cells transfected with LANA1.
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hnRNP A1 co-immunoprecipitates with LANA1 from BC-3 cells lysed 
in RIPA (Fig 6.1B). As all in vivo co-immunoprecipitation experiments 
had so far been carried out in KSHV infected cells, there was a 
possibility that another KSHV protein or transcript may be either 
required for the interaction between LANA1 and hnRNPAI or involved 
in stabilization of the interaction. To investigate this possibility, in vivo 
binding assays were performed on HEK-293 cells, which contain no 
KSHV genes. HEK-293 cells were transfected with pHR CMV LANA1 
or pHR CMV EMP and lysed in RIPA buffer. LANA1 was 
immunoprecipitated from the cell lysates and bound proteins were 
separated by gel electrophoresis. hnRNPAI was detected by western 
blotting. hnRNPAI was found to co-immunoprecipitate only from 
HEK-293 cells transfected with LANA1, indicating that LANA1 alone is 
sufficient for this interaction (Fig 6.1C).
6.3 LANA1 binds hnRNP A1 in vitro.
To further confirm and map the interaction between hnRNP A1 and 
LANA1, as revealed by large-scale immunoaffinity purification, I used 
in vitro pulldown assays. A series of GST-LANA1 fusion proteins were 
used to confirm and map the interaction of LANA1 with hnRNP A1 (Fig 
6.2A). RIPA lysates from BC-3 cells were diluted to 50% with ddH20 
and incubated with the bank of GSTs. I detected binding of hnRNP 
A1 to GST-LANA1 (aa3-236), GST-LANA1 (aa982-1113) and GST- 
LANA1 (aa932-1162), but not GST-LANA1 (aa803-981) (Fig 6.2B). 
Similar to the in vivo experiments, I sought to show that the in vivo 
interaction of LANA1 with hnRNPAI was not dependent on the 
presence of other KSHV proteins or transcripts. To investigate this, in 
vitro binding assays were performed on HEK-293 cells, which contain 
no KSHV genes. hnRNP A1 is also pulled-down by GST-LANA1 in 
KSHV negative mammalian cells, indicating that LANA1 alone is 
sufficient for the formation of this complex (Fig 6.2C).
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Fig. 6.2 LANA1 interacts with hnR N P A I A, GST-LANA1 constructs 
used for in vitro binding studies. B, A bank of GST-LANA1 proteins 
were incubated with BC-3 cell RIPA lysates diluted to 50%. Protein 
bound was washed, eluted in loading dye and hnRNP A1 was 
detected by western blotting. Minimum domains for the binding of 
LANA1 to hnRNP A1 were found both at the amino (aa3-236) and 
carboxyl ends (aa982-1113). C, GST-LANA1 binds hnRNPAI in 
HEK-293 cells. HEK-293 cells were lysed in RIPA buffer, diluted to 
50% RIPA with ddH20 and incubated with a bank of GST-LANA1 
constructs. LANA1 binds hnRNPAI in 293 cells, indicating that no 
other viral transcript or protein is required for this interaction. D, BC-3 
CHAPS lysates were incubated with equal amounts of either GST or 
GST-hnRNP A1 proteins. Protein bound was washed, eluted in 
loading dye and separated on a 6% SDS-PAGE gel. LANA1 was 
detected using anti-LANA1 rat monoclonal (1:1000). Only GST-
hnRNP A1 and not GST alone recovered LANA1.
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These data confirm the immunoaffinity purification data and map the 
interaction domains of hnRNP A1 at the amino terminus (aa3-236) and 
the carboxyl terminus (982-1113).
In reciprocal experiments, I sought to show that recombinant hnRNP 
A1 could pull down LANA1 from cell lysates. BC-3 cells were lysed in 
CHAPS buffer and incubated with GST or GST-hnRNP A1. After 
binding overnight, the beads were washed twice in CHAPS buffer and 
bound proteins eluted with 2x Laemmli loading buffer. Protein was 
separated by SDS-PAGE and subjected to western blotting using anti- 
LANA1 antibody. LANA1, was pulled-down by GST-hnRNP A1, but 
not the GST control (Fig 6.2D).
6.4 LANA1 binds UP1, the proteolytic derivative of hnRNP A1, 
in vitro.
UP1 consists of the first 196 amino acids of hnRNP A1 (Fig 6.3A) and 
unlike full length, has no function in splicing (Mayeda et al. 1994;Riva 
1986). Recombinant UP1 pulls down telomerase activity from cell 
lysates (LaBranche et al. 1998). As LANA1 interacts with hnRNP A1,
I next tested if UP1 is also bound by LANA1. HEK-293 cells were 
transfected with HA tagged UP1 and lysed in RIPA buffer. Lysates 
were incubated with my bank of LANA1 GSTs. This revealed that 
UP1-HA binds LANA1 in the same regions as hnRNP A1 (Fig 6.3B). 
Along with the previous data, this shows that both the amino and 
carboxyl terminus of LANA1 can bind hnRNP A1 and UP1. As UP1 
possesses no splicing activity it suggested that the interaction with 
LANA1 may be involved in telomere biogenesis. This hypothesis was 
reinforced by the in vivo interaction data that showed interactions with 
other proteins that have been proposed to play a role in telomere 
regulation: hnRNP D and hnRNP A2/B1.
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Fig. 6.3 LANA1 interacts with UP1. A, The structure of hnRNP A1 
and its proteolytic derivative, UP1. B, LANA1 interacts with UP1-HA. 
293 cells transfected with UP1-HA were lysed in RIPA buffer, diluted 
to 50% and incubated with a bank of GST-LANA1 proteins. Protein 
bound was detected using anti-HA mouse monoclonal antibody 
(1:1000). In common with hnRNP A1, the minimum domains for the 
binding of LANA1 to UP1-HA were found both at the amino (aa3-236) 
and carboxyl termini (aa982-1113). C, GST-hnRNP A1 pre- and post­
cleavage with Precission Protease. Protein was separated on a 15% 
gel and stained with coomassie brilliant blue. hnRNPAI is seen as a 
34kDa band. D, GST-hnRNP A1 was cleaved of its GST moiety and 
incubated with a bank of GST-LANA1 proteins. hnRNP A1 was 
detected with anti-hnRNP A1 antibody. Recombinant hnRNP A1 
interacted with LANA1 in the same regions as endogenous hnRNP 
A1.
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Previous work by another group has shown that hnRNP A1 can bind 
to a viral protein, immediate early gene 2 (IE2) of human 
cytomegalovirus (CMV) (Wang et al. 1997). The interaction between 
IE2 and hnRNP A1 was found to be located between amino acids 99 
and 490, indicating that regions within both the amino and carboxyl 
terminus of IE2 mediate the interaction with hnRNP A1(Wang et al. 
1997).
6.5 Direct protein-protein interaction
As hnRNP A1 is a DNA and RNA binding protein it is possible that 
mammalian DNA or RNA may mediate the interaction with LANA1, 
which is known to bind histone H1 and tether KSHV episome to 
cellular DNA. To investigate this I prepared GST-hnRNP A1 and 
cleaved off the GST moiety using Precission Protease (Fig 6.3C). 
This recombinant protein was incubated with the bank of GST-LANA1 
in a HEPES buffer (Dallaire et al. 2000). Under these buffer 
conditions, hnRNP A1 and UP1 have been shown to bind an artificial 
telomere sequence (Dallaire et al. 2000). Recombinant hnRNP A1 
bound to the same regions of LANA1 as native hnRNP A1/UP1 
indicating that mammalian DNA/RNA transcripts did not mediate the 
interaction (Fig 6.3D). Furthermore it is possible that under these 
conditions LANA1 and hnRNP A1 may form a complex on mammalian 
telomeres.
6.6 LANA1 and the telomerase complex
In mammalian cells, hnRNP A1 recruits telomerase activity. 
Telomerase activity has been shown to be recruited by UP1 in mouse 
cells (LaBranche et al. 1998) and telomerase activity can be 
recovered by immunoprecipitation of hnRNP A1 from human cells 
(Ford et al. 2002). The telomerase holoenzyme consists of several 
proteins including TEP1, La, p23, Hsp 90 and hTERT. As LANA1 
associates with hnRNP A1/UP1, I sought to establish if LANA1 forms 
a complex with the telomerase holoenzyme. To determine this I used
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the human telomerase reverse transcriptase (hTERT) as a protein 
target.
6.7 LANA1 binds hTERT in vivo
HeLa cells were transfected with 5pg of pHR CMV LANA1 or pHR 
CMV. Cells were lysed 48hrs post-transfection and lysates were 
subjected to immunoprecipitation with anti-LANA1 monoclonal 
antibody (LN53). hTERT was detected using anti-hTERT rabbit 
polyclonal (Santa Cruz Biotechnology Ltd.). hTERT 
immunoprecipitated from HEK-293 cells with anti-hTERT rabbit 
polyclonal and was used for size comparison. hTERT was found to 
only co-immunoprecipitate with LANA1 from transfected HeLa cells 
(Fig 6.4A). In reciprocal experiments I sought to co-immunoprecipitate 
LANA1 with hTERT from BC-3 cells. BC-3 cells were lysed in CHAPS 
buffer and incubated with 5pg of either anti-hTERT rabbit polyclonal or 
5pg of anti-GST polyclonal antibody. LANA1 co-immunoprecipitated 
with hTERT using an anti-hTERT antibody in BC-3 cells, although this 
interaction appeared very weak (Fig 6.4B). I have previously found 
that the expression of hTERT in BC-3 cells is not detectable in cell 
lysates, indicating that the expression of hTERT in these cells may be 
very low. This may account for the very low amounts of LANA1 
recovered. These data represent several forms of evidence for an 
interaction between LANA1 and the hTERT protein. While a physical 
interaction between LANA1 and hTERT suggests a role in telomere 
biogenesis, these data do not show that the hTERT, when bound by 
LANA1, is part of a functional telomerase complex.
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Fig 6.4 A, hTERT co-immunoprecipitates with LANA1 from HeLa 
cells. HeLa cells were transfected with 5jug of pHR CMV LANA1 or 
pHR CMV. Cells were lysed 48hrs post-transfection and lysates were 
subjected to immunoprecipitation with anti-LANA1 monoclonal 
antibody. hTERT was found to co-immunoprecipitate only from HeLa 
cells transfected with LANA1 and not the vector only. B, hTERT 
antibody immunoprecipitates LANA1. BC-3 cells were lysed in 
CHAPS buffer and incubated with 5pg of either anti-hTERT rabbit 
polyclonal or 5pg of anti-GST polyclonal antibody. Bound protein was 
separated by SDS-PAGE and LANA1 was detected by western 
blotting. LANA1 is co-immunoprecipitated by hTERT but not GST 
antibodies.
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6.8 LANA1 binds a functional telomerase complex
While physical interaction between LANA1 and hTERT is strong 
evidence that LANA1 may recruit a telomerase complex, merely 
demonstrating an interaction does not show that the hTERT is part of 
a functional telomerase complex. The most common method of 
showing a functional telomerase holoenzyme complex is by using a 
Telomerase Repeat Amplification Protocol (TRAP) assay. In this 
assay cell lysates that possess telomerase activity extend an artificial 
telomere in vitro. This extended telomere is then amplified using PCR 
with telomere specific primers. The result is a DNA ladder for a 
positive result and a blank lane for a negative result. The TRAP 
assay contains several controls including telomerase positive cells, 
false positive and heat treatment controls. To show that LANA1 
recruits a functional telomerase complex, CB3 cells were chosen, as 
these cells lack endogenous hnRNP A1 (LaBranche et al. 1998). The 
CB3 cells were transfected with UP1-HA and a pulldown using GST 
and GST-LANA1 982-1113 was used to capture a functional 
telomerase complex (Fig 6.5). CB3 cells lack hnRNP A1 due to 
retroviral insertion downstream of the gene (Fig 6.5A) (Ben-David et 
al. 1992). CB3 cells were transfected with pcDNA-UP1-HA and lysed 
in CHAPS buffer. The expression of UP1 was detected using an anti- 
HA antibody (Fig 6.5B). As I had already shown that LANA1 can 
interact with hTERT, telomerase activity would show that LANA1 was 
interacting not only with the hTERT protein, but likely interacting with it 
as part of a complex. The results show that the region of LANA1 that 
binds UP1/hnRNP A1 can pulldown telomerase activity from CB3- 
UP1-HA cells (Fig 6.5C). Therefore UP1 is sufficient to mediate an 
interaction between LANA1 and telomerase. Input lysate was 
assayed for activity at two different dilutions. This was done to show 
that the cell lysate did not contain inhibitors of telomerase activity. 
Telomerase inhibitory products can be present in cell lysates and may 
lead to a false negative result. If this is the case, by diluting the 
sample, the detected TRAP activity would have increased in
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Fig 6.5 - LANA1 and telomerase. A, CB3 cells lack hnRNP A1. Cell 
lysates from CB3, CB7, NIH-3T3 and BC-3 cells were tested for 
hnRNP A1 expression using anti-hnRNP A1 mouse monoclonal 
antibody (4B10) (1:500). CB3 cells show an absence of hnRNP A1 
protein expression. B, CB3 cells were transfected with UP1-HA using 
DMRIE-C. Lysates were separated on a 15% SDS-PAGE gel and 
subjected to western blotting using an anti-HA mouse monoclonal 
antibody. C, GST-LANA1 can pulldown telomerase activity from cell 
lysates. CB3 cells were transfected with UP1-HA and lysates were 
incubated with either GST (lanes 1-4) or GST-LANA1 (982-1113) 
(lanes 5-8). After washing, unbound protein (FT) (lanes 1,2 and 5,6) 
and pulled-down protein (PD) (lanes 3,4 and 7,8) were used in a 
TRAP assay. PCR products were separated on a 12.5% non­
denaturing polyacrylamide gel and stained with 1 in 10,000 dilution of 
CYBR green stain. Step dilutions (1/10 dilution) of both unbound and 
pulled down fractions were included to discount the possibility of 
TRAP assay inhibiting contaminants. Lane 9 shows the PCR 
contamination control and lane 11 a heat-treated cell lysate control. 
Lane 10 shows the telomerase positive control included in the kit. 
Telomerase activity was pulled down only by GST-LANA1 and not 
GST alone.
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strength. This was not seen and by diluting the lysates, the TRAP 
activity was decreased. Therefore I am confident that the result is a 
true negative and indeed telomerase activity was only pulled down by 
recombinant LANA1.
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6.9 Discussion and conclusion
hnRNPs are a large conserved family of proteins playing a role in 
mRNA splicing, mRNA export, mRNA localisation and polyadenylation 
(Dreyfuss et al. 2002;Krecic and Swanton 1999). hnRNP proteins 
associate with pre-mRNA to form the H-complex that is an essential 
part of the spliceosome. More recently evidence has emerged of an 
important role for several hnRNPs at the telomeres of mammalian 
cells (Ford et al. 2002). The telomerase complex whose components 
include hTR, telomerase reverse transcriptase (hTERT) and several 
associated ribonucleoproteins including hnRNP A1, C1/C2 and D, 
maintains mammalian telomeres. Telomerase activity is frequently 
upregulated in human tumors and extended telomeres are associated 
with lifespan extension (Hahn and Weinberg 2002). Both hnRNP A1 
and its proteolytic derivative, UP1, were found to bind telomere 
sequences and UP1 was found to be sufficient for the maintenance of 
mammalian telomeres in vivo (LaBranche et al. 1998). hnRNP A1 and 
UP1 also protect mammalian telomeres from degradation by 
endonucleases and exonucleases (Dallaire et al. 2000). I identified 
here hnRNP A1, A2/B1 and D as LANA1 interacting proteins (Chapter 
5). In this chapter I sought to confirm the interaction of PABP1 and 
hnRNPAI using several binding assays. Results in this chapter 
confirmed the large-scale in vivo data presented in Chapter 5. 
hnRNP A2/B1 has been shown to bind to the TTAGGGn sequence of 
human telomeres (McKay and Cooke 1992). Via this interaction 
hnRNP A2/B1 offers in vitro protection against nuclease activity and 
increases telomerase function (Kamma et al. 2001). hnRNP D has 
also been shown to bind the G-rich telomere strand of telomeres 
(Eversole and Maizels 2000). Furthermore, it was shown that hnRNP 
D could recover the telomerase holoenzyme from human cell lysates 
(Eversole and Maizels 2000). These previously published data, along 
with my interaction data for LANA1 and hnRNPAI, led me to 
investigate a putative role for LANA1 in telomere biogenesis.
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As hnRNP A1/UP1 is known to bind the active telomerase complex, I 
sought to test the ability of LANA1 to bind members of the telomerase 
complex. I demonstrated the ability of LANA1 to bind a functional 
telomerase complex in vitro in CB3 cells transfected with HA tagged 
UP1 (Fig 6.5). This suggests that LANA1 may form a complex with 
telomerase and that UP1 is sufficient for this interaction. However, I 
cannot discount that this interaction is aided by the LANA1/hnRNP D 
complex. Further to this I sought to show an interaction with a 
member of the telomerase complex by co-immunoprecipitation. 
hTERT, a member of the telomerase holoenzyme, co- 
immunoprecipitates with LANA1 from HeLa cells. It is currently 
unclear if the physical interaction of LANA1 with hnRNP A1/UP1 and 
hnRNP D enhances the recruitment of telomerase to telomeres or if 
the interaction with LANA1 enhances physical protection at the 
telomeres afforded by hnRNP A1/UP1, hnRNP D and hnRNP A2. As 
LANA1 binds both the telomere binding hnRNP A1, hnRNP A2/B1 and 
hnRNP D and telomerase-associated hnRNP A1 and hnRNP D, it is 
attractive to propose that LANA1 may act as a bridge to aid in 
recruitment of telomerase to the telomeres.
A major role for LANA1 in the life cycle of KSHV is the maintenance of 
the viral episome. It has previously been shown that LANA1 maintains 
viral episomes via binding to histone H1. The mammalian histone H1 
family contains at least 7 subtypes. In this study two subtypes of 
histone H1 co-immunoprecipitated with LANA1; histone 1.4 and 
histone H1.5, H2B and H2A, respectively (see Chapter 5). In common 
with LANA1, EBNA1 of EBV is involved in the maintenance of the viral 
episome. It has recently been shown that the OriP/dyad symmetry 
element of EBV binds to several telomere related proteins (Deng et al. 
2002). It is possible that the interactions with hnRNP A1, A2 and D 
may also have a role in the persistence of KSHV viral episomes.
The data presented suggest the formation of a LANA1 complex
190
including various hnRNPs, histone H1 and components of the 
spliceosome complex. Together with previously published data that 
LANA1 can upregulate the hTERT promoter (Knight et al. 2001), I 
propose that LANA1, by binding to hnRNP A1/UP1 and hnRNP D, 
aids in the recruitment of the telomerase complex. Both hnRNP A1 
and D have been shown to rescue telomerase activity from cell lysate. 
This suggests a scenario whereby LANA1 aids in the immortilisation of 
primary infected cells (e.g. B cells) through the activation and 
recruitment of the telomerase complex to telomeres. Furthermore the 
physical protection offered by hnRNP A1/UP1, hnRNP D and hnRNP 
A2 to telomeres may be increased in the presence of LANA1. By 
binding to these proteins LANA1 may increase their relative half-life 
and increase their protective capability.
In conclusion, I have used large-scale immunoaffinity purification 
linked to mass spectrometry to identify several novel interaction 
partners of LANA1. Domain analysis has revealed a predominance of 
proteins possessing at least one RRM domain, and I propose that this 
represents a protein-protein interaction target for LANA1. I show that 
LANA1 may have a direct role in the biogenesis of telomeres by 
recruitment of the active telomerase complex.
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Chapter 7 Discussion and Conclusion
The work described in this thesis was set out with distinct aims to be 
achieved. These included both technical problems to be overcome 
and scientific questions to be answered. The major aims of my project 
work are listed below:
7.1 Virus-mediated LANA1 delivery to primary cells
7.2 Transcriptional targets of LANA1 in primary cells
7.3 Purification of a native LANA1 complex
7.4 Identification of novel protein interaction partners of LANA1
7.5 Insight into novel cellular functions of LANA1
7.1 Virus mediated LANA1 delivery to primary cells
The use of primary cells for the study of single proteins is gaining 
popularity. This is due to the increasing availability of primary cells, 
progress in primary cell culture and the continuing development of 
gene delivery systems. I aimed to develop a tool for the study of 
LANA1 in primary endothelial cells. This was done to allow a sensitive 
study of LANA1 in primary cells that have not undergone many of the 
genetic alterations associated with cell lines. Using the pHR CMV 
based system I cloned and developed the expression of LANA1 in test 
cell lines, before studying primary endothelial cells. I have 
demonstrated the use of the lentiviral system for the delivery of 
LANA1 to primary cells, and characterised the expression of LANA1 in 
terms of cellular localization, DNA association and stability.
Lentiviruses carrying this gene successfully infected primary cells. 
These infected cells were positive for LANA1 by western blot and 
show characteristic patterns of expression. Nuclear localisation is 
seen during staining by IFA and LANA1 localises to chromatin during
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mitosis, a known function of LANA1. I aimed to show an application of 
the system by linking it with gene expression microarray technology.
7.2 Transcriptional targets of LANA1 in primary cells
The results from the gene expression microarray experiments on 
LANA1 expressing endothelial cells were disappointing. Expression of 
LANA1 in the primary endothelial cells was high and predicted at over 
90% infection. However, no significant phenotypic or transcriptomic 
changes were seen in primary cells infected with LANA1 lentivirus. 
Furthermore, the GEM technology, in particular the software used, 
provided problems. Despite these problems, these lack of genetic 
changes were not totally unexpected. Despite many reports of LANA1 
effects on cellular promoters (An et al. 2002; Knight et al. 2001;Radkov 
et al. 2000), these effects are usually detected by in vitro reporter 
assays and have rarely been demonstrated at a physiological level i.e. 
by RT-PCR or Northern blot. It is likely that the main function of 
LANA1 is not via transcriptional regulation, but through protein-protein 
interactions or other protein dysregulations.
7.3 Purification of a native LANA1 complex
Many groups have used small-scale immunoprecipitation to 
demonstrate and identify protein-protein interaction partners of 
LANA1. These studies often involve yeast two-hybrid screens 
followed by interaction mapping with GST constructs. I undertook the 
first large scale proteomic analysis of LANA1, to identify a native 
LANA1 complex in primary effusion lymphoma cell lines. Through the 
development of techniques in both affinity chromatography and large- 
scale immunoprecipitation, I achieved purification of the complex, and 
demonstrated its separation into the individual protein components. 
The different methods for the purification of LANA1 provided 
overlapping results, increasing confidence in the data. To 
complement this and identify common protein interaction domains, I 
used a yeast two-hybrid screen.
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7.4 Identification of novel protein interaction partners of LANA1
Proteins that co-purified with LANA1 by affinity chromatography and 
large-scale immunoprecipitation were identified, after separation, by 
mass spectrometry. Some of these proteins, including Histone H1 and 
p32 have previously been identified as LANA1 interaction partners i.e. 
p32 interaction with HVS ORF73 (Hall et al. 2002). The majority of the 
interaction partners identified were novel. These proteins include 
amongst them several important splicing proteins, as well as proteins 
involved in RNA metabolism and transport. Among these was hnRNP 
A1 which not only functions in 5’ site selection, but has also been 
implicated in the biogenesis of mammalian telomeres.
The novel interactions identified by both the yeast two-hybrid and 
large scale IP/MS approaches have proved to be non-overlapping but 
complementary. Using both methods, LANA1 complex interacting 
proteins with common domains were identified. This implies that to 
achieve an overall view of the protein-protein interactions of a gene, 
several different approaches should be utilised. Through the use of 
these different approaches, new putative cellular functions for LANA1 
have been identified. Proteins identified have roles in splicing and 
telomere biogenesis suggesting that LANA1 may affect one or both of 
these areas of the cellular life cycle.
7.5 Insight into novel cellular functions of LANA1
Taken together the two broad approaches used in this thesis have 
provided an interesting insight into the global effects of LANA1 on the 
cellular proteome. The work in this thesis suggests that the main roles 
of LANA1 are achieved by way of protein-protein interactions. I have 
confirmed a role for LANA1 in episome maintenance via an 
association with Histone H1 and provided insight into further roles for 
LANA1 in both RNA splicing and telomere biogenesis.
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14.6239 14.67654 17.14706 18.00899 1.199847 0.021063 AA405989
39.69598 37.63849 29.45587 30.89316 0.780364 0.021143 AA448207
12.8691 15.51423 24.24758 26.15563 1.775803 0.021242 AA476490
26.89934 24.39725 34.0213 34.58425 1.337429 0.021256 AA056465
17.83125 18.53786 25.12595 23.45843 1.335869 0.021282 AA262504
14.79707 14.8974 18.33965 19.56612 1.276526 0.02173 AA054321
28.9034 25.67394 40.84458 38.84707 1.46016 0.022106 AA490996
60.55528 64.00571 78.42178 82.85077 1.294728 0.022599 -
14.3999 13.11793 18.74286 19.85839 1.402773 0.022711 T65736
Human mRNA for SMP-30 (senescence marker protein-30), complete cds 
Zinc finger protein 151 (pHZ-67)
Phosphofructokinase, muscle
H.sapiens mRNA for rat HREV107-!ike protein
Human mRNA for apolipoprotein E receptor 2, complete cds
Human adult heart mRNA for neutral calponin, complete cds
Human N-ethylmaleimide-sensitive factor mRNA, partial cds
Transducin-like enhancer of split 4, homolog of Drosophila E(sp1)
Human retinoic acid- and interferon-inducible 58K protein RI58 mRNA, complete cds 
H.sapiens IL-13Ra mRNA
Glutamic-oxaloacetic transaminase 1, soluble (aspartate aminotransferase 1)
Human Cdc5-related protein (PCDC5RP) mRNA, complete cds 
Glutathione-S-transferase pi-1
Human stimulator of TAR RNA binding (SRB) mRNA, complete cds
V-rel avian reticuloendotheliosis viral oncogene homolog 
H.sapiens mRNA for cyclin G1
Homo sapiens MutS homolog (MSH5) mRNA, complete cds 
Interferon regulatory factor 1
DNA-DIRECTED RNA POLYMERASE I114.4 KD POLYPEPTIDE 
Human putative M phase phosphoprotein 1 (MPP1) mRNA, partial cds 
Homo sapiens Fas-binding protein Daxx mRNA, complete cds 
Deoxycytidylate deaminase
Homo sapiens thyroid receptor interactor (TRIP4) mRNA, 3’ end of cds 
Human 54 kDa protein mRNA, complete cds 
Human EYA3 homolog (EYA3) mRNA, complete cds 
H.sapiens HCG I mRNA
Human interferon-gamma induced protein (IF116) gene, complete cds 
Human selenium-binding protein (hSBP) mRNA complete cds
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21.28581
14.3109
41.16101
69.79562
23.68785
24.36188
11.37659
9.228586
53.52706
30.15636
62.5688
32.0239
12.90496
12.70051
19.6614
11.64626
18.3875
54.51549
16.275
80.08463
15.66785
20.859
18.73655
45.3586
68.63759
31.25305
67.85542
16.36995
22.47479
10.97317
20.95607
19.38037
14.79715
44.66186
70.95867
23.7127
26.48693
12.43146
10.56549
53.18936
29.47201
63.54845
30.95701
13.73191
12.6018
17.69535
12.03606
20.0991
53.40671
17.69464
82.29562
15.1374
21.6589
19.67545
48.58246
70.3948
26.90025
63.72649
18.14875
22.69051
12.28621
20.58239
26.60932
17.19406
22.9877
45.92272
30.96185
36.13774
15.18768
15.4967
60.28094
33.54459
66.07406
48.85646
17.15693
16.32587
25.00189
13.78392
26.13914
68.74448
21.77907
90.2593
18.92866
27.19119
22.8395
56.84154
64.19332
46.87265
53.01953
22.61176
27.97646
15.8445
25.9527
27.34843
18.01471
27.3213
36.90624
28.99143
33.96506
15.36424
17.0134
58.39839
34.7601
66.34295
44.1262
18.35297
17.76424
26.11934
13.36779
28.07849
64.67831
22.81955
88.62492
18.0474
29.40274
22.23996
58.37243
63.42236
52.20721
50.83924
22.49222
26.43292
15.4785
24.48499
1.326846
1.209589
0.586196
0.588465
1.264822
1.378652
1.28326
1.642415
1.1121
1.145507
1.049952
1.476363
1.333111
1.347312
1.36846
1.146497
1.40874
1.236287
1.312896
1.101638
1.200317
1.331061
1.173578
1.22645
0.917885
1.70377
0.789309
1.306653
1.204672
1.346682
1.214241
0.022837
0.023586
0.023735
0.023758
0.023769
0.024021
0.024241
0.02436
0.024621
0.024887
0.025032
0.025142
0.02582
0.025877
0.025947
0.025963
0.025987
0.026245
0.026343
0.02665
0.026678
0.026797
0.026798
0.02701
0.027107
0.027154
0.027214
0.027214
0.027268
0.027406
0.027763
R59927
T72604
AA026626
AA461456
AA432143
AA448685
N30191
T66980
AA136707
AA171463
AA431440
H20856
AA454570
R91550
AA233738
T98472
AA873056
R71093
N68159
AA487588
AA449738
AA598776
AA454819
R17765
R77517
W04674
Human mRNA for cytochrome c oxidase subunit Vic 
Human cytochrome o-1 gene, complete cds 
Chymotrypsin-like 
Collagen, type V, alpha
Human melanocyte-specific gene 1 (msgl) mRNA, complete cds 
Deoxycytidine kinase
PROCHOLECYSTOKININ PRECURSOR
Egf-like module containing, mucin-like, hormone receptor-like sequence 1 
Homo sapiens lysyl hydroxylase isoform 2 (PLOD2) mRNA, complete cds 
Homo sapiens sorting nexin 2 (SNX2) mRNA, complete cds
H.sapiens hnRNP-E2 mRNA 
DNA repair helicase ERCC3
Human clone lambda 5 semaphorin mRNA, complete cds 
Human arginine-rich protein (ARP) gene, complete cds 
Transforming growth factor, beta 2 
Casein kinase 2, alpha 1 polypeptide
Replication protein A (E coli RecA homolog, RAD51 homolog)
Human mRNA for collagen binding protein 2, complete cds
Human multidrug resistance-associated protein homoiog (MRP5) mRNA, partial cds
Human mRNA for ORF, Xq terminal portion
Homo sapiens protein 4.1-G mRNA, complete cds
Human p55CDC mRNA, complete cds
EXTRACELLULAR SIGNAL-REGULATED KINASE 1 
Biotinidase
Human CDK inhibitor p19INK4d mRNA, complete cds 
Homo sapiens mRNA for cytochrome b5, partial cds
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13.24626 16.0133 24.24163 22.95284 1.612959 0.027766 AA709143
14.53086 14.11347 16.74931 17.64094 1.200595 0.028124 T98019
15.11686 16.15493 18.73582 19.23424 1.214195 0.028305 R55490
82.05017 88.51693 111.2574 106.3696 1.275903 0.028412 AA702254
13.31261 13.34946 15.3432 14.74962 1.128675 0.028761 AA676590
13.53515 15.01674 18.47763 18.75114 1.303899 0.028851 AA757754
32.17749 33.25982 28.15446 26.65073 0.837522 0.029049 H85355
45.75406 46.19835 43.57596 42.68773 0.938134 0.029152 AA670438
22.6785 21.41181 31.72049 29.07421 1.378868 0.029489 AA032090
9.530775 11.5589 17.40649 16.44489 1.605116 0.029569 T73558
18.6771 18.99872 20.5869 20.15266 1.081318 0.029729 H29475
14.57061 15.54405 17.75203 17.97358 1.186319 0.03023 R83224
83.10598 78.548 62.84057 66.39386 0.799451 0.030341 W46577
84.66875 76.44045 56.2244 51.40948 0.66808 0.030344 AA448396
37.48755 38.34005 45.39497 43.26732 1.169262 0.030444 H57136
14.15599 14.98015 18.04261 19.24852 1.279892 0.030615 AA775378
82.22938 87.82484 101.4247 100.3887 1.186759 0.030637 AA425861
11.64434 13.31599 17.14451 17.83238 1.4013 0.031058 AA125981
21.97884 23.2192 25.98003 26.10156 1.152297 0.031252 AA598978
9.91296 10.8484 15.74301 17.88272 1.61963 0.031409 H96235
36.19658 37.39864 33.21386 33.53209 0.906933 0.031415 AA027012
29.17678 27.70456 33.35908 32.60837 1.159738 0.031524 R56638
14.66517 15.24825 21.08112 19.26586 1.348792 0.031808 N35888
13.8279 15.03698 18.58936 19.85551 1.331891 0.031812 AA496334
11.39412 12.75156 15.70726 15.94188 1.310757 0.032092 AA683520
9.284274 11.0507 15.55734 16.95524 1.59885 0.032557 AA180013
120.1432 116.808 91.86152 99.60838 0.808056 0.032712 AA187148
29.28212 29.53973 33.69324 35.62598 1.17846 0.032813 T52362
12.62167 12.3043 15.16462 16.35209 1.264413 0.033065 R62813
12.32508 12.00672 13.92138 13.44971 1.124911 0.033314 R89082
19.14025 18.79995 27.85192 25.06118 1.394645 0.033495 T59245
H.sapiens mRNA for TTF-I 
Human Br140 mRNA, complete cds 
Human phospholipase c delta 1 mRNA, complete cds 
Major histocompatibility complex, class II, DN alpha
Homo sapiens TTAGGG repeat binding factor 2 (hTRF2) mRNA, complete cds
Homo sapiens mRNA for dihydropyrimidinase related protein 4, complete cds
ATPase, Ca++transporting, cardiac muscle, slow twitch 2
UBIQUITIN CARBOXYL-TERMINAL HYDROLASE ISOZYME L1
Homo sapiens actin-related protein Arp2 (ARP2) mRNA, complete cds
Human DNase1-Like III protein (DNAS1L3) mRNA, complete cds
Homo sapiens pyruvate dehydrogenase kinase isoenzyme 2 (PDK2) mRNA, complete cds
Human ras inhibitor mRNA 3’ end
H.sapiens mRNA for ESM-1 protein
Heat shock 10 kD protein 1 (chaperonin 10)
Human phospholemman chloride channel mRNA, complete cds 
N-acetylglucosaminyltransferase I
Human peroxisomal enoyl-CoA hydratase-like protein (HPXEL) mRNA complete cds
Activin A receptor, type II
Filamin 1 (actin-binding protein-280)
V-ets avian erythroblastosis vims E26 oncogene homolog 2 
Kinase insert domain receptor (a type III receptor tyrosine kinase)
Glutaryl-Coenzyme A dehydrogenase 
Phosphomannomutase 2 
DYNAMIN-1
ANTILEUKOPROTEINASE 1 PRECURSOR
Human mRNA for HGF activator like protein, complete cds
Core-binding factor, beta subunit
H.sapiens mRNA for Icln protein
Human L-myc protein gene, complete cds
Homo sapiens A-kinase anchoring protein (AKAP18) mRNA complete cds 
S-ADENOSYLMETHIONINE SYNTHETASE GAMMA FORM
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11.68684 11.55691 14.19041 15.37657 1.27204 0.033816 AA777289
11.40516 12.89907 16.93159 16.19207 1.362877 0.033916 AA149097
111.214 101.8281 62.51724 73.64225 0.63912 0.034024 N74956
37.64903 32.92124 22.32711 23.01163 0.642462 0.034027 R38194
459.5402 409.521 597.1828 648.7151 1.433614 0.034453 H54023
59.87162 55.82647 32.1758 39.54386 0.619886 0.034642 H23197
19.80885 19.08847 26.37321 29.56803 1.438177 0.034996 AA419264
29.98141 34.71095 48.09765 53.39613 1.568868 0.035285 AA701455
26.99895 30.46287 40.42197 44.43633 1.476777 0.035476 AA487460
1823.974 1897.418 1239.798 1429.806 0.717367 0.035524 AA293218
12.29707 12.53 15.78503 17.38515 1.336049 0.035571 H86518
22.55051 23.87862 27.55155 28.99762 1.217967 0.035641 AA394127
48.95605 48.2176 46.20174 45.40618 0.942724 0.035994 AA443547
23.36412 21.59025 28.61167 27.38745 1.245688 0.036035 AA456570
12.93649 14.34749 17.32881 17.20979 1.265893 0.03605 AA430178
35.67819 36.25628 50.52037 57.61499 1.503248 0.036556 AA446453
58.31607 61.65066 69.13112 68.30519 1.14562 0.036563 AA157813
11.50147 13.27703 16.81222 17.07402 1.367566 0.036707 AA444049
11.30327 12.61007 15.8655 17.07348 1.377432 0.036746 N35067
31.58377 32.25889 36.77875 35.29086 1.128863 0.037253 AA454810
24.60914 24.42533 29.79488 32.40404 1.268473 0.037283 AA180007
27.87648 26.96707 34.00312 31.97973 1.203111 0.037446 AA485913
12.8329 13.87053 15.94357 16.3778 1.210383 0.037828 AA708161
25.11428 24.38132 28.04803 29.48606 1.162408 0.038032 H78385
13.68521 14.87289 17.46576 18.29301 1.252141 0.038109 AA487593
13.88883 13.36036 16.3021 17.52736 1.241485 0.038747 AA600217
15.99237 17.40953 21.22475 20.34448 1.244517 0.039282 AA487148
19.6487 22.8455 30.0211 32.63452 1.474451 0.039477 AA485653
12.87959 13.21833 16.66987 18.51198 1.348071 0.039981 AA447593
59.09829 60.86134 84.12417 75.99251 1.334755 0.040352 T65786
25.22532 26.71258 22.11491 22.51497 0.859293 0.041658 AA683578
Glutathione reductase
Hemopoietic cell kinase
RNA polymerase II polypeptide B (140 kD)
Human mRNA for LZTR-1, complete cds
Homo sapiens monocyte/macrophage Ig-related receptor MIR-10 (MIR cHO) mRNA, complete cds
Human mRNA for MOBP (myelin-associated oligodendrocytic basic protein), complete cds
Homo sapiens hair and skin epidermal-type 12-lipoxygenase-related protein (ALOX12E) mRNA
Human CENP-F kinetochore protein mRNA, complete cds
Human mRNA for dihydropyrimidinase related protein-2, complete cds
Cleavage stimulation factor, 3’ pre-RNA, subunit 2 ,64kD
X-arrestin
Homo sapiens NF-AT3 mRNA, complete cds
TRANSCRIPTION FACTOR P65
H.sapiens mRNA for interferon regulatory factor 3
Homo sapiens Ran binding protein 2 (RanBP2alpha) mRNA, partial cds
Human mRNA for c-myc binding protein, complete cds
INTERFERON-ALPHA INDUCED 11.5 KD PROTEIN
Human MAP kinase phosphatase (MKP-2) mRNA, complete cds
Human cdc2-related protein kinase (CHED) mRNA, complete cds
Membrane component, chromosome 1, surface marker 1
Protein kinase, cAMP-dependerrt, regulatory, type II, beta
Human nuclear chloride ion channel protein (NCC27) mRNA, complete cds
Human scr3 mRNA for RNA binding protein SCR3, complete cds
Human huntingtin interacting protein (HIP2) mRNA, complete cds
Transferrin receptor (p90, CD71)
CAMP-dependent transcription factor ATF-4 (CREB2)
Human TBP-associated factor (hTAFII130) mRNA, partial cds
Human beta-1,2-N-acetylglucosaminyltransferase II (MGAT2) gene, complete cds
Homo sapiens axonemal dynein light chain (hp28) mRNA, complete cds
PRE-MRNA SPLICING FACTOR SF2, P33 SUBUNIT
ADENOSINE DEAMINASE
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26.27655 24.07382 32.948 31.05993 1.271251 0.042282 N23454
46.05216 50.63513 67.22026 62.01856 1.336668 0.042488 -
64.51113 59.33324 74.1574 73.91723 1.195651 0.042844 -
12.98688 14.48746 19.47726 17.95394 1.362406 0.043156 W51760
219.2486 204.176 114.5668 146.362 0.616234 0.04383 -
10.99637 11.68638 14.47818 16.03376 1.345161 0.04414 N45141
11.70176 12.9816 15.34002 15.24312 1.239018 0.044213 R12373
20.60713 24.18667 31.92885 30.52933 1.394349 0.044224 AA487582
10.39533 11.19881 13.32046 14.38266 1.2829 0.044391 AA702663
571.1043 553.2296 404.8496 319.4926 0.644241 0.044394 T53298
24.2576 21.07047 35.16807 31.7123 1.475474 0.044431 R60847
11.17431 12.77589 15.86511 16.94966 1.370125 0.04446 AA055486
15.20577 13.00471 20.11916 22.30718 1.503921 0.044505 AA481554
52.18162 49.89176 57.6968 60.32594 1.156254 0.044612 -
14.32816 15.47386 20.21347 18.60559 1.302565 0.044747 AA857212
15.27714 17.40102 22.64832 25.21208 1.464599 0.044874 AA488681
124.9324 136.2994 72.31894 90.68338 0.623976 0.045098 H69561
19.46156 19.38244 24.53968 27.43002 1.337908 0.045257 R45640
53.02629 55.26104 67.47205 74.56885 1.311704 0.045313 -
12.36903 12.64076 16.27642 18.38896 1.386073 0.045375 AA159577
24.41258 30.30908 40.9738 40.53666 1.489547 0.045422 AA431321
16.30796 18.26048 24.87257 22.74569 1.377507 0.045625 AA490945
13.14567 13.70386 17.69657 16.22872 1.263534 0.045893 H08545
21.6216 22.01372 38.80142 32.63003 1.63701 0.046098 AA663981
15.62038 14.66827 17.82916 18.90073 1.212662 0.046125 AA173926
72.4865 75.75304 81.2518 81.93709 1.100846 0.046404 -
17.56159 16.63121 14.94582 15.05702 0.877461 0.046547 AA875888
17.94749 16.29775 20.79573 21.54375 1.236361 0.046608 R54807
23.24825 17.70674 32.83718 32.84879 1.603858 0.046718 AA173369
13.70688 14.02148 15.81686 16.89613 1.179767 0.047285 T63988
60.13647 65.13849 73.42034 74.57603 1.181372 0.047447 -
Ubiquitin-activating enzyme E1, like
Fibroblast growth factor 2 (basic)
ADENYLATE CYCLASE, TYPE II
Paraoxonase 1
EXT1
Human myosin-IXb mRNA, complete cds
Prostacyclin-stimulating factor [human, cultured diploid fibroblast cells, mRNA, 1124 nt] 
H.sapiens mRNA for TFG protein
Homo sapiens ataxia-telangiectasia group D-associated protein mRNA, complete cds 
Human ERPROT 213-21 mRNA, complete cds
Galactose-1-phosphate uridyl transferase 
Human mRNA for rab GDI alpha, complete cds 
Mannosidase, alpha type II
Diphtheria toxin receptor (heparin-binding epidermal growth factor-like growth factor)
Mucin 5, subtype B, tracheobronchial
Homo sapiens thyroid receptor interactor (TRIP7) mRNA, 3' end of cds
Homo sapiens secretory carrier-associated membrane protein (SCAMP) mRNA, complete cds
Homo sapiens potassium channel homolog (KCNQ3) mRNA, partial cds
Human Ig germline H-chain G-E-A region B: gamma-2 constant region, 3' end
Homo sapiens mRNA for putative glucosyltransferase, partial cds
BRAIN NEURON CYTOPLASMIC PROTEIN 1 
Human beta-sarcoglycan A3b mRNA, complete cds 
Human mitochondrial ATP synthase subunit 9, P3 gene copy, mRNA 
Human mRNA for DB1, complete cds
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58.84769 62.85428 84.16513 76.34862 1.318908 0.04759 - -
21.58536 22.57456 35.16831 30.41148 1.485052 0.047792 N59150 INTERFERON-ALPHA/BETA RECEPTOR ALPHA CHAIN PRECURSOR
257.6779 282.1547 205.3771 216.3273 0.781176 0.047858 AA890663 Human protein kinase PAK1 mRNA, complete cds
11.93706 14.16259 18.20345 19.69386 1.452024 0.047874 AA052960 Human Cbf5p homolog (CBF5) mRNA, complete cds
11.93086 13.51221 17.18016 19.05956 1.424346 0.048054 R23735 Human R kappa B mRNA, complete cds
11.69299 13.05967 16.11937 17.67079 1.365112 0.048557 H12338 Homo sapiens DNAX activation protein 12 (DAP12) mRNA, complete cds
21.37391 22.0031 28.41784 25.96556 1.253738 0.04905 AA433944 H.sapiens mRNA for mediator of receptor-induced toxicity
4529.848 4593.677 3008.337 3587.713 0.722972 0.049286 AA709414 Nidogen (enactin)
19.32836 18.8765 24.75206 28.11089 1.383671 0.04952 AA447761 Aminoievulinate, delta-, synthase 1
14.38522 16.87973 20.94944 21.10651 1.345147 0.049685 R56562 Human lunatic fringe mRNA, partial cds
12.90092 14.18309 19.29533 17.45546 1.356918 0.049829 N33574 Homo sapiens growth inhibitor p33ING1 (ING1) mRNA, complete cds
14.98717 17.49183 22.61318 25.1479 1.470521 0.050304 AA626867 ER LUMEN PROTEIN RETAINING RECEPTOR 2
62.02984 82.8975 122.8191 115.9648 1.647611 0.050642 R47893 TONSILLAR LYMPHOCYTE LD78 BETA PROTEIN PRECURSOR
20.47757 17.30179 25.54171 26.78405 1.385035 0.050806 R15814 Human malate dehydrogenase (MDHA) mRNA, complete cds
13.59585 11.97833 16.26887 17.14702 1.306626 0.050918 AA055979 Integrin, alpha 7B
Appendix II
Hyperlink data of interaction hits: Hybrigenics 1st screen LANA1 N-terminus 
aa 1-337
KIAA0742
http://www.ncbi.nlm.nih.QQv/entrez/Querv.fcqi?cmd=Retrieve&db=nucleotide&lis 
t uids=17433931 &dopt=GenBank
KIAA1513
http://www.ncbi.nim.nih.qov/entrez/querv.fcqi?cmd=Retrieve&db=nucleotide&lis 
t uids=14736708&dopt=GenBank
KIAA0570
http://www.ncbi.nlm.nih.qov/entrez/querv.fcqi?cmd=Retrieve&db=protein&list ui 
ds=3043664&dopt=GenPept
KIAA0793
http://www.ncbi.nlm.nih.qov/entrez/querv.fcqi?cmd=Retrieve&db=nucleotide&lis 
t uids=3882306&dopt=GenBank
KIAA0120
http://www.ncbi.nlm.nih.qov/entrez/querv.fcqi?cmd=Retrieve&db=nucleotide&lis 
t uids=434762&dopt=GenBank
KIAA0045
http://www.ncbi.nlm.nih.qov/entrez/querv.fcqi?cmd=Retrieve&db=nucleotide&lis 
t uids=460710&dopt=GenBank
KIAA0057
http://www.ncbi.nlm.nih.qov/entrez/querv.fcgi?cmd=Retrieve&db=nucleotide&iis 
t uids=498149&dopt=GenBank
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KIAA1119
http://www.ncbi.nlm.nih.Qov/entrez/Querv.fcQi?cmd=Retrieve&db=nucleotide&lis 
t uids=6329707&dopt=GenBank
NPI-1 - nucleoprotein interactor 1-SRP1 homolog
http://www.ncbi.nlm.nih.QQv/entrez/auerv.fCQi?cmd=Retrieve&db=nucieotide&ns 
t uids=913392&dopt=GenBank
Human hsp27 ERE-TATA-binding protein (HET) Related= SAF-B 
http://www.ncbi.nlm.nih.aov/entrez/auerv.fcai?cmd=Retrieve&db=nucleotide&lis 
t uids=2828536&dopt=GenBank
Homo sapiens mRNA for CDEP
http://www.ncbi.nlm.nih.qov/entrez/querv.fcgi?cmd=Retrieve&db=nucleotide&iis 
t uids=2766164&dopt=GenBank
Homo sapiens actinin, alpha 4 (ACTN4)
http://www.ncbi.nlm.nih.qov/entrez/querv.fcqi?cmd=Retrieve&db=nucleotide&lis 
t uids=12025677&dopt=GenBank
EUROIMAGE 1654781
http://www.ncbi.nlm.nih.gov/entrez/querv.fcqi?cmd=Retrieve&db=nucleotide&lis 
t uids=17066293&dopt=GenBank
Homo sapiens similar to unnamed protein product (LOC90102) 
http://www.ncbi.nlm.nih.gov/entrez/querv.fcqi?cmd=Retrieve&db=nucleotide&lis 
t uids=17435685&dopt=GenBank
Homo sapiens hypothetical gene supported by AK00209 (LOC92751) 
http://www.ncbi.nlm.nih.qov/entrez/querv.fcqi?cmd=Retrieve&db=nucleotide&lis 
t uids=17487840&dopt=GenBank
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HUMELIA Human structural protein 4.1
httD://www.ncbi.nlm.nih.aov/entrez/auerv.fcai?cmd=Retrieve&db=nudeotide&lis 
t uids=182Q75&dopt~GenBank
Human putative monocarboxylate transporter (MCT)
http://www.ncbi.nlm.nih.aov/entrez/auerv.fcai?cmd=Retrieve&db=nucleotide&iis 
t uids=2463627&dopt=GenBank
Homo sapiens Fas binding protein (hDaxx)
http://www.ncbi.nlm .nih.aov/entrez/querv.fcgi?cmd=Retrieve&db=nucleotide&lis 
t uids=2724133&dopt=GenBank
Homo sapiens ras GTPase-activating-like protein (IQGAP1) 
http://www.ncbi.nlm.nih.qov/entrez/querv.fcqi?cmd=Retrieve&db=nucleotide&lis 
t uids=536843&dopt=GenBank
http://www.ncbi.nlm.nih.qov/entrez/querv.fcqi?cmd=Retrieve&db=PubMed&list 
uids=8051149&dopt=Abstract
Homo sapiens EH-domain containing protein testilin
http://www.ncbi.nlm.nih.qov/entrez/querv.fcqi?cmd=Retrieve&db=nucleotide&lis 
t uids=5639664&dopt=GenBank
Homo sapiens cDNA FLJ11046 fis
http://www.ncbi.nlm.nih.qov/entrez/querv.fcqi?cmd=Retrieve&db=nucleotide&lis 
t uids=7023465&dopt=GenBank
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Contig number Contigmember Sequence I.D.
Percentage 
match vs 
Genbank 
sequence
Contig918348 2
gi|8922841|ref|NM_018309.11 Homo 
sapiens hypothetical protein FLJ11046 
(FLJ11046), mRNA
100.0
100.0
99.0
Contig918362 2
gi17706636)ref|NM_016166.11 Homo 
sapiens DEAD/H (Asp-Glu-Ala-Asp/His) 
box binding protein 1 (DDXBP1), mRNA
Contig918353 2
gi177066361ref|NM_016166.11 Homo 
sapiens DEAD/H (Asp-Glu-Ala-Asp/His) 
box binding protein 1 (DDXBP1), mRNA
Contig918329 6
gi|7662309|ref|NM_014808.11 Homo 
sapiens KIAA0793 gene product 
(KIAA0793), mRNA
99.3
Contig918257 1
gi|7662185|ref|NM_014709.11 Homo 
sapiens KIAA0570 gene product 
(KIAA0570), mRNA
100.0
Contig918240 1
gi|69124491ref|NM_012288.11 Homo 
sapiens TRAM-like protein (KIAA0057), 
mRNA
98.8
Contig918236 1
gi|6912449|ref|NM_012288.11 Homo 
sapiens TRAM-like protein (KIAA0057), 
mRNA
98.4
Contig918260 1
gi|6329707|dbj|AB032945.1 |AB032945 
Homo sapiens mRNA for KIAA1119 
protein, partial cds
99.1
Contig918368 1
gi|5803008|ref|NM_006795.11 Homo 
sapiens EH domain containing 1 (EHD1), 
mRNA
97.6
100.0Contig918356 
Contig918333
1
gi|5803008|ref|NM_006795.1| Homo 
sapiens EH domain containing 1 (EHD1), 
mRNA
6
gi150316321ref|NM 005766.1| Homo 
sapiens FERM, RhoGEF (ARHGEF) and 
pleckstrin domain protein 1 (chondrocyte- 
derived) (FARP1), mRNA
100.0
Contig918352 6
gi150316321ref|NM 005766.11 Homo 
sapiens FERM, RhoGEF (ARHGEF) and 
pleckstrin domain protein 1 (chondrocyte- 
derived) (FARP1), mRNA
98.7
Contig918365 
Contig918350
1
gi|4759113|ref|NM_004696.11 Homo 
sapiens solute carrier family 16 
(monocarboxylic acid transporters), 
member 4 (SLC16A4), mRNA
100.0
1
gi|4759113|ref|NM_004696.1| Homo 
sapiens solute carrier family 16 
(monocarboxylic acid transporters), 
member 4 (SLC16A4), mRNA
95.0
Contig918241 1
gi|4758647|ref|NM_004521.11 Homo 
sapiens kinesin family member 5B 
(KIF5B), mRNA
93.8
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Contig918251 1
gi|4758647|ref|NM_004521.11 Homo 
sapiens kinesin family member 5B 
(KIF5B), mRNA
99.4
Contig918279 1
gi|4758273|ref|NM_004437.11 Homo 
sapiens erythrocyte membrane protein 
band 4.1 (elliptocytosis 1, RH-linked) 
(EPB41), mRNA
97.9
Contig918264 2 gi|4507356|ref|NM_003564.11 Homo sapiens transgelin 2 (TAGLN2), mRNA 99.7
Contig918364 6
gi|4506786|ref|NM_003870.11 Homo 
sapiens IQ motif containing GTPase 
activating protein 1 (IQGAP1), mRNA
100.0
Contig918314 6
gi|4506786|ref|NM_003870.11 Homo 
sapiens IQ motif containing GTPase 
activating protein 1 (IQGAP1), mRNA
99.6
Contig918363 2
gi|4506778|ref|NM_002967.11 Homo 
sapiens scaffold attachment factor B 
(SAFB), mRNA
97.9
Contig918358 2
gi|4506778|ref|NM_002967.1| Homo 
sapiens scaffold attachment factor B 
(SAFB), mRNA
99.5
Contig918321 6
gi|4504894|ref|NM_002264.11 Homo 
sapiens karyopherin alpha 1 (importin 
alpha 5) (KPNA1), mRNA
98.8
Contig918345 6
gi|4504894|ref|NM_002264.11 Homo 
sapiens karyopherin alpha 1 (importin 
alpha 5) (KPNA1), mRNA
99.3
Contig918232 1
gi|4503256|ref|NM_001350.11 Homo 
sapiens death-associated protein 6 
(DAXX), mRNA
93.4
Contig918229 1
gi|4503256|ref|NM_001350.11 Homo 
sapiens death-associated protein 6 
(DAXX), mRNA
90.5
Contig918287 1
gi|17487840|ref|XM_047062.3| Homo 
sapiens hypothetical gene supported by 
AK002209 (LOC92751), mRNA
100.0
Contig918310 1
gi|17487840|ref|XM_047062.3| Homo 
sapiens hypothetical gene supported by 
AK002209 (LOC92751), mRNA
100.0
Contig918347 2
gi|17455349|ref|XM_047641,2| Homo 
sapiens high-mobility group 20B 
(HMG20B), mRNA
99.8
Contig918342 2
gi| 17455349|ref|XM_047641.21 Homo 
sapiens high-mobility group 20B 
(HMG20B), mRNA
98.9
Contig918298 1
gi|17445723|ref|XM_033706.3| Homo 
sapiens erythrocyte membrane protein 
band 4.1 (elliptocytosis 1, RH-linked) 
(EPB41), mRNA
99.4
Contig918308 7
gi| 17435685|ref|XM_028958.2| Homo 
sapiens similar to unnamed protein 
product (LOC90102), mRNA
99.7
Contig918233 1 gi|17433931 |ref|XM_034072.3| Homo sapiens KIAA0742 protein (KIAA0742), 99.7
mRNA
Contig918227 1
gi|17433931 |ref|XM_034072.3| Homo 
sapiens KIAA0742 protein (KIAA0742), 
mRNA
99.0
Contig918311 2
gi|17066293|emb|AJ420429.1|HSA420429 
Homo sapiens mRNA full length insert 
cDNA clone EUROIMAGE 1654781
98.8
Contig918346 1
gi| 14736714|ref|XM_043758.11 Homo 
sapiens KIAA1513 protein (KIAA1513), 
mRNA
99.4
Contig918243 1 gi|12025677|ref|NM_004924.2| Homo sapiens actinin, alpha 4 (ACTN4), mRNA 98.8
Contig918238 1 gi1120256771ref|N M_004924.21 Homo sapiens actinin, alpha 4 (ACTN4), mRNA 99.7
Contig918369 1
gi|10863902|ref|NM_004238.11 Homo 
sapiens thyroid hormone receptor 
interactor 12 (TRIP12), mRNA
99.7
Contig918366 1
gi|10863902|ref|NM_004238.1| Homo 
sapiens thyroid hormone receptor 
interactor 12 (TRIP12), mRNA
96.5
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